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Abstract 
In recent years, there has been a rise in antimicrobial-resistant bacteria caused by 
overdependence on, and misuse of, antibiotics. This has led to an increase in research for 
identifying alternatives to combat pathogens. One promising means of combating 
pathogenic bacteria, particularly for those residing in the gastrointestinal tract (GIT), is 
the use of probiotics. This thesis focuses on a potential probiotic strain Lactobacillus 
fermentum 3872, the genome sequence of which was circularised during the study, 
identifying genes that may contribute to probiotic activity. Several genes involved in GIT 
survival, such as acid symporters were discovered, along with genes that encode adhesion 
proteins such as those involved in mucus, fibronectin and collagen binding. The genes 
mentioned above may contribute to L. fermentum 3872 survivability within the GIT and 
have an antagonistic effect on enteric pathogens via competitive exclusion. Other 
interesting genes identified in L. fermentum 3872 were potentially involved in bacterial 
aggregation, exopolysaccharide and vitamin synthesis, along with four prophage 
encoding regions. Genes that encode a class III bacteriocin was also identified. An 
additional gene encoding a collagen binding protein (CBP) of a newly discovered plasmid 
pLF3872, was recognised. The chromosomal sequence also had a partial CBP encoding 
gene. pLF3872 has a toxin-antitoxin gene pair that ensures stable maintenance of the 
plasmid, along with conjugation-related genes. Functional analysis of the recombinant 
CBP via ELISA experiments found that the protein had the ability to bind to collagen I, 
a protein present on the epithelial lining of cells of the GIT. ELISA experiments also 
demonstrated that a common gastrointestinal pathogen, Campylobacter jejuni, can bind 
to collagen I in a concentration-dependent manner. In addition, mass spectrometry 
analysis identified that C. jejuni strains 11168H and 81-176 may utilise flagellar 
components (FlaA and FlaB) for adhesion. Furthermore, C. jejuni 11168H and 81-176 
binding to collagen I was inhibited in the presence of either L. fermentum 3872 or CBP, 
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thus reducing C. jejuni adherence via competitive exclusion. Using an in vitro assay, it 
was also demonstrated that L. fermentum 3872 cell-free supernatant could inhibit the 
growth of C. jejuni, due to the acidic environment brought about by L. fermentum 3872.  
During the completion of the genome sequence of L. fermentum 3872, comparison of 
various sequence assembly techniques which focused on the quality of the genome 
assembly was conducted. The results showed that further extension of the genome 
sequence during sequence assembly may lead to assembly errors when over-relying on a 
commonly-used sequence quality indicator, referred to as read mapping. It is suggested 
that care must also be taken when using long read technology to complete the genome 
sequence of a bacteria, as this may result in nucleotide sequence redundancies. 
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Chapter 1: Introduction  
1.1 The early concept and definition of health-promoting bacteria 
Even before the discovery of microorganisms, fermented food products have been used 
to promote health in humans. For example, both the Greek physician Hippocrates and 
the Roman historian Plinius advocated fermented milk as a medicinal aid (Vijaya et al., 
2013; Ho and Prasad, 2013). The actual concept of consuming live microorganisms to 
promote health and longevity was proposed by immunologist Elie Metchnikoff, who 
deduced that not all bacteria are harmful (Butel, 2014). Metchnikoff suggested that the 
consumption of fermented food products with their active ingredient of live bacteria 
may help displace pathogenic gastrointestinal organisms (Butel, 2014; Sánchez et al., 
2017; Mackowiak, 2013). The term ‘probiotic’, meaning ‘for life’, was first used in 
1965 by Lilly and Stillwell (Lilly and Stillwell, 1965). They defined the term as ‘growth 
promoting factors produced by microorganisms’. This definition was adapted by the 
World Health Organisation (WHO) and the Food and Agriculture Organisation (FAO) 
in 2001 to incline more towards Metchnikoff’s concept of probiotics to ‘Live 
microorganisms which when administered in adequate amounts, confer a health benefit 
to the host’ (World Health Organization and, Food and Agriculture Organization of the 
United Nations, 2001). The definition took into consideration that the benefits brought 
about by probiotics are not restricted to a specific delivery system, or limited to a 
specific organ/body part of the host (Sánchez et al., 2017). Nonetheless, some studies 
have shown that bacteria do not necessarily have to be viable for them to provide a 
beneficial effect to its host (Sanders, 2008; Lahtinen, 2012). 
1.2 Categorising a microbe as a probiotic 
For a microbe to be classified as a probiotic, it should be taxonomically identified using 
molecular techniques, must be deposited in an internationally recognised culture 
collection bank, and must not be able to transmit certain antibiotic-resistance genes 
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(Moal and Servin, 2014). Furthermore, according to WHO and FAO, the microbe must 
not provide a harmful effect to the host when administered, and its beneficial effect on 
the host must be proven (Butel, 2014). The microbe should be able to survive and reach 
the site of its action when administered (i.e. ingested microbes must survive the harsh 
conditions of the GIT) (Butel, 2014). The microbe must also remain stable during the 
manufacturing and packaging process and maintain its probiotic characteristic (Butel, 
2014).  
1.3 Probiotics and their mechanisms of action 
A probiotic can benefit the host either by directly interacting with an infectious agent 
and/or disease (Butel, 2014). A probiotic can also interact with the host to enhance its 
defence against infectious agents, improving the host’s barrier function, and/or benefit a 
host by modulating the host’s immune system (Butel, 2014). The molecular means by 
which a probiotic provides its beneficial effect(s), known as its mechanism(s) of action, 
is diverse and has not been determined completely (Bermudez-Brito et al., 2012). 
Mechanisms of action of probiotics vary and are dependent on the genus, species, and 
strains of microbes (Islam, 2015). To use probiotics more effectively, it is important to 
know the mechanism of action, as in the past the European Food Safety Authority 
(EFSA) had refused the health claims of marketed probiotics mainly due to a lack of 
information about their mechanism of action (Butel, 2014). As previously noted, many 
studies focus on the effect a probiotic has in treating a condition rather than on how it 
provides its beneficial effect (Butel, 2014). Understanding a probiotics mechanism of 
action would enable more efficient utilisation of probiotics as tools for improving 
health. 
1.3.1 Synthesis of antimicrobials and competitive exclusion  
As discussed above, one of the ways probiotics benefit the host is by interacting with an 
infectious agent and/or competing with a pathogen for nutrients and space (Butel, 
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2014). A probiotic could release antimicrobials such as bacteriocins, metabolites or 
biosurfactants (Butel, 2014). A probiotic could also compete for, and inhibit, adhesion 
sites utilised by microbes for host colonisation (Butel, 2014). Probiotics may also 
neutralise microbial toxins and play a role in the detoxification of host food products, 
preventing damage to the host (Oelschlaeger, 2010). 
The most common type of antimicrobial substances synthesised by probiotics is short 
chain fatty acids, such as lactic acid (Oelschlaeger, 2010). Fatty acids can lower the 
local pH environment of the host, harming pathogens that are not adapted to a low pH 
environment. Bacterial toxins can also be neutralised by short chain fatty acids, such as 
the inhibition of Shiga toxin produced by enterohaemorrhagic Escherichia coli (EHEC) 
O157: H7 via the production of butyric and lactic acid by probiotic Clostridium 
butyricum MIYAIRI (Takahashi et al., 2004). Probiotics such as Lactobacillus 
rhamnosus GG can also bind to mycotoxin deoxynivalenol and reduce its effect on the 
host (Turner et al., 2008). Another example of an antimicrobial substance produced by 
probiotics is hydrogen peroxide, which can cause oxidative stress on other microbes 
(Berstad et al., 2016). Hydrogen peroxide is particularly effective against anaerobes, 
which are more sensitive to the effects of reactive oxygen species (Berstad et al., 2016). 
The production of hydrogen peroxide by various Lactobacillus strains has been 
implicated in anti-Candida infection activity (Verdenelli et al., 2014).  
The production of bacteriocins, which are a diverse group of antimicrobial peptides, has 
also been of interest in combating pathogenic bacteria (Dobson et al., 2012). A 
bacteriocin can act against closely related species of bacteria that synthesise it (narrow-
spectrum) or can act against a wide range of bacteria (broad-spectrum) (Yang et al., 
2014). These peptides do not harm the host bacteria due to the presence of immunity 
proteins (Yang et al., 2014). Bacteriocins can be low molecular weight (< 10 kDa) and 
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heat stable, which are grouped as Class I lantibiotic peptides that either disrupt the 
membrane structure or have an enzymatic action against microbes (Yang et al., 2014; 
Sonomoto and Yokota, 2011). Bacteriocins can also be Class II non-lantibiotic peptides, 
which may cause microbial death via depolarization of the cell wall, due to their 
amphiphilic structure (Yang et al., 2014; Cotter, Hill and Ross, 2005). Bacteriocins can 
be high molecular weight (> 30kDa) and heat labile Class III bacteriocins, which can 
break the peptide bonds of a peptidoglycan layer (Yang et al., 2014; Sonomoto and 
Yokota, 2011). The latter classes of bacteriocins are further subdivided into various 
groups (Yang et al., 2014). An example of the potential use of bacteriocin can be seen 
in a broad-spectrum class II bacteriocin Abp118 produced by the probiotic 
Lactobacillus salivarius UCC118 that protected mice from Listeria monocytogenes 
infection. However, the mutant L. salivarius UCC118 strain had no protective effect 
against L. monocytogenes (Corr et al., 2007).  
As mentioned previously, competitive exclusion of pathogenic bacteria may also 
contribute to probiotic function. Probiotics may compete for limited resources against 
pathogens to make it difficult for pathogens to colonise a host (Oelschlaeger, 2010). For 
example, Lactobacilli sp such as L. acidophilus bind to ferric hydroxide, thus 
preventing pathogens from obtaining iron (Oelschlaeger, 2010). Another important 
competition tool utilised by probiotic bacteria is competition for adhesion ligands. 
Probiotics can protect the host from infectious diseases by competing for the same 
adhesion ligand as that of a pathogen, thus reducing the pathogen’s potential to colonise 
a host (Oelschlaeger, 2010). Bacterial surface proteins, such as mucin binding proteins, 
are the most commonly studied proteins for competition experiments for attachment to 
adhesion ligands (Oelschlaeger, 2010). Probiotics may also form biofilms protecting the 
host against pathogen colonisation (Oelschlaeger, 2010). Adhesion is also an important 
precursor of other beneficial effects on the host as it allows the probiotic bacteria to 
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attach and colonise a host. Probiotics may also produce biosurfactants that could act as 
antimicrobials or help in probiotic microbial adhesion and biofilm formation 
(Oelschlaeger, 2010; Singh and Cameotra, 2004; Sharma and Saharan, 2016). 
1.3.2 Improvement of the host barrier function 
Improvement of the hosts barrier function includes enhancement/stabilisation of the 
host epithelial cell tight junctions, such as those of the gut. The latter was observed in 
human cell lines (T84) when the probiotic E. coli strain Nissle 1917 maintained the 
epithelial barrier and protected against the enteropathogenic E. coli strain E23486/69 
disruption of the gut’s barrier (Zyrek et al., 2007). The study concluded that the 
probiotic E. coli strain Nissle 1917 promoted the production of ZO-2 protein, which 
helped stabilise and maintain the epithelial tight junction structure of the gut (Zyrek et 
al., 2007). Improvement of the host barrier function can also involve promotion of the 
host mucus expression (Butel, 2014). For example, studies have shown that multiple 
Lactobacillus strains could induce MUC3 production after attachment to epithelial cells, 
reducing the potential of the pathogen, E. coli E2348/69, adhering to epithelial cells 
(Mack et al., 2003). Probiotics may also deconjugate bile salts produced in the gut to 
make them more potent antimicrobials, thus protecting the host from infectious 
pathogens (Oelschlaeger, 2010).   
1.3.3 Modulation of the host immune system 
A probiotic may also modulate the host immune system. Immune modulation could be 
used for the prevention and treatment of infectious and inflammatory diseases, as well 
as for the removal of neoplastic cells (Oelschlaeger, 2010). Immune modulation can 
involve both the adaptive and innate immune response and could be brought about by 
the interaction of bacterial products with epithelial and dendritic cells, along with 
macrophages or lymphocytes (Bermudez-Brito et al., 2012). The most common 
mammalian host cells that interact with probiotics to provide an immune response are 
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intestinal epithelial cells and, to a lesser extent, dendritic cells (Bermudez-Brito et al., 
2012). An immune response could be mediated by the detection of pathogen-associated 
molecular patterns (PAMPs), which are conserved products such as bacterial 
metabolites, cell wall components, and/or DNA that are recognised by pattern 
recognition receptors (PRRs) of the host cells (Bermudez-Brito et al., 2012; 
Oelschlaeger, 2010). PRRs could be Toll-like receptors (TLRs), extracellular C-type 
lectin receptors (CLRs), and Nucleotide-binding oligomerization domain-like receptors 
or NOD-like receptors (NLRs) (Bermudez-Brito et al., 2012). An example of utilising 
probiotics for the treatment of infectious disease is the administration of probiotic 
bacterium Lactobacillus casei CRL 431. This probiotic was found to induce TLR2, 
TLR4 and TLR9, regulating the production of cytokines TNFα, IFNγ and IL-10, and 
reducing the severity of Salmonella enterica serovar Typhimurium infection in murine 
models (Castillo, Perdigon and de Moreno, 2011). Studies have also shown that 
Lactobacillus casei Shirota enhances natural killer cell activity through the action of 
interleukin 1, which in turn can be used against neoplastic cells (Takeda et al., 2006). In 
addition, probiotic E. coli Nissle 1917 and Lactobacilli strains can induce the 
production of antimicrobials such as human beta-defensin-2 in Caco-2 intestinal 
epithelial cells. Defensins tend to have a broad spectrum of antimicrobial activity and 
can be used against pathogenic bacteria and fungi (Wehkamp et al., 2004). 
1.4 Potential uses of probiotics 
There has been increasing interest in probiotic research, both for clinical and industrial 
purposes (Evivie et al., 2017; Mackowiak, 2013). The rise in interest in probiotic 
research for clinical purposes can be attributed to the realisation of the importance of 
commensal organisms in human health, disease, and immunology (Sánchez et al., 
2017). This realisation was made more evident by the human microbiome (Hsiao and 
Fraser-Liggett, 2009), Metagenomics of the human intestinal tract (MetaHit) 
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(http://www.metahit.eu/index.php?id=410, 2017), and MyNewGut 
(http://www.mynewgut.eu/, 2017) projects, which helped characterise microorganisms 
associated with healthy and diseased humans (Sánchez et al., 2017). In the past, interest 
in clinical probiotic research had decreased due to the advent of antibiotics (Butel, 
2014), but with the current rise in antimicrobial-resistant bacteria, probiotics are being 
studied as potential pathogen antagonists.  
1.4.1 Infectious diarrhoea  
More than 20 microbes can cause infectious diarrhoea, the most common of which are 
rotavirus, Salmonella, Campylobacter, Shigella and enterotoxigenic E. coli (Sánchez et 
al., 2017; Allen et al., 2010). Many probiotics are ideal candidates for surviving the 
harsh environment of the GIT and thus are being considered for the treatment of 
infectious diarrhoea. As already noted, some of the ways in which probiotics can tackle 
pathogens of the gut are by competing for limited nutrients, and binding sites (Sánchez 
et al., 2017). Probiotics can also produce antimicrobials such as lactic acid and enhance 
the antimicrobial agents of the GIT itself (i.e. by deconjugating bile salts) (Sánchez et 
al., 2017). Probiotics can also generate a host immune response to tackle pathogens 
(Sánchez et al., 2017). A meta-analysis of 63 studies, conducted by Allen et al. (2010), 
concluded that the use of probiotics for the treatment of acute infectious diarrhoea can 
help shorten the duration of diarrhoea and fever, particularly in children, although the 
effectiveness of probiotic treatment varied greatly between each study (Allen et al., 
2010). This conclusion was mirrored by Salari et al. (2012), who added that the efficacy 
of the use of probiotics in the treatment of infectious diarrhoea is still unknown (Salari, 
Nikfar and Abdollahi, 2012). The variability in treatment effectiveness may have been 
caused by the fact that both of the studies mentioned above did not consider the 
strain/species of the microbes being tested and treated against. The European Society 
for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) also stated that 
8 
 
the use of probiotics Lactobacillus rhamnosus GG, Saccharomyces boulardii, 
Lactobacillus reuteri DSM 17938, and heat-killed Lactobacillus acidophilus LB can be 
used in children with acute gastroenteritis as adjuncts to rehydration therapy (Szajewska 
et al., 2014).  
A promising use of probiotics is in the treatment of antibiotic-associated diarrhoea, as 
antibiotic treatment tends to cause dysbiosis of the GIT microbiota. Dysbiosis can result 
in an increase of Clostridium difficile and thus C. difficile associated diarrhoea (Sánchez 
et al., 2017). Studies have shown that probiotics such as Lactobacillus rhamnosus GG 
and Saccharomyces boulardii can protect against C. difficile related diarrhoea (Sánchez 
et al., 2017). The use of faecal transplant, where a healthy individual's microbiome is 
transferred to a person being treated with antibiotics, is also an effective tool in the 
prevention of C. difficle related diarrhoea (Hevia et al., 2015). Faecal transplantation 
may contain probiotic bacteria. 
1.4.2 Inflammatory bowel disease 
Crohn's disease (CD), pouchitis and ulcerative colitis (UC) are conditions grouped as 
inflammatory bowel disease (IBD), which is represented by chronic inflammation of the 
GIT (Mattos et al., 2015). It is hypothesised that the conditions are caused by a 
deregulation of the immune system resulting in a host inflammatory response and that 
dysbiosis of the GIT microbiota plays a major role in this (Sánchez et al., 2017). 
Currently, many of the treatments for IBD modulate the immune response and 
inflammatory cytokines (Mattos et al., 2015). A probiotic’s ability to modulate the host 
immune system to reduce inflammation and normalise a GIT that has undergone 
dysbiosis are hopeful signs for the treatment of IBD (Sánchez et al., 2017). The use of 
probiotics has lead to promising results in the treatment of UC, and more so for 
pouchitis (Sánchez et al., 2017; Lichtenstein, Avni-Biron and Ben-Bassat, 2016). 
Probiotic #VSL3, which consists of a combination of probiotic bacteria, is known to be 
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particularly useful in the treatment of IBD (Penner and Fedorak, 2005). However, the 
effectiveness of probiotics in the treatment of CD has not been promising to date 
(Lichtenstein, Avni-Biron and Ben-Bassat, 2016).  
1.4.3 Irritable bowel syndrome 
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder that causes 
abdominal discomfort along with bowel dysfunction, with current treatments having 
low efficacy (Hoveyda et al., 2009). The aetiology of the condition is unknown, 
although it is thought to be multifactorial, with indications that dysbiosis of the GIT 
microbiota, inflammation, stress, infectious diseases, and/or abnormal gut movement 
may all play roles in its manifestation (Butel, 2014). Probiotics are thought to be a 
promising tool in the treatment of IBS, as they can strengthen the gut barrier, normalise 
the gut microbiota, and improve GIT dysmotility (Cozma-Petrut et al., 2017). A meta-
analysis of 14 randomised control trials found that probiotics may be useful in treating 
IBS (Hoveyda et al., 2009). Studies conducted by Zhang et al. (2016) that looked at 21 
randomised control trials, and Ford et al. (2014), which examined 43 randomised 
controls trials, also found probiotics to be effective in the treatment of IBS. However, it 
must be noted that it is hard to compare different randomised control trials as study 
parameters vary (for example, the duration of study/treatment, age, dosage differences) 
(Hoveyda et al., 2009; Cozma-Petrut et al., 2017). Comparison is further complicated 
by the fact that different strains, species, and genera of probiotics have different effects 
on IBS, as some probiotics may help against specific symptoms while others would 
have an effect on a range of symptoms (Hoveyda et al., 2009; Cozma-Petrut et al., 
2017).  
1.4.4 Helicobacter pylori infections 
Probiotics are being investigated for the treatment of Helicobacter pylori infections, 
which can cause peptic ulcers, gastritis (inflammation of the stomach lining), stomach 
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cancer, and cancer of the mucosal lymphoid tissue (MALT lymphoma) (Homan and 
Orel, 2015). One of the ways that probiotics can be used against H. pylori infections is 
by reducing the inflammatory response induced by H. pylori via pro-inflammatory 
cytokines such as IL-8, IL6, IL-2, IL-1ß, and thus alleviate the symptoms of the 
diseases caused by H. pylori (Homan and Orel, 2015). For example, in vitro 
experiments have shown that probiotic Lactobacillus bulgaricus could reduce IL-8 
production by inhibiting the TLR4 pathway utilised by H. pylori SS1-LPS to upregulate 
IL-8 in SGC-7901 cells (Zhou et al., 2008). As already mentioned, probiotics can also 
produce antimicrobials, such as short-chain fatty acids, which can reduce the pH 
environment of the host and have a negative effect on H. pylori colonisation (Lesbros-
Pantoflickova, Corthesy-Theulaz and Blum, 2007). H. pylori reduces host epithelial 
mucin production by suppressing the expression of MUC5AC and MUC1. Probiotics 
such as Lactobacillus plantarum strain 299v and Lactobacillus rhamnosus GG can 
stimulate mucin production by increasing expression of MUC2 and MUC3 genes, 
which may prevent H. pylori adhesion to gastric epithelial cells by improving the 
epithelial barrier (Homan and Orel, 2015). Probiotics, such as Lactobacillus reuteri, can 
also compete for adhesion sites, preventing H. pylori adhesion and thus colonisation 
(Homan and Orel, 2015). Meta-analysis studies on the effects of probiotics against H. 
pylori have concluded that probiotics are effective adjuncts to antibiotic therapy in the 
treatment of H. pylori infections, as the addition of probiotics can improve the efficacy 
of the treatment and reduce the side effects introduced when using antibiotics 
(Ruggiero, 2014).  
1.4.5 Allergy  
An allergic reaction is the result of a highly sensitised immune system that overreacts in 
the presence of a foreign antigen. According to the hygiene hypothesis, the lack of 
exposure to infectious agents and the absence of commensal microorganisms at an early 
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age, along with an overuse of antibiotics, prevent the immune system from developing 
normally (Waligora-Dupriet and Butel, 2012). This hypothesis also coincides with the 
fact that most allergic conditions are found in industrialised countries where hygiene 
and the use of antibiotics are prevalent (Waligora-Dupriet and Butel, 2012).  
Some of the first microbial colonisers of infants (i.e. Lactobacilli spp) originate from 
the mother and reside in the gastrointestinal tract. These microbes may combat 
pathogens and modulate the immune system, thus aiding its natural development 
(Waligora-Dupriet and Butel, 2012). Many probiotics are also commensal 
microorganisms (Papadimitriou et al., 2015), and it is proposed that the use of these 
bacteria may aid the natural development of the immune system and thus reduce the risk 
of allergies (Renz-Polster et al., 2005). For example, probiotics may be used on children 
born by caesarean section as studies have shown that these infants do not receive 
microbes that would normally be obtained from their mother’s vaginal tract and thus, 
they are highly likely to have allergic conditions (Renz-Polster et al., 2005).  
A study conducted by the World Allergy Organisation (WAO) stated that the evidence 
currently available on the supplementation of probiotics in infants does not indicate a 
decrease in risk of developing an allergy. Nonetheless, there are indications that the 
administration of probiotics is beneficial in preventing eczema (Fiocchi et al., 2015). A 
double-blind study consisting of 62 pregnant women with a family history of atopic 
dermatitis found that the group that received probiotic Lactobacillus rhamnosus GG had 
offspring with lower risks of contracting atopic dermatitis as opposed to the placebo 
group (Rautava, Kalliomaki and Isolauri, 2002). Furthermore, a double-blind trial on 27 
infants with eczema also found that in contrast to the control group, the condition of 
infants that had received L. rhamnosus GG and Bifidobacterium lactis improved (Islam, 
2015). The WAO guideline recommends the use of probiotics on pregnant women, 
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women who are breastfeeding and infants with a high risk of developing allergic 
diseases (Fiocchi et al., 2015).  
1.5 An introduction to Lactobacillus fermentum 3872, a lactic acid bacterium 
Bacteria are the predominant type of microbes that are classified as probiotics (Alok et 
al., 2015). Among bacteria, the most common genera of probiotics are Lactobacillus 
and Bifidobacterium (Bermudez-Brito et al., 2012; Islam, 2015). Lactobacillus 
fermentum belongs to the order Lactobacillales, which is the largest order in the phylum 
Firmicutes, and the class Bacilli (Claesson, Sinderen and O’Toole, 2007). Lactobacillus 
also belongs to the family Lactobacillacea (Claesson, Sinderen and O’Toole, 2007). 
Lactic acid bacteria (LAB), especially those that belong to Lactobacillus species, are 
often used in commercial food products such as in the meat, dairy and vegetable 
industries (Tajabadi et al., 2013). Lactobacilli helps make up the normal microflora of 
many mammals including humans, contributing to the microbiota at several body sites, 
including the GIT (Bermudez-Brito et al., 2012). Therefore, Lactobacillus have a 
generally regarded as safe (GRAS) status, which makes them good candidates for 
probiotic research (Anderson et al., 2013). Within the GIT, Lactobacilli are commensal 
in the stomach (pH of 2), colon (pH 5–5.7) and the small intestine (pH 5–7), which also 
makes them useful in probiotic research relating to the GIT, as they can be ingested to 
reach their site of action (Jandhyala et al., 2015).  
As already noted, Lactobacilli are one of the earliest colonisers of the GIT and play a 
crucial role in reducing the risk of allergy in infants with a predisposition to heredity 
allergy, and thus may play a role in immune maturation (Johansson et al., 2011). LABs 
also commonly produce antimicrobials such as bacteriocins and lactic acid which, as 
previously discussed, can be useful against infectious pathogens (Bermudez-Brito et al., 
2012). Nonetheless, Lactobacillus fermentum AGR1487 can lower the intestinal barrier 
13 
 
in vitro, and thus a safety profile of any potential probiotic must always be generated 
prior to its use (Anderson et al., 2013).  
The probiotic under investigation for this study is Lactobacillus fermentum 3872. The 
strain has been found in healthy human milk, in both mothers’ and children’s faecal 
matter, along with vaginal secretions. Thus, the strain is commensal to humans and can 
colonise various parts of the human body without adverse effects (Abramov et al., 2014; 
Lehri, Seddon and Karlyshev, 2017a). In vitro experiments have demonstrated that L. 
fermentum 3872 is resistant to gastric and intestinal stress and have strong adhesion to 
human HeLa and buccal cells. The bacteria also produce antimicrobials such as 
hydrogen peroxide and lactic acid (Abramov et al., 2014). The strain’s commensal 
nature and its ability to produce antimicrobials, along with its adhesive traits makes L. 
fermentum 3872 a potential probiotic candidate. The strain, as a mixture of other 
probiotics, has been patented due to its ability to combat mastitis, which is an infection 
of the breast caused by Staphylococcus sp (Abramov et al., 2014).  
1.6 OMIC technologies and their importance in probiotic research  
OMIC technologies are an umbrella of tools, which include genomics, transcriptomics, 
proteomics, metabolomics, glycomics and lipomics. There has been an increase in 
interest in using OMIC approaches for probiotic research and to collect better evidence 
on how probiotics provide benefit to a host (Johnson and Klaenhammer, 2014). 
Genomics is the study of the genetic makeup of an organism (Horgan and Kenny, 
2011). Transcriptomics measures the expression of RNA at a given time or under a 
certain environmental condition or infection (Horgan and Kenny, 2011). Proteomics is 
the study of proteins expressed by the genes of an organism including microbes (Horgan 
and Kenny, 2011). Glycomics and lipomics are involved in the study of cellular 
carbohydrates and lipids respectively. Metabolomics is the identification of the entire 
metabolite (end product) profile of an organism for a particular environmental 
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condition. An organism’s metabolite profile can be useful in providing information 
about the interaction between the probiotic and host (Horgan and Kenny, 2011; 
Vernocchi, Chierico and Putignani, 2016).  
The current study focuses on genomic analysis. Sequencing a probiotic’s genome assists 
in characterising the microbe as a potential probiotic and helps to accurately categorise 
a probiotics phylogeny (Oelschlaeger, 2010). Identifying genomic relatedness via 
comparative genomics to another probiotic that has previously been studied may help 
direct the potential use of a probiotic and aid in determining the type of studies to be 
conducted. For example, comparative analysis was performed on the genomes of 34 
strains of Lactobacillus acidophilus. The analysis found that there was very little 
genetic diversity between the strains and that they were almost identical at a nucleotide 
level, indicating that the strains, by and large, would provide similar health benefits 
(Bull et al., 2014; Walsh et al., 2016).  
Genome sequencing may also aid in building a safety profile for a probiotic through the 
identification of genes involved in antibiotic resistance (Papadimitriou et al., 2015). 
Genome sequencing may provide an indication of the likelihood of a probiotic’s ability 
to transfer genetic material to another microbe by looking for genes involved in 
conjugation (Doron and Snydman, 2015). This would allow for precautions to be taken 
in preventing other microbes from acquiring virulence genes. Sequencing also permits 
the selection of candidate genes for functional analysis, such as the selection and 
expression of a candidate gene for in vitro experiments, or gene knockout experiments 
(Johnson and Klaenhammer, 2014). This approach may also help tailor the products of 
probiotics for pharmaceutical use (i.e. drug development) and aid in identifying a 
probiotics mechanism of action (Papadimitriou et al., 2015; Johnson and Klaenhammer, 
2014).  
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As previously mentioned, stability and viability of a probiotic is recommended by the 
WHO and FAO. Thus, sequencing, followed by re-sequencing of a microbe’s genome, 
could be conducted after storage and/or administration to a host. This would help 
determine whether genomic changes such as gene loss or gain have been introduced 
during storage or after administration to a host, as genomic changes may result in a 
phenotypic effect (Walsh et al., 2016). The ability of a probiotic to reach the site of 
action and survive long enough to be able to administer a beneficial effect is important. 
Genome sequencing can provide an idea of the probiotic’s survivability for a specific 
host anatomical location by identifying genes related to bacterial survival (Walsh et al., 
2016), such as those involved in acid resistance systems (e.g. F1F0-ATPase), which is 
involved in the homeostasis of cellular pH (Papadimitriou et al., 2015). Genes involved 
in adhesion provide information about survival and help determine whether a microbe 
can colonise the host at a particular anatomical location (Johnson and Klaenhammer, 
2014). Identifying adhesion genes would also provide information on the ability of the 
probiotic to compete for host adhesion ligands against a pathogen, preventing it from 
colonising a host via competitive exclusion.  
Comparative analysis of other probiotic genome sequences would allow further studies 
to be conducted to determine an ideal combination of probiotics that would 
synergistically provide a beneficial effect to a host (Johnson and Klaenhammer, 2014). 
Comparative genomics can also be used to identify why different strains of probiotics 
impose varying effects, such as a study that identified why some Lactobacillus spp are 
associated with host weight gain and others with weight loss (Drissi et al., 2014). 
Genome sequencing, may be used for other OMIC technologies. For example, 
proteomics and metabolomic studies often require mass spectrometry data, which is 
dependent on a genome sequence and annotations of the sequence (Johnson and 
Klaenhammer, 2014), while transcriptomics needs an understanding of the genetic 
16 
 
makeup of an organism for measuring expression of transcribed genes (Johnson and 
Klaenhammer, 2014; Horgan and Kenny, 2011).  
In summary, OMIC technologies can provide a holistic view of an organism and the 
effects it has on its host (Johnson and Klaenhammer, 2014). The data generated can be 
used to build a profile of a microbe by identifying both genotypic and phenotypic 
markers that comply with traits that are attributed to its probiotic properties (Johnson 
and Klaenhammer, 2014). Such information could be used to identify a probiotic’s 
capacity to survive and reach its target region, its safety to the host, and its stability and 
possible mechanism of action, as recommended by the WHO and FAO (Johnson and 
Klaenhammer, 2014).  
1.6.1 Genome sequencing and its complexities 
There has been an exponential rise in the amount of genome sequencing data being 
generated and made publicly available via data repositories such as GenBank (Land et 
al., 2014). This increase in sequencing data is mainly due to a reduction in the cost of 
sequencing technologies (Reuter, Spacek and Snyder, 2015). Nonetheless, despite the 
rapid accumulation of genomic data, most relate only to draft or incomplete genome 
sequences (Land et al., 2014). This is seen by the fact that, since October 2013, more 
than eighty percent of the microbial sequencing data deposited in GenBank were of 
draft quality, with even relatively small genomes of around 1 MB left as incomplete 
sequences (Land et al., 2014). Draft genome sequences are useful in obtaining minimal 
genetic information of a microbial genome, which can often miss out genes that may 
play a role in the phenotypic traits of microbes. It is essential to obtain a complete 
genome sequence of a microbe, particularly for probiotic research, in order to get a 
more complete picture of the probiotics genotype. This is because a probiotic’s trait can 
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be strain-specific (Islam, 2015) and thus is reliant on genes that may not be discovered 
simply through a draft genome sequence.  
Currently, even though there is a reduction in the cost of obtaining sequencing data, the 
cost and complexity involved in completing a genome sequence is a major reason for 
bacterial genome sequences being left in a draft state (Land et al., 2014). To understand 
the complexities of a genome sequencing project, a brief overview and explanation of 
the sequencing assembly process is given. Initially, DNA from an organism is 
fragmented and the fragments are then sequenced. The sequence data generated is 
referred to as a ‘read’ (Ekblom and Wolf, 2014). The length of each read can vary from 
hundreds of bases to kilo-bases depending on the sequencing technology used (Ekblom 
and Wolf, 2014). Before submission to a data repository (e.g. Genbank), the read data 
generated needs to be assembled into longer genomic fragments, referred to as contigs. 
To assemble the reads, contiguation can be achieved using de novo assemblers, which 
utilise algorithms that find matches between reads and merge them to extend the reads 
(Ekblom and Wolf, 2014). This process does not require a reference genome.  
An alternative assembly process is a reference-based assembly in which reads are 
mapped onto a closely related pre-assembled reference genome. Often the drawback of 
a reference-based assembly can be that novel genomic features of a sequenced genome 
are absent (Silva et al., 2013). A reference-based assembly is also reliant on the quality 
of the reference genome assembly. Often assemblers do not contiguate beyond a 
repetitive region as it is difficult to determine the location of the repetitive regions on 
the genome (Treangen and Salzberg, 2011). Repetitive regions are commonly RNAs 
and/or transposons, where multiple copies of the same sequence are present in the 
genome. Many genome sequences deposited in data repositories use high throughput 
sequencers due to their affordability. High throughput sequencers such as the Ion 
Torrent Personal Genome Machine (PGM) generate high quality short sequencing reads 
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of about 400 bp. The sequencing machine also produces large amounts of the reads, 
resulting in a high coverage, which can help with nucleotide variant calling during 
genome assembly (Hunt et al., 2013). The drawback of high throughput sequencing 
technology is that the de novo assembly of short reads often generate short contigs that 
fail to span across large repetitive regions of a genome, making genome sequence 
completion difficult (Hunt et al., 2013). Certain manual bioinformatic techniques, such 
as BLASTN extension and read extension, can be used to extend contigs and merge 
contigs further, but this is often time-consuming.  
Another genome completion method is to use sequencing machines, such as the PacBio 
RSII sequencer (Pacific Biosciences), which can generate reads of kilobases in length 
(i.e. >14 kb) (Reuter, Spacek and Snyder, 2015), although the technology is relatively 
new and expensive. Long reads also have a high sequencing error rate and generate little 
coverage, which can result in low-quality base calling and thus assembly (Reuter, 
Spacek and Snyder, 2015; Antipov et al., 2016). Currently, a good approach is to use a 
hybrid of the two technologies, known as a hybrid sequence assembly, which uses 
contigs generated from long low-quality reads as a scaffolding tool and then maps short 
high-quality reads to identify nucleotide variations (Antipov et al., 2016). Nonetheless, 
there could still be assembly errors introduced as described in this study, and thus a 
sequence-free tool that uses a restriction digest map of the genome, such as an optical 
map can help to validate the genome assembly (Mendelowitz and Pop, 2014).  
1.6.2 Currently sequenced L. fermentum spp 
At the start of this study, two complete and 16 draft genome sequences of L. fermentum 
strains were deposited in the Genbank database. The GenBank database had classified 
L. fermentum CECT 5716 as complete and circular, but this strain consisted of many 
nucleotide ambiguities and thus was classified as incomplete for this study (Lehri, 
Seddon and Karlyshev, 2017a). Currently, there are five complete genome sequences 
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with the inclusion of L. fermentum 3872, and 19 draft genome sequences of L. 
fermentum strains. 
1.7 An introduction to Campylobacter 
As previously mentioned, many Lactobacilli spp, being one of the earliest colonisers of 
the human GIT, are well-suited for GIT survival. For the current study, after sequencing 
the genome of L. fermentum 3872 and identifying a potential protein that could be 
utilised for competitive exclusion studies, functional analysis of the antagonistic effect 
of L. fermentum 3872 on the enteric pathogen Campylobacter jejuni was conducted.  
Campylobacter is one of the leading causes of food-related illness worldwide 
(Kaakoush et al., 2015; Johnson, Shank and Johnson, 2017) and is categorised by the 
WHO as a pathogen that urgently requires antimicrobial alternatives due to an emerging 
number of antibiotic-resistant species (World Health Organisation, 2017). Once 
consumed, Campylobacter spp binds to the mucus layer or the epithelial cell lining of 
the gastrointestinal tract. It has been theorised that after adhesion, clinical symptoms 
occur due to invasion of intestinal mucosa by Campylobacter spp (Janssen et al., 2008), 
leading to an inflammatory response and diarrhoea (Janssen et al., 2008), or by the 
prevention of intestinal fluid reabsorption (Janssen et al., 2008; Johnson, Shank and 
Johnson, 2017). Campylobacter jejuni causes Campylobacteriosis (an infection by 
Campylobacter spp), contributing to 90% of Campylobacter infections in the UK 
(Johnson, Shank and Johnson, 2017; Acheson and Allos, 2001). C. jejuni infections is 
one of the most frequent cause of acute gastroenteritis worldwide, with symptoms such 
as loose, watery or bloody diarrhoea, abdominal cramps and fever that can last up to a 
week (Kaakoush et al., 2015). The onset of symptoms is dependent on the dose of C. 
jejuni, although it tends to be around 24–72 hours (Kaakoush et al., 2015). Symptoms 
of Campylobacter infections are also similar to other gastrointestinal infections such as 
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those caused by Salmonella and Shigella, making it difficult to distinguish between the 
various types of infections (Acheson and Allos, 2001).  
C. jejuni infections have been implicated with IBD. As previously described, IBD is 
characterised by chronic inflammation of the GIT, including CD and UC (Kaakoush et 
al., 2015). There is promising research being conducted on using probiotics to tackle 
IBD (Sánchez et al., 2017). Campylobacter infections have also been associated with 
colorectal cancer and oesophageal disease, which can lead to oesophageal 
adenocarcinoma (Kaakoush et al., 2015). Post C. jejuni infection can lead to IBS and 
functional dyspepsia (FD). IBS is characterised by recurrent discomfort or pain within 
the abdominal region for at least three months, for a minimum of three days each month 
(Kaakoush et al., 2015). Studies have shown that between 3%–36% of IBS is related to 
enteric infection (Spiller and Garsed, 2009), with 9%-13.8% of C. jejuni infections 
leading to post-infectious IBS (Kaakoush et al., 2015). Studies have also found that C. 
jejuni associated IBS can persist for up to 10 years (Schwille-Kiuntke et al., 2011). FD 
is characterised by abdominal pain or discomfort in the upper abdomen for three months 
with the absence of observable structural abnormality of the upper abdomen during 
endoscopy examination (Kaakoush et al., 2015). Studies have shown that between 
9.6%-30.5% of individuals infected with enteric pathogens tend to get post-infectious 
FD (Kaakoush et al., 2015).  
Campylobacteriosis also increases the risk of celiac disease (Riddle et al., 2013). Celiac 
disease is a disorder where an individual is unable to digest gluten, which causes 
damage to the lining of the small intestine. C. jejuni infections may also rarely cause 
extra-gastrointestinal disorders such as reactive arthritis, occurring in nine of every 1000 
Campylobacter infections (Ajene, Walker and Black, 2013). Campylobacter-induced 
reactive arthritis can exhibit itself a month after infection, and can resolve within 1–5 
years (Kaakoush et al., 2015). Although extra-gastrointestinal infections are rare, 
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bacteraemia and septicaemia are common types of extra-gastrointestinal disorders 
caused by Campylobacter infections. A study by Nielsen et al. (2010) showed that 
bacteraemia and septicaemia could occur in the Danish population in 2.9 cases per 
1,000,000 people every year. Extra-gastrointestinal conditions mainly occur in 
immunocompromised patients, or very young/old patients (Kaakoush et al., 2015; 
Acheson and Allos, 2001).  
C. jejuni can also be dangerous for pregnant females with infections linked to septic 
abortion and neonatal sepsis (Kaakoush et al., 2015). They are also associated with 
autoimmune disorders such as Guillain-Barré syndrome (GBS) and Miller Fisher 
syndrome (Kaakoush et al., 2015). GBS is a disorder characterised by a weakness or 
loss of sensation in the legs and arms caused by damage to the nervous system (Van 
Doorn, Ruts and Jacobs, 2008). The incidence of GBS is 1.2-2.3 cases per 100,000 
people per year, with C. jejuni infection being a major trigger for the disease (Van 
Doorn, Ruts and Jacobs, 2008). The risk of GBS infection increases with age and is 
more common in men (Van Doorn, Ruts and Jacobs, 2008). GBS is thought to be 
caused by cross-reactivity of host antibodies to C. jejuni lipooligosaccharide and human 
gangliosides (Kaakoush et al., 2015; Van Doorn, Ruts and Jacobs, 2008). Miller Fisher 
syndrome is a variant of GBS; and causes paralysis or defect of the eye muscle and is 
thought to be a result of C. jejuni molecular mimicry (Kaakoush et al., 2015).  
1.7.1 Epidemiology of Campylobacter infections 
There is a global rise in Campylobacter infections (Kaakoush et al., 2015). In 
industrialised countries, the annual incidence of Campylobacter infections ranges from 
4.4-9.3 per 1000 people (World Health Organization, Food and Agriculture 
Organization of the United Nations, World Organisation for Animal Health, 2013). In 
many industrialised countries, Campylobacter infections often occur in individuals less 
than a year old and during young adulthood (between the ages of 15 and 44 years) 
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(Acheson and Allos, 2001). However, according to a recent public health report, the 
majority of UK Campylobacter infections in 2015 occurred in people aged between 50 
and 59 years (Public Health England, 2017). Campylobacter infection rates show a 
seasonal increase during the spring/summer months in the UK (Public Health England, 
2017; Nichols et al., 2012). As already noted, in the UK, males are more likely to suffer 
from Campylobacter infections, with 14% more male cases of Campylobacteriosis than 
female cases reported (Nichols et al., 2012).  
An important risk factor for Campylobacter infection is international travel, with C. 
jejuni contributing significantly to travellers’ diarrhoea (Kaakoush et al., 2015). In 
Europe, the cases of travellers’ diarrhoea related to Campylobacter infections has 
increased from 7% (2008) to 12% (2010) (Gautret et al., 2012), and in England, 17% of 
Campylobacter infections are related to travel (Zenner and Gillespie, 2011). In the UK 
as a whole, one-fifth of reported Campylobacter spp cases are travel-related (Nichols et 
al., 2012). In developing countries, Campylobacter infections are endemic and tend to 
occur in children less than two years old, although they are rare among adults (Acheson 
and Allos, 2001; Platts-Mills and Kosek, 2014). Campylobacter infections are also an 
important cause of childhood morbidity due to diarrheal symptoms in the developing 
world (Acheson and Allos, 2001). In the developing world, infants infected with 
Campylobacter spp also exhibit stunting (Amour et al., 2016). Furthermore, in contrast 
to industrialised countries, Campylobacter infections do not show a seasonal increase in 
developing countries and can be asymptomatic (Nichols et al., 2012).  
1.7.2 Reservoir of Campylobacter infections 
Campylobacter transmission to humans is commonly zoonotic, with 50%–80% of 
infections related to chickens (EFSA Panel on Biological Hazards, 2011). This is 
mainly caused by a high Campylobacter spp carriage rate in broiler chickens, resulting 
in a large number of poultry farms being contaminated with Campylobacter spp 
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(Kaakoush et al., 2015). C. jejuni has also been known to survive in chicken faeces for 
about six days, which can lead to soil and water contamination, especially if manure 
from poultry is used as fertiliser (Kaakoush et al., 2015). A survey conducted by the UK 
Food Standards Agency found that the prevalence of infection with Campylobacter spp 
was 73.3% in chickens sold in the UK from 2014 to 2015 (Jorgensen et al., 2017). 
Campylobacter spp abundance is more common in organic chickens than non-organic 
sources, with the risk of infection being 1.7 times higher from organic sources 
(Kaakoush et al., 2015). Furthermore, frozen and fresh meats tend to be more frequently 
contaminated with Campylobacter spp than commercially cooked meat, with C. jejuni 
accounting for 69% of Campylobacter spp contamination (Moore et al., 2002). Apart 
from chicken, other forms of domestic animals, such as cattle, pigs, sheep, goat, cats 
and dogs, contribute to Campylobacter infections (Kaakoush et al., 2015). Another 
leading risk of Campylobacter infection is untreated water. Contaminated water is a 
more common vector of transmission than poultry in developing nations (Kaakoush et 
al., 2015). Campylobacter infections can also result from drinking unpasteurized milk 
(Kaakoush et al., 2015) and, according to a study conducted by the UK Health 
Protection Agency, 3% of infections are also a result of person-to-person contact caused 
by poor hygiene (Kaakoush et al., 2015).  
1.7.3 Current treatments  
Campylobacter infections are commonly treated with hydration therapy to maintain 
normal body fluid and electrolyte balance (Kaakoush et al., 2015; Acheson and Allos, 
2001). Nonetheless, antibiotics are administered to individuals who are 
immunocompromised or who show severe/persistent or extra-gastrointestinal symptoms 
(Kaakoush et al., 2015; Acheson and Allos, 2001), and individuals who are pregnant, 
have high fevers or have a prolonged illness (Kaakoush et al., 2015; Acheson and Allos, 
2001). When antibiotics are needed, fluoroquinolones such as ciprofloxacin are usually 
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given. These target topoisomerase IV and DNA gyrase. The latter enzymes are essential 
for DNA replication. Fluoroquinolones are favourable as they are effective against 
various pathogens that cause gastroenteritis and thus can be quickly prescribed, 
although the rate of ciprofloxacin antibiotic resistance is high and rising amongst 
Campylobacter species (Kaakoush et al., 2015; Acheson and Allos, 2001). In the US, 
ciprofloxacin resistance rose from 11% in 1997 to 25% in 2011 (Hampton, 2013), while 
in South Korea and Thailand, ciprofloxacin resistance is 92% (Han et al., 2007) and 
100% (Serichantalergs et al., 2007) respectively. In European states, resistance to 
fluoroquinolones is up to 91.5% (European Food Safety Authority and European Centre 
for Disease Prevention and Control, 2016). This increase in resistance is due to the 
misuse of ciprofloxacin in poultry farming, animal husbandry and, to a lesser extent, 
due to suboptimal use in the treatment of human disease (Kaakoush et al., 2015). If 
Campylobacteriosis is diagnosed, then macrolides are preferred which block 
translocation required for protein synthesis (Kaakoush et al., 2015). A study conducted 
by Tribble et al. (2007) showed that treatment of travellers’ diarrhoea caused by C. 
jejuni and C. coli with levoflaxin (fluoroquinolone) had a 72% cure rate, which was 
lower than treatment with azithromycin (macrolide), which had a 98% cure rate. 
Erythromycin, another macrolide, is also an effective antibiotic against Campylobacter, 
as there is low antibiotic resistance, and the antibiotic can be given to children and 
pregnant women (Acheson and Allos, 2001). Nonetheless, macrolides are being used in 
the food production industry to promote the growth of animals, as well as for 
therapeutic reasons, leading to macrolide-resistant strains of Campylobacter (Kaakoush 
et al., 2015). Ciprofloxacin has been recommended for macrolide-resistant 
Campylobacter (Kaakoush et al., 2015). Various strains of Campylobacter resistant to 
tetracycline, amoxicillin, cephalosporins, ampicillin, metronidazole, along with 
trimethoprim, vancomycin and rifampin have been found (Acheson and Allos, 2001). In 
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rare cases, Campylobacter infections are treated with aminoglycosides such as 
gentamicin, which affect protein synthesis (Kaakoush et al., 2015). Therefore, due to a 
rise in antimicrobial resistance, alternative means of combating Campylobacter 
infections are needed (Johnson, Shank and Johnson, 2017). 
1.7.4 Possible methods to tackle C. jejuni infections  
One of the possible ways to reduce Campylobacter infections is to introduce hygiene 
measures in farms, such as the introduction of boot dips, house-specific boots/overshoes 
and hand washing facilities (Kaakoush et al., 2015). This would prevent the spread of 
Campylobacter between broiler houses, ultimately reducing the number of chickens 
infected with Campylobacter and thus prevent its spread to humans (Kaakoush et al., 
2015). These methods are effective in reducing Campylobacter in chicks, although the 
downside of the aforementioned strategies is the willingness of the workers to adhere to 
the hygiene measures (Kaakoush et al., 2015).  
Another approach to combating Campylobacter infections is the use of bacteriocins. 
Many anti-Campylobacter bacteriocins have been isolated from Lactobacillus bacteria. 
For example, bacteriocin L-1077 isolated from Lactobacillus salivarius 1077 was found 
to reduce C. jejuni infection in chickens (Svetoch et al., 2011). Furthermore, a class II 
bacteriocin produced by Paenibacillus polymyxa NRRL B-3059 also reduced C. jejuni 
colonisation of chickens (Johnson, Shank and Johnson, 2017). Nonetheless, C. jejuni 
and C. coli have been known to develop resistance against bacteriocins, as was the case 
for bacteriocins OR-7 and E-760 (Johnson, Shank and Johnson, 2017). A study by 
Johnson, Shank and Johnson (2017) showed that the mechanism of resistance was due 
to the multidrug CmeABC efflux pump. In addition, studies have also shown phages, 
many of which have been isolated from sources such as sewage, poultry, livestock and 
manure, to be effective against Campylobacter (Johnson, Shank and Johnson, 2017). 
Bacteriophages added to a chicken’s water source have been found to successfully 
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reduce the Campylobacter load (Kaakoush et al., 2015), although prolonged studies 
show that Campylobacter levels return to their original level over time after constant 
use of a particular bacteriophage (Kaakoush et al., 2015). This loss of effectiveness may 
be caused by Campylobacter bacteria having a high rate of genomic variation, which 
would make the bacteria resistant to a phage (Johnson, Shank and Johnson, 2017). 
Nonetheless, phages can evolve consistently to attack the host (Johnson, Shank and 
Johnson, 2017). So far, studies that utilise phage therapy to treat Campylobacter 
infections in humans have not been conducted. A cocktail of phages may be used to 
treat Campylobacter infections, as currently there are no individual phages known to be 
effective against all Campylobacter strains (Kaakoush et al., 2015; Johnson, Shank and 
Johnson, 2017). There have also been strategies to vaccinate humans and chickens 
against Campylobacter infections, such as delivering flagellar components of C. jejuni 
and using Campylobacter inner membrane antigens, although none of the approaches 
have successfully prevented Campylobacter colonisation in chickens or protected 
humans against Campylobacter infections (Kaakoush et al., 2015; Johnson, Shank and 
Johnson, 2017). Removal of Campylobacter during food processing, by using organic 
acids, sodium chlorite, or UV may successfully prevent human cases of 
campylobacteriosis. However, either the costs are high and/or there is a potential effect 
on the taste of the food product (Kaakoush et al., 2015). Studies have also shown that 
probiotics can be an effective tool in reducing or preventing Campylobacter infections 
as mentioned in a review article by Johnson, Shank and Johnson, (2017). These studies 
have predominantly utilised competitive exclusion as a tool for reducing Campylobacter 
infections with promising results (Johnson, Shank and Johnson, 2017). Probiotics may 
be utilised as a prophylaxis against Campylobacter associated travellers’ diarrhoea, and 
can be useful in countries where Campylobacter infections are endemic (Johnson, 
Shank and Johnson, 2017). The most common types of probiotics used for anti-C. jejuni 
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studies are Lactobacillus and Enterococcus due to their common presence within the 
human GIT, along with Bifidobacterium and Saccharomyces cerevisiae (Johnson, 
Shank and Johnson, 2017). A study conducted by Nishiyama et al. (2014) treated chicks 
with daily doses of Lactobacillus gasseri SBT2055 (LG2005) over a 14-day period. The 
results showed a significant decrease in C. jejuni 81-176 in the treated chicks compared 
to controls (Nishiyama et al., 2014). This study concluded that the probiotic strain 
inhibited C. jejuni 81-176 adhesion to human intestinal epithelial cells and that there 
was co-aggregation between the probiotic and C. jejuni 81-176 (Nishiyama et al., 
2014). Another study, conducted by Wine et al. (2009) determined that probiotic 
Lactobacillus helveticus R0052 could reduce C. jejuni NCTC 11168 and 81-176 
invasion to human colon T84 cells and C. jejuni NCTC 11168 invasion to intestine 407 
cells. The authors deduced that competitive exclusion as a result of L. helveticus R0052 
adhesion to the latter cells played a role in the reduction of invasion of the two C. jejuni 
strains (Wine et al., 2009).  
Another means of utilising probiotics to combat Campylobacter is through the release 
of organic acids commonly produced by Lactobacillus spp, as studies such as that 
conducted by Neal-McKinney et al. (2012) have shown that species of Lactobacillus 
inhibit C. jejuni growth in vitro by disrupting the membrane of C. jejuni by releasing 
lactic acid. The study demonstrated that low pH may play a role in inhibiting C. jejuni 
growth, as after neutralising the pH, C. jejuni growth was not affected. Interestingly, the 
study also demonstrated that reducing the pH environment with hydrochloric acid had a 
weaker inhibitory effect than when using lactic acid, indicating that the pH is not the 
only inhibitory factor (Neal-McKinney et al., 2012). Nonetheless, the effect of lactic 
acid within a gut environment may be limited due to the buffering effect of bicarbonate 
released by the pancreas (Johnson, Shank and Johnson, 2017). Along with combating 
Campylobacter, probiotics may also have a beneficial effect on the growth of livestock. 
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Studies have shown that probiotics in chicken feed increased livestock’s nutrient 
transport capacity, metabolic rate, and protein production (Johnson, Shank and Johnson, 
2017). Probiotics also have an added benefit in that they are easy to administer as food, 
they are cheap, and they may stay within their host for a prolonged period (Neal-
McKinney et al., 2012). 
1.7.5 C. jejuni adhesins 
Adhesion is an important tool utilised by pathogenic bacteria to colonise and invade a 
host and thus for pathogenesis (Rubinchik, Seddon and Karlyshev, 2012). For this 
reason, a better understanding of the means by which C. jejuni adheres and thus 
colonises a host is important. Some examples of C. jejuni adhesins are provided in this 
section.  
The most important adhesins of Campylobacter are the cell surface membrane proteins 
CadF, FlpA and JlpA. FlpA and CadF which attach to fibronectin, a component of the 
extracellular matrix proteins (ECM) (Rubinchik, Seddon and Karlyshev, 2012; Konkel, 
Larson and Flanagan, 2010). Proteins that attach to the ECM are referred to as microbial 
surface adhesive matrix molecules (MSCRAMMS), and are often utilised as primary 
tools for host pathogenesis and invasion; thus, they are good targets for competitive 
exclusion experiments (Kline et al., 2009). A study by Kuusela et al. (1989) showed 
that C. jejuni binds to various other ECM proteins such as collagen I, III, IV and V. 
These proteins are found in the GIT although, to the authors’ knowledge, the proteins 
involved in collagen adhesion have not been identified for C. jejuni. The JlpA protein of 
C. jejuni binds to Hep-2 epithelial cells (Rubinchik, Seddon and Karlyshev, 2012). JlpA 
also starts a host inflammatory response by initiating the NF- κB and p38 MAP kinase 
production (Kawai et al., 2012). The gene Cj1349, contains fibronectin (Fn) type III 
domains, indicating a potential ability to adhere to fibronectin. This protein plays a role 
in adhesion to chicken epithelial cells (Flanagan et al., 2009). The Campylobacter 
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protein A (CapA protein) of C. jejuni plays a role in adhesion and invasion, with C. 
jejuni capA mutant genes showing reduced adhesion and invasion potential to Caco-2 
cells (Ó Cróinín and Backert, 2012). The Cj0091 protein of C. jejuni plays a role in 
adhesion to INT 407 cells, with mutants showing reduced adhesion ability (Oakland et 
al., 2011). The major outer membrane protein (MOMP) and a flagella subunit protein 
(FlaA) of C. jejuni also play a role in adhesion to INT 407 cells (Rubinchik, Seddon and 
Karlyshev, 2012). MOMP, as well as FlaA, is associated with adhesion to human histo-
blood group antigens (Mahdavi et al., 2014). Mutation analysis of the tylA gene of C. 
jejuni 81-176 resulted in a reduction in adhesion to human Caco-2 cells, and thus, it is 
also a potential adhesin. The Peb1 protein of C. jejuni is found to play a role in 
adhesion, with peb1 mutants showing a reduction in adherence to HeLa cells and a 
reduction in invasion to INT-607 cells (Ó Cróinín and Backert, 2012). The Peb4 protein 
is thought to be a molecular chaperone for adhesion proteins such as CadF (Ó Cróinín 
and Backert, 2012). Other potential adhesion proteins utilised by C. jejuni are CapB, 
which has amino acid sequence similarity to CapA, and P95. These have been 
associated with adhesion to Caco 2 cells in other pathogenic bacteria such as 
Haemophilus and Bordetella (Rubinchik, Seddon and Karlyshev, 2012).  
1.7.6 C. jejuni sequencing information 
To date, 33 species belonging to the genus Campylobacter have been recorded. 
Campylobacter belongs to the class Epsilonproteobacteria and the order 
Campylobacteria. The order includes the genera Helicobacter and Wolinella. The 
Campylobacter genera have genomes ranging from 1.6–2.0 Mb. The C. jejuni genome 
sequence tends to have high levels of genetic variations with hyper variable regions, 
many of which are involved in the biosynthesis of capsule, lipooligosaccharide (LOS) 
and flagella structures (Parkhill et al., 2000; Young, Davis and DiRita, 2007). Genomic 
variations tend to occur due to phase variation or insertions, deletions, duplications, 
30 
 
point or frameshift mutations (Parkhill et al., 2000; Young, Davis and DiRita, 2007). C. 
jejuni can also acquire DNA via transformation, transduction and conjugation (Johnson, 
Shank and Johnson, 2017). C. jejuni prefers taking DNA from closely related 
strains/species, rather than other bacterial populations (Young, Davis and DiRita, 2007). 
This is more common under low carbon dioxide and high cell density levels (Johnson, 
Shank and Johnson, 2017; Young, Davis and DiRita, 2007), indicating that 
environmental factors control the increase in DNA uptake, although the exact reasoning 
for increased horizontal gene transfer is unknown (Johnson, Shank and Johnson, 2017). 
The high genomic variability potentially contributes to the bacterium's propensity to 
develop antibiotic resistance. (Young, Davis and DiRita, 2007). 
1.8 Aims and objectives 
The aim of this study was to complete the genome sequence of L. fermentum 3872 in 
order to identify potential genes attributed to probiotic properties of the bacterium. The 
study also aimed to select a candidate gene that could be used for competitive exclusion 
experiments against C. jejuni strains 11168H and 81-176. 
Objectives of the study were to: 
1. Circularise the genome sequence of L. fermentum 3872. 
2. Check the quality of the L. fermentum 3872 genome assembly.  
3. Identify genes of L. fermentum 3872 potentially involved in the probiotic 
activity of the bacterium. 
4. Investigate whether putative CBP of L. fermentum 3872 binds to collagen I, a 
protein found on the epithelial lining of the GIT. 
5. Investigate the binding of C. jejuni strains 11168H and 81-176 to collagen I and 
identify the protein(s) involved in collagen I adhesion. 
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6. Determine whether recombinant CBP protein and L. fermentum 3872 inhibit 
binding of C. jejuni strains 11168H and 81-176 to collagen I. 
7. Identify whether C. jejuni strains 11168H and 81-176 growth is inhibited in the 
presence of L. fermentum 3872. 
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Chapter 2: Materials and Method 
2.1 Laboratory consumables: 
Laboratory consumables were purchased from Fisher Scientific and Sigma-Aldrich.  
2.2 Water 
Distilled water for microbiology work was obtained from the PureLab Option ELGA 
DV35 water purification device. For molecular biology work distilled water was 
obtained from Milli-Q Millipore Direct-Q UV. 
2.3 Growth media and supplements 
2.3.1 Growth media 
All media were made sterile by autoclaving at 121°C for 15 minutes unless otherwise 
stated. Nutrient media (powdered) were all suspended in water (ELGA DV35) and 
made using manufacturers’ guidelines. Additional supplements added during media 
preparation are indicated alongside the manufacturer of the media used below: 
De man, Rogosa, Sharpe (MRS) agar (Oxoid) and De man, Rogosa, Sharpe (MRS) 
broth (Oxoid) were prepared following the manufacturer’s instructions. 
Luria-Bertani (LB) Lennox broth (Fisher) was developed in accordance with the 
manufacturer's guidelines. Luria-Bertani (LB) agar was prepared by mixing 10 g LB 
broth Lennox (Fisher) and 7.5 g agar (Fluka) in 500 ml water (ELGA DV35). For some 
experiments, chloramphenicol (CAM; Sigma) was added to make a final concentration 
of 25 µg/ml. 
Columbia blood agar base (CBA; Oxoid) was prepared according to the manufacturer’s 
instructions. After sterilisation, the agar was cooled to about 50°C and supplemented 
with 5% defibrinated horse blood (Oxoid) and 0.2% Skirrow supplement (Oxoid). 
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Mueller-Hinton (MH) broth (Fluka) and Muller-Hinton (MH) agar (Fluka) were 
prepared in accordance with the manufacturer’s instructions in water (ELGA DV35). 
For agar well diffusion assay experiments, MH soft agar was prepared by mixing MH 
broth (Fluka) and 0.75% agar (Fluka). To store bacterial cultures at -80°C MH broth 
(Fluka) was mixed with 15% glycerol. 
For NEB express E. coli transformation, Super optimal broth with catabolite repression 
(SOC) medium (NEB) was used following manufacturers guidelines. The SOC medium 
was pre-sterilised by the manufacturer. 
2.3.2 Antibiotic supplements 
Premade chloramphenicol (CAM) in a concentration of 34 mg/ml (purchased from 
Sigma) was stored at -20°C. A final concentration of 25 µg/ml was used for 
experiments. Skirrow supplement (Oxoid) was made in accordance with the 
manufacturer’s instructions using Milli-Q water. Milli-Q water was used as it contained 
a 0.22 µm filter for sterilisation purposes. The Skirrow supplement was stored at -20°C. 
2.4 Buffers and reagents 
2.4.1 PBS buffer 
Phosphate buffered saline (PBS) (Fisher) was made to 1x in water (ELGA DV35) and 
sterilised by autoclaving. 
To store bacterial culture, glycerol PBS solution was made by mixing 1x PBS (Fisher) 
with a final concentration of 15% glycerol (Fisher). 
2.4.2 Western blot buffers 
Tris-buffered saline (TBS) 10x concentrate was made by adding 18.2 g of 
Tris(hydroxymethyl)amino-methane (Sigma) with 87 g NaCl (Sigma) in 900 ml in 
water (ELGA DV35). The buffer was then adjusted to a pH of 8 using 1M hydrochloric 
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acid (HCl; Sigma) and made to 1 L in water (ELGA DV35). A 1x dilution was used for 
all experiments. 
Tris-buffered saline Tween (TBST) 1x was made by adding 0.1% Tween 20 (Sigma) to 
1x TBS.  
Transfer buffer was made by mixing 3 g Tris(hydroxymethyl)amino-methane (Sigma) 
to 15 g of Ultra-Pure Glycine (National Diagnostics) to which 800 ml of water (ELGA 
DV35) was added. Two hundred millilitres of methanol was also added to the buffer to 
make a final volume of 1 L. The buffer was stored at 4°C. 
2.4.3 Enzyme linked immune absorbance assay (ELISA) buffers and consumables  
ELISA coating buffer was prepared by mixing 0.19 g Sodium Carbonate (Fisher) and 
0.37 g Sodium Bicarbonate (Sigma) in 125 ml Milli-Q water; pH 9.6. The buffer was 
filter sterilised using a 0.22 µm filter (Fisher). 
Phosphate buffered saline with tween 20 (PBST), used as a wash buffer for ELISA 
experiments, was prepared by adding tween 20 (Sigma) to a final concentration of 0.1% 
in sterile 1x PBS (Fisher). 
For ELISA experiments the plates used were 96-well flat bottom and transparent. The 
plates were either UV-treated Nunclon Delta (ThermoFisher Scientific), UV-treated 
High Bind Corning Costar and Untreated Med Bind Corning Costar plates. 
2.4.4 Silver stain reagents 
Gel fix reagent was made by mixing Milli-Q water with molecular biology grade 
ethanol (Fisher) and acetic acid (Fisher) at a ratio of 6:3:1 respectively. 
Ethanol wash was made by adding molecular biology grade ethanol (Fisher) to Milli-Q 
water for a final ethanol concentration of 10%. 
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Reaction stop reagent was prepared by adding acetic acid (Fisher) to Milli-Q water to 
get a 5% acetic acid concentration.  
2.4.5 Preparation of Collagen I 
Collagen I Bovine (Sigma) was dissolved in 0.1 M acetic acid (Fisher) for 1-3 hours at 
room temperature to obtain a concentration of 1 mg/ml collagen I. The solution was 
stored at 4°C before use.  
2.5 Bacterial growth and storage  
2.5.1 Bacterial strains and plasmid used for experiments 
L. fermentum 3872 was isolated from a healthy human female’s milk. As recorded by 
Lehri, Seddon and Karlyshev (2017a), the bacterium was deposited in the All-Russian 
Collection of Microorganisms at the Moscow regions in Pushchino, with the accession 
number VKM B-2793D.  
C. jejuni strains used for this study were 11168H and 81-176. C. jejuni 11168H is a 
hypermotile variant of C. jejuni NCTC 11168 and was isolated from human faeces 
(Karlyshev et al., 2002). C. jejuni 81-176 was originally isolated from raw milk, and is 
a highly virulent strain (Hu and Kopecko, 1999).  
NEB express E. coli, a derivative of E. coli BL21, was used for cloning experiments. 
NEB express E. coli is deficient in proteases Lon and OmpT and is not resistant to 
chloramphenicol (CAM) used for cloning experiments.  
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Figure 2.1. Diagram of the expression vector pBAD33. The recombinant gene is to be 
placed between the red boxed restriction enzymes XbaI and SphI on the MCS2 region.  
The expression vector pBAD33 was used for the protein expression experiment (Figure 
2.1). The circular plasmid is 5.3 kb in size and contains a PBAD promoter region that 
allows control of protein expression via regulation by arabinose. The plasmid also 
contains a chloramphenicol resistance gene for selection of transformed cells.  
2.5.2 Bacterial growth conditions 
Lyophilised L. fermentum 3872 was re-suspended in 1 ml PBS (Fisher) 1x, 50 µl of 
which was streaked onto MRS (Oxoid) agar to isolate single colonies. The bacteria were 
grown overnight at 37°C in an anaerobic container (BD GasPak), under anaerobic 
conditions. Three single colonies were re-streaked onto MRS agar (Oxoid) and grown 
overnight. Each of the three samples were stored in 15% glycerol-PBS (Fisher) at -
80°C.  
For experiments, ten microliters of L. fermentum 3872 culture stocks were plated onto 
MRS agar (Oxoid) plates and grown overnight at 37°C under anaerobic conditions. For 
agar well diffusion assay, L. fermentum 3872 was initially grown on MRS agar (Oxoid) 
under anaerobic conditions and then suspended in 10 ml MRS broth (Oxoid), the culture 
was then grown on a shaker at 120 rpm overnight. 
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C. jejuni strains 11168H and 81-176 culture stocks were stored in MH broth (Oxoid) 
with 15% glycerol (Fisher) at -80°C. Twenty microliters of the stock were aliquoted 
onto CBA agar (Oxoid) for growth. The strains were grown at 37°C in a microaerobic 
incubator (Don Whitley) overnight, under conditions 10 % CO2, 5% O2, and 85 % N2. 
C. jejuni was again restreaked onto CBA agar (Oxoid) plates and grown for 24 hours 
before use. 
NEB express E. coli was grown overnight on LB agar (Fisher) or in LB broth (Fisher) at 
37°C. For some cultures, the LB broth/agar was supplemented with CAM (25 µg/ml). 
Transformed E. coli culture stocks were stored at -80°C in 15% glycerol-PBS. 
All culture stocks were prepared from fresh one-day-old bacterial growth. 
2.6 Agarose gel electrophoresis  
Tris/Borate/EDTA (TBE) buffer 10x (BIO-RAD) was diluted to 1x in water (ELGA 
DV35), which was added to agarose (Fisher) to make a 1% agarose gel. The mixture 
was heated in a microwave and left to cool. Once cool, ethidium bromide 0.5 µg/ml 
(Fisher) was added to the solution, which was swirled to mix. The solution was poured 
into a gel tank (Fisher Scientific) with a 12 well comb and left to solidify. 
Electrophoresis was conducted in 1x TBE buffer (BIO-RAD) at 120 V for one hour 
using a VWR power unit. Blue gel loading dye (NEB) diluted to 1x was used to help 
load samples onto each well. For all agarose gel electrophoresis experiments, the DNA 
size molecular marker used was 2-log DNA Ladder (NEB). The gel was visualised 
using a G: BOX UV-transilluminator (Syngene) to excite the ethidium bromide. Image 
processing was conducted using GenSnap software (Syngene). 
2.7 DNA extraction 
Qiagen Gentra Puregene Yst/Bct kit was used to extract DNA from L. fermentum 3872, 
following the manufacturer's protocol. For Ion Torrent (Life Technologies) sequencing, 
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DNA was extracted from the confluent growth of two L. fermentum 3872 clonal isolates 
labelled clonal isolate 1 and 2. 
For PacBio RSII (Pacific Biosciences) sequencing, DNA was extracted from clonal 
isolate 1. The Qiagen Gentra Puregene Yst/Bct kit protocol was also modified, with L. 
fermentum 3872 being incubated for 30 minutes at 37°C in a customised lysozyme 
buffer. The buffer consisted of 20 mg/ml egg white lysozyme (Sigma) with 1% Triton 
(Sigma) and 10% TE (Sigma) in Milli-Q water. After incubation, the sample was spun 
down using an Eppendorf mini spin plus micro-centrifuge at 14,104 x g for two 
minutes, and then the supernatant was discarded. Cell lysis solution provided by the 
Qiagen Yst/Bct kit was supplemented with 20 µl of proteinase K (Invitrogen), 300 µl of 
which was added to the sample and incubated at 80°C for five minutes as per standard 
protocol. The sample was incubated in protein precipitation solution provided by the 
Qiagen Gentra Puregene Yst/Bct kit for one hour on ice followed by one hour 
incubation with RNase (Qiagen). The latter was done to remove protein and RNA 
contaminants as very pure samples are required for PacBioRSII sequencing due to the 
absence of a DNA amplification step during template preparation. 
E. coli plasmid extraction was conducted for cloning experiments. DNA was extracted 
using the QIAprep Spin Miniprep kit (Qiagen) following the manufacturer’s protocol.  
2.8 DNA quality assessment 
DNA quality and concentration were determined by using a NanoVue 
spectrophotometer (GE Healthcare Life Sciences), gel electrophoresis, Qubit 
fluorometer (Invitrogen), DropSense (Trinean) and Bioanalyzer 2100 (Agilent 
Technologies). 
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2.9 Next-generation sequencing 
2.9.1 Fragmentation and library preparation for Ion Torrent PGM sequencing 
L. fermentum 3872 clonal isolate 1 and 2 were sequenced using the Ion Torrent Personal 
Genome Machine (PGM; Life Technologies). DNA fragmentation and library 
preparation were conducted using NEBNext fast DNA fragmentation and library 
preparation kit for Ion Torrent (NEB). During the fragmentation step, the samples were 
incubated in NEBNext fragmentation master mix at 25°C for 10 minutes, followed by 
10 minutes heat inactivation of the fragmentation enzyme at 70°C. The rest of the 
protocol was followed in accordance with the kit’s guidelines.  
The protocol for 100 ng - 1 µg was followed for adapter ligation as the concentration of 
the DNA was above 100 ng. Standard protocol for clean-up of adapter ligated DNA was 
followed using AMPure XP Beads (Invitrogen). 
A 2% E-Gel cassette (Invitrogen) and an E-gel imaging device (Invitrogen) were used 
to select fragmented DNA of around the 490 bp mark, as recommended by the Ion 
Torrent 400 bp sequencing kit guidelines. Twenty microliters of L. fermentum 3872 
DNA from clonal isolate 1 and 2 were mixed with bromophenol blue loading dye 
(NEB) 1x. The samples were added to each E-Gel well. A 2-log DNA Ladder (NEB) 
was used as a molecular marker. The lower wells of the E-Gel cassette were filled with 
20 µl of Milli-Q water. The E-Gel was run until the ladder reached the 490 bp mark at 
which time the lower wells were filled with 20 µl of Milli-Q water. The E-Gel was run 
for another two minutes to extract DNA fragments of around 490 bp in size.  
The fragmented samples, with adapters attached, were amplified using polymerase 
chain reaction (PCR). The protocol for 100 ng - 1 µg was followed as recommended by 
the NEBNEXT fast DNA fragmentation and library preparation kit’s instructions (NEB) 
and the reaction was made to 50 µl. The PCR cycling conditions are shown in Table 2.1. 
40 
 
Table 2.1. PCR cycling conditions used for adapter ligated DNA. 
Initial Denaturation  98°C (30seconds) 1 cycle 
Denaturation  
Annealing 
Extension 
98°C (10seconds) 
58°C (30seconds) 
72°C (30seconds) 
10 cycles 
Final extension  72°C (5minutes) 1 cycle 
 
The amplified library was cleaned using 50 µl of Ampure Xp beads (Invitrogen), 
following the NEBNEXT fast DNA fragmentation and library preparation kit protocol.  
Bioanalyzer 2100 (Agilent Technologies) and the Agilent DNA 1000 kit (Agilent 
Technologies) were used to determine the size of the DNA fragment and the 
concentration. Two readings were taken for each amplified sample in order to take 
pipetting error into consideration. The samples were prepared in accordance with the 
manufacturer's protocol. 
2.9.2 Template preparation and sequencing for Ion Torrent PGM  
Three sequencing runs were conducted on the Ion Torrent PGM (Life Technologies) for 
L. fermentum 3872. Two sequencing runs were for clonal isolate 1 and one sequencing 
run was for clonal isolate 2. 
Ion PGM template OT2 400 bp kit (Life Technologies) was used for template 
preparation. Clonal 1 sequencing run 1 concentration was initially made to 26 pM/L as 
recommended by the kit’s protocol. This was reduced to 20 pM/L for sequencing run 2. 
The DNA for clonal isolate 2 was made to 26 pM/L. The Ion One Touch 2 (Life 
Technologies) was used for emulsion PCR and sample recovery. The Ion Torrent ES 
system (Life Technologies) was used for sample enrichment. For sequencing, the Ion 
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PGM 400 bp sequencing kit (Life Technologies) and the Ion 314v2 chip (Life 
Technologies) were used following the manufacturer's protocol. 
2.9.3 PacBio RSII sequencing 
PacBio RSII sequencer (Pacific Biosciences) was used to sequence L. fermentum 3872 
clonal isolate 1. This generated long reads used for genome scaffolding. The P6-C4 
sequencing kit (Pacific Biosciences) and a single SMRT-Cell chip (Pacific Biosciences) 
were used. Template preparation and sequencing was conducted by the TGAC genome 
analysis centre. 
2.9.4 Optical mapping 
A restriction digest map (optical map) of L. fermentum 3872 clonal isolate 1 was created 
by OpGen (http://www.opgen.com/sequencing/, 2017) using an Argus Optical mapping 
system with restriction enzyme SpeI. The data generated was used for genome assembly 
validation for L. fermentum 3872 and to aid in genome completion.  
2.10 Bioinformatics 
2.10.1 Genome sequence assemblers used 
For L. fermentum 3872 genome assembly, the Ion Torrent generated reads were de novo 
assembled using SPAdes V3.5.0 (Bankevich et al., 2012) and MIRA V3.4.2.0 
(Chevreux et al., 2004) on the Ion Torrent server. The reads were also de novo 
assembled on the CLC Genomics Workbench (CLC GWB) programme. Default CLC 
GWB assembler parameters (mismatch cost 2, length fraction 0.5, insertion cost 3, 
deletion cost 3, and similarity fraction 0.8) were used, the minimum contig size was set 
to 1 kb. To assess genome assembly quality, read mapping was conducted using CLC 
GWB with default, stringent and very stringent read mapping parameters. As mentioned 
by Lehri, Seddon and Karlyshev (2017b), stringent read mapping parameters had a 
length fraction value of 0.8 and a similarity fraction of 0.9. Very stringent read mapping 
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parameters used a length fraction of 0.9 and a similarity fraction of 1, with all other 
parameters kept at default. Mapsolver software was used to align sequence-generated 
contigs to the SphI restriction digest map produced by OpGen. The software was run 
using default parameters. 
2.10.2 Identifying and assembling the plasmid pLF3872  
Contigs generated by MIRA V3.4.2.0 (Chevreux et al., 2004) and CLC GWB 
assemblers were combined using CISA contig integrator (Lin and Liao, 2013). The 
quality of the assembly was determined by read mapping using CLC GWB with default 
parameters. Using the non-redundant NCBI database, the NCBI BLASTN similarity 
search tool identified that some of the contigs aligned to plasmid sequences plca36 
(CP000935.1; Lactobacillus casei str. Zhang), pWCFS103 (CR377166.1; Lactobacillus 
plantarum WCFS1) and plasmid 1 (CP002392.1) from Lactobacillus paracasei subsp. 
Reads were mapped onto the closest plasmid sequence plca36 to generate consensus 
sequences. To circularise the contig, the consensus sequence was merged with the Ion 
Torrent assembled contig. To confirm that the plasmid sequence was circular, sequence 
homology between reads from one end of the sequence was found with the other end of 
the sequence. 
2.10.3 Assembly of the chromosomal sequence (misassembled) 
The Ion Torrent PGM (Life Technologies) generated sequence read data were de novo 
assembled using CLC GWB, SPAdes V3.5.0 (Bankevich et al., 2012) and MIRA 
V3.4.2.0 (Chevreux et al., 2004) assemblers. The contigs produced by the sequencing 
runs were combined using CISA contig integrator (Lin and Liao, 2013). Default read 
mapping parameters were used to determine sequence quality. Contigs were split if read 
mapping indicated regions where the nucleotide sequence consisted of unaligned read 
ends, gaps in read mapping, or low read coverage. The nucleotide sequence ends of 
each contig were then selected and run using BLASTN and a non-redundant database. If 
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a match was identified, the matching sequence with the highest hit was extended and 
added to its corresponding contig. After extension, some contigs could be joined by 
finding overlaps between the ends of contigs. Each extended/joined contig was verified 
using read mapping (default parameters). Further contiguation was also conducted by de 
novo assembling unmapped reads (collected after read mapping) and extending/joining 
contigs. The remaining contigs were verified using default, stringent and very stringent 
read mapping parameters using CLC GWB. After contiguation, the remaining contigs 
were aligned to the closest correctly assembled reference sequence Lactobacillus 
fermentum IFO 3956 using Contiguator 2.7.4 (Galardini et al., 2011) to design primers 
for Sanger sequencing, in order to fill in the remaining gaps. Contiguator orientates and 
aligns contigs by assuming that even if there are strain-to-strain nucleotide variations, 
the overall genome sequence organisation is similar to a closely-related reference 
sequence. BLASTN with a cut-off value of 1e-20; and a .ptt file obtained from the 
NCBI GenBank website for L. fermentum IFO 3956 was used for alignment. The .ptt 
file improves sequence alignment accuracy by also looking for amino acid homology 
between sequences.  
2.10.4 Correct chromosomal assembly 
The genome sequence was completed using a hybrid sequencing approach. This 
combined long low coverage reads generated by the PacBio RSII (Pacific Biosciences) 
sequencing machine with short high coverage reads generated by the Ion Torrent PGM 
(Life Technologies). The size of the long reads, which are on average >14 kb in length, 
results in less sequencing gaps, although these reads are error-prone due to low read 
coverage and poor base calling capability (Reuter, Spacek and Snyder, 2015). The Ion 
Torrent PGM reads are less error-prone because of high read coverage but generate 
multiple contigs as the machine can only accurately sequence for a length of 
approximately 400 bp. 
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As described in our articles (Lehri, Seddon and Karlyshev, 2017a; Lehri, Seddon and 
Karlyshev, 2017b), sequencing reads generated by the PacBio RSII (Pacific 
Biosciences) sequencer were assembled using the HGAP3 (hierarchical genome 
assembly process) pipeline, which utilises the CELERA assembly programme (Myers et 
al., 2000). Large redundant sequenced regions for the chromosomal sequence and 
plasmid were determined and removed using Artemis Comparison Tool (ACT) (Carver 
et al., 2005). To confirm that the chromosomal sequence was circular, homology 
between reads from one end of the sequence to the other end of the sequence was found. 
Ion Torrent reads were mapped onto the assembled sequence using default read 
mapping parameters on CLC GWB to correct nucleotide errors. The assembly was also 
verified using stringent and very stringent read mapping parameters on the CLC GWB. 
Reads from clonal isolate 2 from the Ion Torrent sequencing run were mapped onto the 
complete genome sequence using CLC GWB with default read mapping parameters to 
determine if there were clonal variations. 
2.10.5 Annotation of the genome  
As described in Lehri, Seddon and Karlyshev (2017a), once the genome of L. 
fermentum 3872 was complete, it was annotated using RAST (Overbeek et al., 2014), 
PROKKA (Seemann, 2014), BASys (Van Domselaar et al., 2005), and the NCBI 
GenBank annotation pipeline (Angiuoli et al., 2008). Annotation irregularities (e.g. 
truncated coding sequences, or missing gene annotations) between the tools mentioned 
above were detected and corrected using Geneious software (Kearse et al., 2012).  
2.10.6 Genome sequence analysis 
The LASTZ programme (Harris RS, 2007), run on Geneious software (Kearse et al., 
2012) was used to compare the chromosomal sequence of L. fermentum 3872 to that of 
other circular L. fermentum spp genomes, namely L. fermentum strains F6, IFO 3956, 
and CECT 5716. This would allow identification of unique regions and nucleotide 
45 
 
variations between L. fermentum 3872 and L. fermentum spp used for comparison. 
Spine/AGEnt Pan-core analysis software with default parameters (Ozer, Allen and 
Hauser, 2014) was used to identify unique genes of L. fermentum 3872 along with genes 
that are common among L. fermentum strains F6, and IFO 3956. PHAST (Zhou et al., 
2011) software was used to identify any prophage-related regions of the L. fermentum 
3872 genome, while BAGEL3 (Heel et al., 2013) was used to identify bacteriocin 
encoding regions.  
2.11 Cloning techniques used for expression of collagen binding protein  
2.11.1 Primer design 
Primer pairs were designed to PCR amplify the cbp gene of plasmid pLF3872 (Table 
2.2). Primers were also designed to check for potential PCR errors (Table 2.3). Sigma 
Genosys synthesised all primers.  
To generate sticky ends, XbaI and SphI restriction enzyme sites and a Shine-Dalgarno 
(S-D) sequence were incorporated to the cbp sequence. Initially, the cbp gene had a C-
terminal hexa histidine tag. This was then changed to an N-terminal hexa histidine tag 
and by the removal of a leader peptide encoding region. Primers were also made to 
amplify the adhesion domain of the CBP protein (partial CBP), with an N-terminal hexa 
histidine tag and no leader peptide. To identify and remove the leader peptide sequence, 
Softberry software ProtCompB 
(http://www.softberry.com/berry.phtml?topic=pcompb&group=programs&subgroup=pr
oloc, 2017) was used. NCBI CDD was also used to determine the CBP ‘A domain’, for 
construction of the partial cbp gene sequence. The forward primer used to construct the 
partial cbp gene sequence was the same as that used for the construction of the full cbp 
gene sequence, labelled CBPFOR2 in Table 2.2. 
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Table 2.2. Primers used for cloning experiment.  
 
Table 2.3. Primers used for recombinant cbp gene sequence nucleotide validation.  
Primer Name primer sequence (5’-3’) 
pBADFor GATTAGCGGATCCTACCTGACGC 
pBADRev GCTTCTGCGTTCTGATTTAATC 
CBPseq1 CTCAGTTCCAGATTCAGCCA 
CBPseq2 CTGAGGGTTATGCAATTGTCTAC 
CBPseq3 GGCATCAGACAACTGGAAGTAC 
 
2.11.2 Preparing primers for PCR 
Lyophilised primers were spun down and then reconstituted in Milli-Q water to make 
100 µM stock. Working primer solutions were diluted to 10 µM in Milli-Q water. All 
primers were stored at -20°C. 
Primer name Primer 
description 
primer sequence (5’-3’) 
CBPREV1 CBP reverse 
primer (C- 
terminal 
histidine tag) 
ATGAGCATGCTCAATGGTGATGGTGATGGTGAATAGTAAA
TCTACTTATAACTACTAAACC 
CBPFOR1 CBP forward 
primer (C- 
terminal 
histidine tag)  
AACAATCTAGAAGAAGGAGGCAACAGTATGAGTAATAAA
TCTAGGCATCGTCGAC 
 Primer Name primer sequence (5’-3’) 
CBPREV2 CBP reverse 
primer (N- 
terminal 
histidine tag) 
ATGAGCATGCTCAAATAGTAAATCTACTTATAACTACTAA
ACC 
CBPFOR2 CBP forward 
primer (N- 
terminal 
histidine tag) 
ATATGCTTCTAGAAGAAGGAGGCAACAGTATGCACCATCA
CCATCACCATGATAGCAAGACAAATATTACTCAGAACGGT
ACG 
CBPREV3 Partial CBP 
reverse primer 
(N- terminal 
histidine tag) 
CTTTGCATGCTCAATTTATAGTTAAACTATGATTATATCCA
TTAG 
47 
 
2.11.3 PCR amplification 
For cloning experiments, PCR was conducted using Q5 High-Fidelity DNA polymerase 
(NEB). The reaction was prepared as described in Table 2.4. The dNTPs were 
purchased from Fisher. Thermocycler conditions are described in Table 2.5.  
Table 2.4. PCR reaction mixture for cbp gene amplification 
5x Q5 reaction buffer 10 µl  
10 mM dNTPs 1 µl  
10 µM forward primer 1 µl  
10 µM reverse primer 1 µl  
DNA 1 µl  
Q5 High-Fidelity DNA polymerase 0.5 µl  
Milli-Q water 35.5 µl 
Total 50 µl 
 
Table 2.5. PCR thermocycler conditions for cbp gene amplification. 
 Temp Time 
Initial denaturation  98°C 30 seconds 
20 cycles 98°C 
55°C 
72°C 
10 seconds 
30 seconds 
4 minutes 
Final extension 72°C 2 minutes 
 
PCR products were analysed and sample quality was determined by gel electrophoresis. 
For cloning experiments, PCR products were purified using the QIAquick PCR 
purification kit (Qiagen) following standard manufacturer instructions. The sample was 
eluted using 30 µl of elution buffer.  
2.11.4 Restriction analysis  
Sticky ends were generated using restriction enzymes XbaI and SphI on both the insert 
DNA and pBAD33 vector with NEB buffer 4 diluted to 1x. The enzymes were 
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incubated for one hour at 37°C, and then heat inactivated at 65°C for 20 minutes. The 
reaction mixture is described in Table 2.6. 
Table 2.6. Reaction mixture for restriction digestion of insert and vector DNA used for 
cloning experiments. 
  Insert DNA Vector DNA 
NEB buffer 4 10x 5 µl 2.5 µl 
XbaI 1 µl 1 µl 
SphI 1 µl 1 µl 
Sample DNA 20 µl 10 µl 
dH2O 23 µl 10.5 µl 
Total 50 µl 25 µl 
 
2.11.5 Gel extraction  
Gel extraction was conducted using the Invitrogen Purelink Quick Gel extraction kit. 
Restriction digested samples were run on a 1% agarose gel to separate and remove 
unwanted oligonucleotide fragments. A scalpel was used to excise a band from the gel 
using long UV wavelength on G: BOX (Syngene). To determine the appropriate amount 
of gel solubilisation buffer, the cut gel sample was weighed in a Lo-Bind 1.5 ml 
Eppendorf. The rest of the protocol was followed in accordance with the manufacturer's 
guidelines. After gel extraction, sample concentration was determined using a NanoVue 
spectrophotometer (GE Healthcare Life Sciences).  
2.11.6 Ligation and transformation 
Ligation of vector and insert was conducted using the NEB quick ligation kit following 
the manufacturer's protocol. 
NEB express E. coli was transformed with the ligation mixture. Standard manufacturer 
protocol for transformation was followed. As per the manufacturer’s protocol, after heat 
shock, SOC medium (NEB) was added to the mixture of vector and competent E. coli. 
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The mixture was then diluted 10x with SOC medium (NEB). Fifty microliters of both 
the diluted and undiluted mixture were grown overnight on separate 25 µg/ml CAM 
supplemented LB agar (Fisher) plates. After growth, single colonies were selected and 
grown to confluence for plasmid extraction and analysis. 
2.11.7 Analysis of transformants 
To confirm the presence of the cbp gene on vector pBAD33. The plasmid DNA was 
extracted using QIAprep spin miniprep kit (Qiagen) and a restriction digest was 
conducted by mixing 12 µl NEB buffer 4 diluted to 1x with 1 µl of XbaI and SphI, 
along with 1 µl of plasmid DNA. The samples were incubated for 30 minutes at 37°C 
and then run on an 1% agarose gel.  
2.11.8 Validation of the recombinant cbp gene 
The recombinant cbp gene sequence was validated using Sanger sequencing performed 
by GENEWIZ. The primers used are shown in Table 2.3. Chromas software 
(Technelysium) was used to determine the quality of the Sanger sequencing data, after 
which the Sanger sequenced data was compared to that generated by high-throughput 
sequencing.  
2.12 CBP protein expression 
Transformed NEB express E. coli was grown overnight at 37°C on LB agar (Fisher), 
supplemented with 25 µg/ml CAM. The E. coli was suspended in 10 ml LB broth 
(Fisher) supplemented with 25 µg/ml CAM and grown overnight in a shaker at 120 rpm 
and 37°C. The 10 ml culture was transferred into 250 ml of LB broth (Fisher) and 
allowed to reach an OD600 of 0.6 at 37°C on a shaker at 120 rpm. The sample was 
induced with 0.1% L-arabinose (Acros Organics) for three hours. Before and after 
induction, OD600 measurements were taken along with one millilitre aliquots of E. coli. 
The aliquots were spun down using an Eppendorf mini spin plus micro-centrifuge at 
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14,104 x g for one minute and then the supernatant was removed. NuPAGE LDS buffer 
x1 (Invitrogen) was added to the sample for lysis and SDS-PAGE analysis. The stock 
samples were spun down using an Eppendorf centrifuge 5810R at 3220 x g for 10 
minutes at 4°C to remove the LB broth. The spun down sample was either stored at -
80°C or protein purification was conducted immediately. Initially, a small-scale protein 
purification using the MagneHis protein purification kit (Promega) was conducted 
following manufacturer’s guidelines. This was preceded by large-scale protein 
purification. For large scale purification, NEB express E. coli was initially lysed in 5 ml 
of a mixture of 1 mg/ml egg white lysozyme (Sigma), protease inhibitor cocktail 
(Sigma) of which 1 ml was added for every 20 g of E. coli, and 3 µl DNAse I (Promega) 
in wash buffer (QIAGEN fast start kit) for 30 minutes at room temperature. Ultimately, 
for large scale protein purification, 5 ml of 10x Promega fastbreak cell lysis reagent 
supplemented with 3 µl DNAse I was added to the induced E. coli as the initial custom 
lysis buffer resulted in degraded protein. For every 10 ml of E. coli suspension, 1 ml of 
10x Promega fastbreak cell lysis reagent was added, with 20 minutes’ incubation at 
room temperature.  
Protein purification was conducted using His60 Ni Superflow gravity column 
(Clonetech). The column was equilibrated at room temperature and then washed with 
2.5 ml wash solution (Qiagen). Clarified lysate was added to the column and inverted 
three times. The lysate was incubated in the column for five minutes at room 
temperature. The column was then washed twice with 5 ml of wash solution (Qiagen). 
The protein was eluted using 3 ml of elution buffer (Qiagen), collecting in 1 ml 
fractions.   
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2.13 Protein detection 
2.13.1 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
NuPAGE LDS 1x sample buffer (Invitrogen) was added to samples and heated for 10 
minutes at 70°C. The samples were then loaded on to NuPAGE Novex 4%–12% Bis-
tris gel (Invitrogen). The gel was run at 150 V for one hour in NuPAGE MOPS SDS 
running buffer 1x (Invitrogen). An X-cell sure-lock mini gel electrophoresis unit 
(Invitrogen) was used for running the gel. The molecular marker used was PageRuler 
Plus Prestained protein ladder (FisherScientific). 
2.13.2 Coomassie staining 
Simply-blue safe stain (Invitrogen) was used after running SDS-PAGE for Coomassie 
staining following standard manufacturer’s guidelines. Gel images were taken using G: 
Box (Syngene) with the GenSnap (Syngene) software. 
2.13.3 Western blot 
After running an SDS-PAGE, the NuPAGE Novex 4%-12% Bis-tris gel (Invitrogen) 
was placed in transfer buffer (see 2.4.2 for recipe) for 15 minutes, the amount added 
was enough to cover the gel. An Immobilon –P 0.45 µM polyvinylidene difluoride 
membrane (PVDF; Millipore) used for blotting was activated in 100% methanol for 15 
seconds and washed twice for two minutes in water (ELGA DV35). The membrane was 
placed in transfer buffer for five minutes. Six western blot filter papers (ThermoFisher 
Scientific) were incubated in transfer buffer for 15 minutes. A semi-dry transfer unit 
(Sigma) was used at 15 V for 90 minutes to blot the membrane with protein(s). Once the 
transfer was complete, the membrane was washed twice for 10 minutes in 15 ml TBS 
buffer diluted to 1x (see 2.4.2 for recipe). The membrane was then blocked using 3% 
BSA (Sigma) in 20 ml 1x TBS and incubated for one hour at room temperature. The 
membrane was washed twice in 15 ml TBST buffer (see section 2.4.2 for recipe), and 
then once in 15 ml TBS 1x for 10 minutes. Then Penta-His primary antibody (Qiagen) 
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(0.2mg/ml) was diluted to 1:1000 in TBS 1x and 3% BSA (Sigma). The membrane was 
incubated with 10 ml of the primary antibody solution for one hour at room 
temperature. After incubation, the membrane was washed twice in 15 ml TBST 
followed by a single 15 ml TBS 1x wash for 10 minutes. The membrane was incubated 
with Anti-mouse IgG, HRP-linked secondary antibody (cell signalling technologies) 
diluted to 1:1000 in 10 ml TBS 1x and 10% non-fat dried milk powder (Marvel 
original). The membrane was incubated with secondary antibody for one hour at room 
temperature. Once incubated, the membrane was washed four times with 15 ml TBST 
for 10 minutes each. SuperSignal West Pico Chemiluminescent substrate 
(ThermoFisher Scientific) was used for detection of protein following manufacturer’s 
guidelines. Syngene G: Box was used for detection of protein(s) using GenSnap 
(Syngene) software. 
2.13.4 Silver staining 
Silver staining was used to visualise protein samples obtained from Co-
Immunoprecipitation (Co-IP) experiments. Silver staining is a highly sensitive 
visualisation procedure that allows for the detection of proteins of less than 0.25 ng. The 
sample was initially prepared by adding 7.5 µl of sample to 2.5 µl of 4x NuPAGE LDS 
sample buffer (Invitrogen), and then heated for 10 minutes at 70°C. Ten microliters of 
the sample were loaded onto a NuPAGE Novex 4%–12% Bis-tris gel (Invitrogen). The 
gel was run following the standard SDS-PAGE protocol described above. Samples were 
stained using a Pierce silver stain kit for mass spectrometry (ThermoFisher Scientific) 
following the manufacturer's protocol. The gel was visualised using a Syngene G: Box 
(Syngene) using GenSnap (Syngene) software. 
2.14 BCA assay 
Protein concentration was determined using a Pierce BCA protein assay kit 
(ThermoFisher Scientific) following the manufacturer's guidelines. Bovine serum 
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albumin (BSA) provided by the kit was diluted to varying concentrations and used as a 
protein standard for determining concentration. A line of best fit of the absorbance 
generated by the BSA against the concentration of BSA used was made using a 
Microsoft Excel spreadsheet. The absorbance of the query protein was then used against 
the line of best fit to determine the concentration of the query protein. The absorbance 
was read at 562 nm using a Tecan Infinite M200 Pro microplate reader. 
2.15 Enzyme-linked immuno absorbance assay experiments 
For all ELISA experiments, 96-well plates were coated with 100 µl (0.36 µg/well) of 
collagen I (Sigma) at 4°C overnight. The wells were washed twice with 200 µl PBST 
(section 2.4.3 for recipe) and then blocked with 200 µl 2% BSA (Sigma) in PBS for one 
hour at room temperature. The wells were washed three times with 200 µl PBST, and 
then 100 µl of samples (CBP, bacteria or PBS) were incubated on the plates at 37°C for 
one hour in an incubator. If C. jejuni was used a microaerobic incubator (Don Whitley) 
was used. The wells were washed four times with 200 µl PBST and then incubated with 
100 µl primary antibody diluted to 1:1000 in PBS with 0.05% Tween 20 (Sigma) and 1 
mg/ml BSA (Sigma), see Table 2.7 for antibodies used. The plate was incubated at 37°C 
and washed four times with 200 µl PBST. This was followed by incubation with 100 µl 
secondary antibody diluted to a ratio of 1:1000 in PBS with 0.05% Tween 20 (Sigma) 
and 3% BSA (Sigma) for one hour at 37°C, see Table 2.7 for antibodies used. The wells 
were washed another four times using 200 µl PBST, followed by incubation with 100 µl 
of 3,3′,5,5′-Tetramethylbenzidine substrate (TMB) at room temperature for 15 minutes. 
The reaction was stopped with 1M H2SO4 and the optical density was read at 450 nm 
using a Tecan Infinite M200 Pro microplate reader. After each washing step, the wells 
were tapped gently three times on tissue paper. 
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Table 2.7. Antibodies used for each ELISA experiment. 
ELISA experiments Primary antibody  Secondary antibody 
CBP detection  Thermo Scientific Pierce 6x-His 
Epitope Tag monoclonal 
primary antibody (MA1-21315) 
Cell Signaling Technology anti-
mouse IgG, HRP-linked 
secondary polyclonal antibody 
(#7075) 
C. jejuni binding assay, and 
competition between C. jejuni 
and CBP in binding to 
collagen I 
Bio-Rad; Campylobacter jejuni 
monoclonal primary antibody 
(BGN/2E10) 
Bio-Rad; Goat anti-mouse 
polyclonal secondary antibody 
(STAR87P) 
Whole cell competition 
between C. jejuni and L. 
fermentum 3872 in binding to 
collagen I 
Antibodies-online; anti-
Campylobacter jejuni (PEB1) 
polyclonal primary antibody 
(ABIN488113) 
SAB; Goat-anti-rabbit IgG 
polyclonal HRP conjugated 
secondary antibody (L3012) 
 
2.15.1 Sample preparation for ELISA experiment 
For ELISA experiments, bacteria were suspended in PBS. The amount of bacteria added 
to each well was determined by the optical density at 600 nm, measured using a cell 
density meter (WPA Biowave-CO800). 
2.15.2 Choosing optimal ELISA plates 
ELISA experiments were initially conducted to determine the ideal type of plates and 
BSA to use for future experiments. The plates tested were UV-treated Nunclon Delta 
(ThermoFisher Scientific), UV-treated High Bind Corning Costar and Untreated Med 
Bind Corning Costar plates. Standard ELISA protocol was followed, as described in 
section 2.15. CBP (0.36 µg/well) was prepared in PBS for the sample incubation step of 
the ELISA experiment. BSA from Sigma (99% purity) and Acros Organics (western 
blot grade) were coated on wells and used as negative controls. For all future ELISA 
experiments, untreated Med Bind Corning Costar plates and BSA (Sigma) were used. 
2.15.3 Choosing buffers for coating 
To determine the optimal type of buffer for coating Collagen I (Sigma) onto 96-well 
plates for ELISA experiments, coating was performed under acidic and basic 
conditions. To achieve a pH of 3.6, collagen I (Sigma) was made to 3.6 µg/ml in 
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distilled Milli-Q water. To achieve a pH of 9.6, collagen I (Sigma) was made to 3.6 
µg/ml in ELISA coating buffer (see section 2.4.3 for recipe). One hundred microliters of 
the samples were added to each well. For the experiment, standard ELISA protocol was 
followed. For the incubation step, CBP 0.05, 0.2, and 0.36 µg/wells were prepared in 
PBS. BSA (Sigma) coated wells were used as negative controls. For all future ELISA 
experiments, the ELISA coating buffer (pH 9.6) was used. 
2.15.4 CBP binding assay 
ELISA experiments were conducted to determine whether CBP would bind to collagen 
I. Wells were coated with collagen I and BSA (negative control) using 0.36 µg/well 
prepared in PBS. ELISA protocol as described in section 2.15 was followed. CBP in 
PBS of 0.05, 0.2, and 0.36 µg/wells were used for the incubation step.  
2.15.5 C. jejuni 11168H and 81-176 binding assay 
To determine whether C. jejuni binds to collagen I, C. jejuni suspensions were made to 
an OD600 of 1, 0.1 and 0.01 in PBS, of which 100 µl were added to each well. The final 
amount of C. jejuni bacterial suspension added to each well was 2 x 108 CFU/well, 2 
x107 CFU/well and 2 x 106 CFU/well. Negative controls used BSA (Sigma) coated 
wells incubated with C. jejuni strains 11168H and 81-176.  
2.15.6 Determining whether CBP and C. jejuni strains 11168H and 81-176 compete 
with each other in binding to collagen I 
To discover whether CBP inhibited C. jejuni 11168H and 81-176 binding to collagen I, 
0.36 or 2 µg/well of CBP was mixed with either C. jejuni 11168H or 81-176 strains at 2 
x 107 CFU/well. Controls used for the experiment included collagen I or BSA (Sigma) 
coated wells with CBP, C. jejuni or PBS incubated to each well. 
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2.15.7 Whole cell competition between L. fermentum 3872 and C. jejuni strains 
11168H and 81-176 
To determine whether L. fermentum 3872 inhibits C. jejuni attachment to collagen I, L. 
fermentum 3872 suspension was made to an OD600 of 0.5 (1 x 10
8 CFU/ml), 1 (2 x 108 
CFU/ml), 5 (1 x 109 CFU/ml), and 9 (2 x 109 CFU/ml) mixed with C. jejuni strains of 
OD600 0.1 (2 x 10
8 CFU/ml) in PBS. One hundred microliters of the samples were added 
to wells with a ratio of L. fermentum 3872 to C. jejuni of 1:2, 1:1, 5:1 and 10:1. The 
controls used were L. fermentum 3872, C. jejuni, and PBS incubated in collagen I 
coated wells where appropriate.  
2.16 Agar well diffusion assay 
An agar well diffusion assay was conducted to find out if L. fermentum 3872 cell-free 
supernatant inhibited the growth of C. jejuni 11168H and 81-176 strains. Following the 
method described by Nishiyama et al. (2014). One-day C. jejuni cultures were made to 
an OD600 of 1 in PBS and 300 µl of the suspension was added on to 15 ml soft MH agar 
(0.75%) at 41°C. The agar was poured on top of 20 ml solidified MH agar. Overnight 
cultures of L. fermentum 3872 were grown in 10 ml MRS broth in a microaerobic 
incubator at 37 °C. The L. fermentum 3872 culture was then filter sterilised using a 0.22 
µm filter (Fisher). Four 10 mm wells were made on the agar plate. The MH agar wells 
were filled with 300 µl of MRS broth (pH 6.3) used as a control, L. fermentum 3872 
supernatant (pH 4.2), pH adjusted L. fermentum 3872 supernatant adjusted by 1M 
NaOH (pH 6.3), or boiled L. fermentum 3872 supernatant at 100°C for five minutes (pH 
4.2).  
2.17 Detection of C. jejuni proteins involved in collagen I adhesion 
2.17.1 Co-immunoprecipitation assay 
A Dynabeads Co-Immunoprecipitation Kit (Co-IP; Life Technologies) was used to 
investigate any collagen I interacting proteins expressed by C. jejuni strains 11168H and 
57 
 
81-176. Each mg of beads was coated with 15 µg of collagen I (Sigma). To couple 
collagen I to the beads, they were incubated for 24 hours on a rotator at 37°C. The rest 
of the protocol was followed as recommended by the manufacturer. 
To prepare bacterial lysates for incubation with collagen I-coated beads, 20 ml 
suspensions of OD600 1 in PBS was made for C. jejuni strains 11168H and 81-176. To 
remove the supernatant, the suspensions were spun down in an Eppendorf centrifuge 
5810R at 3220 x g for 10 minutes at 4°C. IP buffer 4x supplied with the Dynabeads Co-
IP Kit was diluted to 1x in Milli-Q water, to which 100 mM molecular biology grade 
NaCl (Sigma) and 5 µl of DNAse 1 (Promega) were added to make a lysis buffer. A 
ratio of cell weight to lysis buffer volume of 1:9 was mixed as recommended by the 
manufacturer and incubated on ice for 10 minutes and then sonicated (Soniprep 159) on 
ice with 10-second bursts of sonication and 30-second rest cycles for 10 cycles. The 
clarified lysate was spun down at 4°C at 3220 x g using an Eppendorf centrifuge 5810R 
for five minutes. For each experiment, the clarified lysate was mixed with 2 mg of 
collagen I-coupled beads. The clarified lysates of C. jejuni 11168H and 81-176 were 
incubated for one or three hours at room temperature at 30 rpm in a rotator 
(ThermoFisher Scientific). The rest of the protocol was completed as recommended by 
the manufacturer. 
2.17.2 Mass spectrometry analysis 
Mass spectrometry on Co-IP eluates for C. jejuni strains 11168H and 81-176 was 
performed by the Cambridge Centre for Proteomics Core Service.  
SDS-PAGE was run using MOPS SDS running buffer 1x prepared with Milli-Q water. 
Initially, staining was conducted using Coomassie, although the approach was 
unsuccessful. Therefore, a silver stain was run using the Pierce Silver Stain kit for mass 
spectrometry (ThermoFisher Scientific) following the manufacturer's protocol. All 
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buffer exchanges and gel handling were conducted with fresh gloves, and under a 
laminar flow hood to avoid contamination. Bands observed for C. jejuni eluates were 
cut using sterile scalpels and placed into Lo-bind Eppendorf containing 50 µl of Milli-Q 
water and then sent for mass spectrometry analysis. The instrument used was the LC 
MS/MS ESI-ORBITRAP-HCD.  
To recognise and assemble protein sequences, the data output was run through 
MASCOT software. The data was run against protein fasta files of C. jejuni NCTC 
11168 and 81-176, retrieved from the NCBI GenBank database. 
2.18 Statistical analysis  
Standard deviation was calculated using one way analysis of variance (ANOVA). For 
ELISA experiments, the relevant negative control values were subtracted from the test 
values. Each of the error bars indicated on graphs for ELISA experiments represent 
standard error of the mean (SEM). The p values on the graphs for ELISA experiments 
are labelled as: * for 0.005<p≤0.05, ** for 0.001<p≤0.005 and *** for p≤0.001. For 
agar well diffusion assay standard deviation (SD) is shown. 
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Chapter 3: Results  
3.1 Sequencing the genome of L. fermentum 3872 
3.1.1 Ion Torrent PGM sequencing  
Initially, the genome of L. fermentum 3872 was sequenced using the Ion Torrent PGM 
sequencer. The first step of the sequencing process was to isolate DNA. Two clonal 
isolates of L. fermentum 3872 were grown to confluence and sequenced. One of these 
was used for genome assembly and the other was used to determine sequence variations 
between the clonal isolates of L. fermentum 3872. 
3.1.2 DNA extraction for Ion Torrent PGM sequencing  
Once DNA had been extracted from the L. fermentum 3872 clonal isolates 1 and 2, the 
samples were run on an agarose gel to obtain a primary yield estimate, as well as to see 
if there was any rRNA contamination. The above mentioned cases may affect the 
quality of base calling, which in turn would affect genome assembly. The concentration 
and purity of the DNA samples were further validated using a NanoVue 
spectrophotometer.  
 
Figure 3.1. Agarose gel electrophoresis image of purified DNA from L. fermentum 
3872 used for Ion Torrent PGM sequencing;1, 2-log DNA ladder (NEB); 2, DNA clonal 
isolate 2; 3, DNA clonal isolate 1. 
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Table 3.1. NanoVue spectrophotometer readings for DNA isolated from L. fermentum 
3872 clonal isolate 1 and 2. 
Clonal isolate 1 Clonal isolate 2 
concentration:  322.8 µg/ul concentration:  347 µg/ul 
A260/A280 1.838 A260/A280 1.922 
A260/A230 1.528 A260/A230 1.881 
 
DNA extracted from clonal isolates 1 and 2 were of high concentration and quality 
(Figure 3.1 and Table 3.1). Both samples had an A260/A280 reading of above 1.8 
(Table 3.1). The A260/A230 value of clonal isolate 1 was 1.528, which is lower than the 
standard 1.8–2.0 (Table 3.1). The lower A260/A230 value was likely caused by 
reagents used during the DNA extraction procedure, such as ethanol, which would not 
influence DNA sequencing as the minute quantities of reagents would be removed 
during the various sample preparation steps.  
3.1.3 DNA size selection for Ion Torrent library preparation 
After determining the quality, concentration and purity of the DNA for L. fermentum 
3872, the NEBNext fast DNA fragmentation and library preparation kit for Ion Torrent 
was used to prepare the DNA samples for sequencing (see section 2.9). The purified 
DNA samples of L. fermentum 3873 were first enzymatically fragmented, followed by 
sequence end repair and nick translation. The 5’ prime ends of the fragmented DNA 
were then phosphorylated for blunt end ligation of adapters. PCR of the adapter ligated 
DNA was conducted to amplify the DNA, which increases sample concentration and 
selects fragments with correctly attached adapters used for Ion Torrent sequencing. The 
samples were then size selected using a 2% E-Gel to select the manufacturer 
recommended DNA size for the 400 bp Ion Torrent sequencing kit. The recommended 
size is around 490 bp as both adapters attached to the ends of the fragmented DNA are 
45 bp in length.  
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Figure 3.2. E-Gel cassette used for DNA size selection. The image was taken after 
extracting size selected DNA. The wells are: 1, fragmented DNA from clonal isolate 1; 
2, fragmented DNA from clonal isolate 2; 3, 2-log DNA ladder (NEB).  
The DNA samples have been sheared, as can be seen by the smearing on the E-Gel 
cassette image (Figure 3.2). The lower wells of the 2-log DNA marker are around 490 
bp. Thus, fragmented DNA of clonal isolates 1 and 2 were extracted at approximately 
490bp.  
3.1.4 Bioanalyzer result 
To accurately determine DNA fragment size and concentration, a Bioanalyzer 2100 was 
used after DNA size selection. Accurately determining the concentration of DNA is 
important in order to have the correct Ion Sphere particle (ISP) to DNA ratio. This 
would help clonality of DNA after emulsion PCR. The analysis was conducted in 
duplicate and the average concentration of the sample was used for template 
preparation, which would help account for pipetting errors. 
0.1 
0.2 
0.3 
0.4 
1 2 3 
kb 
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Clonal isolate 2 
 
Figure 3.3. Graph showing Bioanalyzer 2100 result of size selected L. fermentum 3872 
DNA of clonal isolates 1 and 2. 
Table 3.2. Bioanalyzer 2100 result of size selected DNA of L. fermentum 3872 clonal 
isolates 1 and 2. 
 
 
Clonal isolate 1 Clonal isolate 2 
Size [bp] Molarity [pmol/l] Size [bp] Molarity [pmol/l] 
Reading 1 
458 4,592.30 488 1,705.80 
Reading 2 
459 4,130.30 495 
 
1,416.30 
 
The molarity for both size selected DNA samples was high enough for template 
preparation (Table 3.2). The sizes of the fragmented DNA samples were smaller than 
490 bp, but were acceptable for the Ion Torrent 400 bp sequencing kit (Table 3.2 and 
Figure 3.3).  
3.1.5 Quality of Ion Torrent PGM sequencing  
Once the fragment size and concentration were determined using the Bioanalyzer 2100 
equipment, emulsion PCR was conducted. During emulsion PCR, adapter-ligated DNA 
were denatured and attached to complementary sequences located on ISPs. The DNA 
attached to each ISP was amplified. Once emulsion PCR was completed, enrichment of 
the samples was conducted to remove beads without amplified DNA, followed by 
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loading of the samples on to an Ion 314v2 chip for sequencing. Two sequencing runs 
were conducted on clonal isolate 1 to provide sufficient data necessary for genome 
assembly. One sequencing run was carried out for clonal isolate 2 for sequence 
validation.  
(A) Sequencing run 1 (clonal isolate 1) 
 
(B) Sequencing run 2 (clonal isolate 2) 
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(C) Sequencing run 3 (clonal isolate 1) 
 
 
Figure 3.4. Summary of the Ion Torrent PGM sequencing output for L. fermentum 3872 
sequencing runs 1 (A), 2 (B), and 3 (C).  
The ISP loading indicates the number of wells on the Ion 314v2 chip loaded with 
samples. For sequencing run 1, the ISP loading was 68%. The low ISP loading would 
not affect the quality of sequenced reads, and as sequencing was performed on the 
samples multiple times, the final coverage would still be high. For sequencing run 1, the 
enrichment was good at 97%. Thus, many DNA fragments with correctly primed 
adapters were sequenced. The mean was 288 bp, less than the desired read length of 400 
bp, with the most common read length being 427 bp. Sequencing run 2 had better ISP 
loading at 73%, with an enrichment of 98%. The mode read length was 388 bp with a 
mean of 291 bp, both being smaller than the preferred read length of 400 bp. For 
sequencing run 3, the ISP loading was 68%, and 91% of the reads were enriched. The 
number of polyclonals was reduced considerably to 25% when compared to sequencing 
runs 1 and 2 due to a reduction in the concentration of DNA used during the template 
preparation step. For sequencing run 3, the mean read length was 275 bp and the mode 
was 427 bp. Overall, sequence runs 1, 2 and 3 generated 47%, 53% and 55% useable 
data. Although the data generated may not have the desired read length it is still 
sufficient for genome assembly as the read lengths are longer than that generated by the 
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Ion Torrent 200 bp kit (Life Technologies) also used for genome assembly projects. 
Data from sequence run 2 with DNA from clonal isolate 1 were also sufficient for 
validating sequence variations between DNA from the two clonal isolates. 
3.2 Assembling the genome of L. fermentum 3872 
3.2.1 L. fermentum 3872 genome sequence assembly using Ion Torrent PGM 
generated reads 
The plasmid pLF3872 sequence was circularised using the Ion Torrent PGM generated 
reads, which were de novo assembled using MIRA V3.4.2.0 (Chevreux et al., 2004) and 
CLC GWB, as described in section 2.10.2. 
Table 3.3. The data output of CLC, MIRA and SPAdes de novo assemblers for the three 
Ion Torrent PGM sequencing runs, along with CISA contig integrator and HGAP3 data 
output of PacBio RSII sequencer. The table was obtained from Lehri, Seddon and 
Karlyshev, (2017b). 
 
  
Ion Torrent PacBio 
RSII 
  Run 1 Run 2 Run 3 
  
Assembly  
tool 
CLC MIRA SPAde
s 
CLC MIRA SPAde
s 
CLC MIRA SPAde
s 
CISA  HGAP3 
Number  
of contigs  
162 162 288 152 178 291 180 139 288 43 7 
Total  
assembly 
(bp) 
210339
9 
232129
4 
218533
4 
210611
9 
231359
5 
218484
6 
207929
3 
232812
9 
218426
8 
249736
2 
2430608 
Largest  
contig (bp) 
89244 153205 123470 89537 124270 123504 55652 126522 123449 152374 2302236 
 
Prior to using a combination of PacBio RSII and Ion Torrent PGM generated reads, an 
initial attempt was made in only using Ion Torrent reads to complete the chromosomal 
sequence of L. fermentum 3872. As described in section 2.10.3 and article by Lehri, 
Seddon and Karlyshev (2017b), each of the Ion Torrent sequenced reads were de novo 
assembled using SPAdes V3.5.0 (Bankevich et al., 2012), MIRA V3.4.2.0 (Chevreux et 
al., 2004) and CLC GWB. The contigs generated were merged using CISA contig 
integrator (Lin and Liao, 2013). After the merger, the number of contigs indicated in 
66 
 
Table 3.3 was reduced to 43. Read mapping using default parameters showed that 
88.16% of nucleotides mapped onto the sequence. The total number of contigs was 
increased to 48 by identifying and splitting contigs where read mapping did not confer 
with the contig assembly. The latter was done by looking for regions on a contig that 
had unaligned read sequencing ends, low read coverage, and regions where reads did 
not map onto a contig. After further contiguation using BLASTN followed by 
unmapped read extension, the total number of contigs was reduced to 18. The estimated 
genome size of L. fermentum 3872 had also increased to 2.5 Mb, which was larger than 
the genome size estimated by the de novo assemblers initially used for the Ion Torrent 
reads (Table 3.3, on row ‘Total assembly (bp)’). Read mapping using default parameters 
showed an improvement in read map coverage with 99.65% of nucleotides mapped onto 
the assembly, as opposed to 88.16%, indicating a near complete genome.  
The contigs were aligned to a closely related reference sequence L. fermentum IFO 3956 
using Contiguator (Galardini et al., 2011) to generate primers for Sanger sequencing.  
 
Figure 3.5. Contiguator alignment result for the 18 contigs of L. fermentum 3872 
mapped to reference sequence L. fermentum IFO 3956. BLASTN was used with default 
parameters. Only contigs that aligned to the reference sequence in blue are shown. The 
red lines indicate matching alignments between the latter two strains. The diagram was 
obtained from Lehri, Seddon and Karlyshev (2017b). 
Figure 3.5 shows that regions of each contig from L. fermentum 3872 align to multiple 
areas of the reference strain L. fermentum IFO 3956. Thus, there may either be strain to 
strain variation between L. fermentum 3872 and L. fermentum IFO 3956, or the L. 
fermentum 3872 contigs are misassembled. Misassembly was unlikely as the reads 
mapped well to the chromosomal sequence with no signs of unaligned read ends, gaps, 
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and low coverage when using default, stringent and very stringent read mapping 
parameters. Nonetheless, an optical map of the chromosomal sequence for L. fermentum 
3872 was generated to confirm genome assembly quality.  
3.2.2 Optical map data to determine initial assembly quality  
An optical map uses a restriction enzyme to cleave DNA at specific sites. A spectrum of 
the cleavage sites is used to generate a genetic fingerprint of the genome. The genome 
sequence is then mapped onto the restriction enzyme map (optical map). The method is 
suitable for deducing assembly quality of the nucleotide sequence without being 
dependent on traditional quality indicators that require nucleotide sequence data such as 
read mapping.  
 
 
Figure 3.6. Alignment result of the 18 contigs of L. fermentum 3872 to the restriction 
map of L. fermentum 3872. The blue regions on the optical map indicate areas of each 
contig that are correctly assembled, while the white regions indicate areas that are 
misassembled. The red regions are areas that are duplicated. The diagram was obtained 
from Lehri, Seddon and Karlyshev (2017b). 
The 18 assembled contigs of L. fermentum 3872 were aligned to the optical map 
generated by OpGen using Mapsolver software. Figure 3.6 shows that of the 18 contigs, 
one of which was the plasmid pLF3872, only eight align to the optical map and none 
were correctly assembled. 
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3.2.3 Determining the point of assembly error 
To identify the point at which misassembly occurred, along with its cause, the CLC 
GWB, SPAdes V3.5.0 (Bankevich et al., 2012), MIRA V3.4.2.0 (Chevreux et al., 2004) 
and CISA-generated contigs used to produce the 18 contigs were aligned to the optical 
map using Mapsolver software. Read map analysis of the point at which the genome 
assembly differed from the optical map, along with its surrounding areas, were also 
examined to determine whether read mapping had identified misassembly of the L. 
fermentum 3872 genome sequence. 
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Figure 3.7. Optical map and read map comparison in determining genome assembly 
error. The read colours red, green and yellow represent forward, reverse and 
complementary reads respectively. The blue regions on the optical map indicate areas of 
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the sequenced genome that align to the optical map, while red regions indicate duplicate 
alignments and white regions indicate areas where there is no sequence alignment to the 
optical map. The diagram was obtained from Lehri, Seddon and Karlyshev (2017b). 
 
Table 3.4. The number of contigs that aligned to the optical map for the various 
assemblers used, along with the number of contigs that were identified as 
misassembled. The table was obtained from Lehri, Seddon and Karlyshev (2017b). 
 Ion Torrent  PacBio 
RSII 
Run 1 Run 2 Run 3 
   
C
L
C  
MI
RA 
SPA
des 
C
L
C 
MI
RA 
SPA
des 
C
L
C 
MI
RA 
SPA
des 
CI
SA  
18 
Con
tigs 
Final 
assembly 
(HGAP3) 
Contigs aligned 
to the optical 
map 
9 7 12 8 12 10 5 11 11 12 8 1 
Misassembled 
contigs 
1 2 2 1 1 1 1 4 1 4 8 0 
 
Many of the assembly errors occurred near repetitive regions. An example is provided 
in Figure 3.7, where the point at which the optical map differs from the incorrect 
genome assembly is either near a transposon/mobile element or an rRNA region (Lehri, 
Seddon and Karlyshev, 2017b). Figure 3.7 also demonstrates that read mapping did not 
identify the misassembly, and thus can sometimes fail as a determinant for sequence 
assembly quality. Read mapping of the region where misassembly occurred (point of 
misassembly) shows no indication of misassembly, yet the optical map clearly shows a 
misassembled genome. Analysis of the de novo assembled contigs that aligned to the 
optical map also showed that some of the errors occurred during de novo assembly and 
were software specific while others were specific to a sequence region of the genome. 
For example, aligning the CISA-generated contigs to the optical map showed that 
assembly errors were transferred from de novo assembled contigs to CISA contigs. This 
can be observed in Figure 3.7 where the de novo assembled contig MIR_R1_4 
transferred its misassembled region to CISA_0036. As previously mentioned, of the 18 
contigs, none aligned correctly to the optical map (Figure 3.6, Table 3.4). Thus, 
additional contiguation steps on the CISA generated contigs resulted in a far worse 
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genome assembly. A summary of the misassembled contigs is provided in Table 3.4, 
which also shows that some de novo assemblers had more misassembled contigs than 
others. 
3.2.4 PacBio RSII sequencing result 
To complete the genome sequence of L. fermentum 3872, a hybrid sequencing approach 
was needed. This combined short reads generated by the Ion Torrent PGM and long 
reads generated by the PacBio RSII sequencer. For PacBio RSII sequencing, fresh DNA 
that had not been stored at -20°C was required to avoid shearing caused by cycles of 
freezing/thawing. Thus, DNA was isolated from L. fermentum 3872 clonal isolate 1 as 
described in section 2.7. DNA from clonal isolate 1 was used for PacBio RSII 
sequencing and for Ion Torrent PGM genome assembly.  
 
Figure 3.8. Agarose gel image of DNA isolated from L. fermentum 3872 used for 
PacBio RSII sequencing. The wells are: 1, Sample 1 (1:10 dilution); 2, Sample 1 (neat); 
3, 2-log DNA marker (NEB); 4, Sample 2.  
Both samples looked concentrated and of good quality. There is a light smear observed 
below the bright band for Sample 1 (Figure 3.8), this may be caused by the higher 
concentration of the DNA as the smearing is not evenly distributed. Both samples were 
sent to TGAC genomics for PacBio RSII sequencing. 
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3.2.5 Pacbio RSII sequencing sample quality 
TGAC genomics conducted PacBio RSII sequencing and sample quality analysis. 
Unlike Ion Torrent PGM, the PacBio RSII sequencer does not amplify DNA and thus, 
must be of high quality and free from contaminants, such as RNA and proteins, before 
sequencing. Multiple DNA quality analysis tools such as a Qubit fluorometer, and 
DropSense spectrophotometer were used to accurately determine DNA purity. A 
Tapestation was used to determine DNA fragment size after fragmentation of DNA.  
Table 3.5. Concentration, purity, and fragment size of the isolated DNA of L. 
fermentum 3872 for PacBio RSII sequencing.  
Samp
le 
Qubit Values DropSense Values Tapestation 
Values 
Total 
Amou
nt (µg) 
OVERA
LL P/F 
 ng/
µl 
Pass/F
ail 
ng/
µl 
260/2
80 
260/2
30 
Over
all 
P/F 
Avera
ge 
insert 
size kb 
Pass/F
ail 
1 318 Pass 38.9
5 
1.78 1.43 Pass >60 Pass 30.21 Pass 
2 618 Pass 8.78 1.48 1.19 Fail >60 Pass 358.44 Fail 
 
For Sample 2, the A260/280 value was 1.48, which was lower than the 1.8 
recommended by TGAC genomics (Table 3.5). The A260/230 value of 1.19 was also 
lower than the recommended 1.8-2.0. Sample 1 had an A260/280 value of 1.78, which 
was almost within the acceptable range of 1.8-2.0, although the A260/230 value was 
1.43 (Table 3.5). As previously mentioned, small amounts of DNA extraction reagents 
used, commonly cause low A260/230 values, which would be removed during PacBio 
RSII library preparation as a clean-up is performed before sequencing, and thus is not 
much of a concern. The low A260/280 value is concerning as this indicates nucleic acid 
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purity. Contaminants such as proteins may cause a lower value, the presence of proteins 
would affect the average read length of the sequencing data. Thus, Sample 1 was chosen 
for PacBio RSII sequencing. 
3.2.6 The final assembly of the L. fermentum 3872 chromosomal sequence 
 
Figure 3.9. pLF3872 assembly comparison of the Ion Torrent PGM generated plasmid 
sequence (top) and the PacBio RSII generated plasmid (bottom). The red regions show 
alignment to similar areas between the two plasmid assemblies, with the redundant 
region of the pLF3872 PacBio RSII assembly underlined in green. The diagram was 
obtained from Lehri, Seddon and Karlyshev (2017b). 
As the initial attempt in trying to complete the chromosomal sequence of L. fermentum 
3872 was unsuccessful, PacBio RSII reads were de novo assembled using HGAP3 
software. The 74,588 reads produced by the PacBio RSII sequencer generated seven 
contigs. The smallest contig was 14,320 bp in length, while the largest contig was 
2,302,236 bp. The largest contig aligned to the optical map of the chromosomal 
sequence of L. fermentum 3872. The size of the chromosomal sequence generated by 
the HGAP3 assembly tool was larger than that of the optical map. The map and Artemis 
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Comparison Tool (ACT) (Carver et al., 2005) indicated that the ends of the sequence 
had large redundancies, with both ends aligning to each other. Merging overlapping 
regions resulted in a circular chromosomal sequence of 2,297,851 bp. This was also 
observed for the plasmid pLF3872, as the PacBio RSII generated contig of 48,472 bp 
represented the already completed plasmid sequence pLF3872. The plasmid size was 
larger than the predetermined pLF3872 size of 32,641 bp. Comparison of the two 
sequences using the Artemis comparison tool (ACT) (Carver et al., 2005) identified 
redundant overlapping regions for the plasmid sequence of 48,472 bp in length (Figure 
3.9). Once the redundant sequence was merged together, the plasmid was circularised 
and matched with the pLF3872 plasmid generated using the Ion Torrent PGM. The 
remaining five contigs generated by the PacBio RSII sequencing data ranged from 14-
18 kb in size. BLASTN comparison of the five contigs to the completed chromosomal 
sequence of L. fermentum 3872 identified that these sequences were fragments of the 
chromosome matching to repetitive sequences, namely transposons or integrase 
encoding genes. Mapping of PacBio RSII reads to the contigs resulted in only a single 
read aligning to the map. Thus, the five sequences were low quality reads that were 
inaccurately classified as contigs by the HGAP3 software.  
 
Figure 3.10. Final assembly of the L. fermentum 3872 genome sequence aligned to the 
optical map of L. fermentum 3872. Alignment was conducted using Mapsolver software 
with default parameters. The blue regions indicate regions of the chromosomal sequence 
that aligned to the optical map. The diagram was obtained from Lehri, Seddon and 
Karlyshev (2017b). 
The circularised chromosomal sequence mapped with no indication of misassembly 
(Figure 3.10). As the PacBio RSII generated reads had low coverage of 19.47x, Ion 
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Torrent PGM reads were mapped onto the chromosomal sequence of L. fermentum 
3872. The Ion Torrent PGM reads revealed artefactual variations (predominantly SNPs) 
introduced by the PacBio RSII reads, which were corrected using the Ion Torrent 
generated data.  
To determine if clonal variations were present on both the chromosomal and plasmid 
(pLF3872) sequence of L. fermentum 3872, Ion Torrent reads generated from clonal 
isolate 2 were mapped onto the finalised genome sequence. This did not detect any 
clonal variations and thus the genome sequence was representative of L. fermentum 
3872.  
 
Figure 3.11. Contiguator alignment of correctly assembled L. fermentum 3872 genome 
artificially split at 100,000 bp and aligned to reference sequence L. fermentum IFO 
3956. BLASTN with default alignment parameters were used. Only contigs (blue) that 
aligned the reference strains are shown, with red lines indicating regions that match 
between the two strains. The diagram was obtained from Lehri, Seddon and Karlyshev 
(2017b).  
Purposefully splitting the correctly assembled chromosomal sequence of L. fermentum 
3872 at 100,000 bp intervals and then aligning to reference sequence L. fermentum IFO 
3956 using Contiguator revealed that the alignment (Figure 3.11) was better than 
initially observed in Figure 3.5. Thus, sequence misassembly was the main cause of 
having multiple regions of the L. fermentum 3872 contigs aligning to various areas of 
the reference L. fermentum IFO 3956 (Figure 3.5).  
After completion of the L. fermentum 3872 genome sequence, the genome was 
annotated using various annotation tools and manually inspected using Geneious 
software (Kearse et al., 2012), as certain annotation programmes would classify genes 
as hypothetical while others would be able to name the genes and assign function. The 
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annotations were also inspected to identify and correct premature start and stop codons. 
Once annotation was complete, the genome of L. fermentum 3872 was analysed. 
3.3 L. fermentum 3872 genome sequence analysis 
3.3.1 General overview of the L. fermentum 3872 genome 
The final genome sequence of L. fermentum 3872 consists of a circular plasmid 
(pLF3872) of 32,641 bp, while the chromosomal sequence of L. fermentum 3872 is 2, 
297,851 bp in length. Together with the plasmid, the genomic size of L. fermentum 
3872 is 2,330,492 bp. The genome of L. fermentum 3872 consists of 2,328 genes, with 
2,127 genes encoding proteins and 128 pseudogenes. There are 73 RNA genes, 15 
encoding for rRNAs (23S, 16S and 5S) and 58 encoding for tRNAs. The G+C content 
of the chromosomal and plasmid sequences are 55.6% and 40.1% respectively. 
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Table 3.6. Plasmid pLF3872 genes, their functions and the closest BLASTX hits in the 
NCBI non-redundant database. The table was obtained from Lehri, Seddon and 
Karlyshev (2015). 
Loci Gene  Gene product  Putative function Reference strain Identity % 
(coverage%) 
1-1335 ykgC Pyridine nucleotide-disulphide 
oxidoreductase YkgC  
Energy production 
(oxidoreductase activity) 
Lactobacillus plantarum 
CMPG5300 
100 (99) 
1663-
2247 
tnpR Putative resolvase Recombination Lactobacillus salivarius CECT 
5713 
99 (99) 
2571-
3197 
hyp4 Conserved hypothetical protein   Lactobacillus salivarius 99 (99) 
3409-
3693 
dinJ DNA damage inducible protein 
J 
Antitoxin Lactobacillus brevis ATCC 367 93 (98) 
4083-
4535 
hyp5 Hypothetical protein   Multiple Lactobacillus bacteria 99 (99) 
5007-
5798 
parA Plasmid partitioning protein 
ParA  
Cell division, 
partitioning (replication) 
Multiple Lactobacillus bacteria 100 (99) 
5840-
6109 
hyp6 Hypothetical protein   Lactobacillus hilgardii 96 (98) 
6670-
7833 
repA Replication initiator protein 
RepA  
Replication Lactobacillus crispatus EM-LC1 100 (99) 
7808-
8104 
hyp7 Hypothetical protein  Lactobacillus crispatus EM-LC1 100 (98) 
8388-
8660 
eatL Epsilon anti-toxin Post-segregation killing 
system 
Multiple Lactobacillus bacteria 97 (98) 
8663-
9493 
zetL Zeta toxin Post-segregation killing 
system 
Lactobacillus antri 99 (98) 
9577-
9855 
hyp10 Hypothetical protein   Lactobacillus oris PB013-T2-3 99 (98) 
9878-
10120 
hyp11 Hypothetical protein   Lactobacillus casei Zhang 100 (92) 
10346-
12421 
traA Nickase Conjugation Lactobacillus rhamnosus  99 (99) 
12506-
12817 
hyp1 Hypothetical protein   Lactobacillus plantarum 
CMPG5300 
99 (99) 
12853-
13467 
hyp9 Hypothetical protein   Lactobacillus plantarum 
CMPG5300 
99 (99) 
13469-
13804 
traB Transfer complex protein TraB Conjugation  Lactobacillus paracasei  99 (99) 
13825-
14187 
trsC TrsC Conjugation Lactobacillus paracasei 99 (99) 
14156-
14815 
trsD TrsD Conjugation Lactobacillus plantarum 
CMPG5300 
99 (99) 
14827-
16845 
trsE TrsE Conjugation  Lactobacillus paracasei  99 (99) 
16838-
18256 
trsF TrsF Conjugation  Lactobacillus plantarum 
CMPG5300 
97 (99) 
18257-
19414 
tcpG Peptidoglycan hydrolase  Hydrolysis of 
peptidoglycan 
Lactobacillus casei Zhang 99 (99) 
19428-
20045 
hyp12 Hypothetical protein   Lactobacillus oris PB013-T2-3 99 (99) 
20032-
20400 
Trx Thioredoxin  Reduction of oxidising 
compounds  
Lactobacillus oris PB013-T2-3 94 (99) 
20401-
20871 
trsJ TrsJ Conjugation  Lactobacillus helveticus CIRM-BIA 
101 
96 (99) 
21101-
22651 
traG Conjugal transfer protein TraG Conjugation Lactobacillus oris PB013-T2-3 98 (99) 
22651-
23055 
hyp2 Hypothetical protein   Lactobacillus coryniformis CECT 
5711 
99 (99) 
23074-
23913 
trsL TrsL Conjugation  Lactobacillus paracasei Lpp189 100 (99) 
23928-
24338 
hyp3 Hypothetical protein   Multiple Lactobacillus bacteria 100 (99) 
24345-
26480 
topB DNA topoisomerase III  Replication Lactobacillus paracasei  98 (99) 
26602-
26817 
hyp8  Hypothetical protein   Lactobacillus oris PB013-T2-3 99 (98) 
26821-
27945 
ltrC Low temperature requirement 
C protien 
Phosphatidylglycerophos
phatase activity 
Lactobacillus coryniformis 97 (99) 
28656-
31823 
cbp Collagen binding protein Adhesion Lactobacillus casei, Lactobacillus 
oris 
94 (99) 
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Plasmid pLF3872 contains 33 genes (see Table 3.6), 12 of which are hypothetical. 
There are toxin-antitoxin gene pairs eatL and zetL, potentially involved in stable 
maintenance of the plasmid in L. fermentum 3872 (Zielenkiewicz et al., 2009), along 
with an additional antitoxin gene dinJ (Hu, Benedik and Wood, 2012). Genes traA, 
trsC, trsD, trsE, trsF, trsG, trsJ, and trsL of pLF3872 are potentially involved 
conjugation. The protein sequence of a peptidoglycan hydrolase (TcpG) encoding gene 
has a lytic transglucosylase domain and an amidase-5 domain both of which may play a 
role in conjugation (Scheurwater, Reid and Clarke, 2008). The plasmid contains a 
putative cbp gene potentially involved in promoting bacterial adhesion to collagen 
(Pietrocola et al., 2007).  
 
Figure 3.12. pLF3872 CBP protein domains, identified by the NCBI conserved domain 
(CD) program and the CD database. The diagram was obtained and modified from 
Lehri, Seddon and Karlyshev (2015). 
The CBP protein has an LPXT domain at the C-terminal end, essential for cell wall 
anchoring (Davies, Svensäter and Herzberg, 2009). The N-terminal region is predicted 
to form an A-domain, in other CBP proteins the domain is involved in adhesion 
(Deivanayagam et al., 2000). The A-domain is followed by six repetitive B domains 
that form stalks presenting the A domain for attachment to host cells (Figure 3.12) 
(Deivanayagam et al., 2000).  
The chromosomal sequence of L. fermentum 3872 contains genes that play a role in the 
production of vitamins B1, B2, B5, B7 and B9. L. fermentum 3872 also contains acid 
symporter genes such as sugar/H+, amino acid/H+, and four copies of Na+/H+. Lactic 
acid bacteria such as L. fermentum 3872 utilise amino acid decarboxylation/deamination 
and sugar metabolism to sustain pH levels for bacterial survival (Pessione, 2012). L. 
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fermentum 3872 contains 27 genes involved in arginine and proline metabolism and 14 
genes involved in glutathione metabolism. The latter is found to participate in acid 
stress response in Lactobacillus salivarius (Lee et al., 2010). The L. fermentum 3872 
sequence also consists of a gene that encodes dTDP-glucose 4,6-dehydratase (Locus 
tag: N573_RS00605), a homologue of which is known to be involved in gastric acid 
tolerance in Lactobacillus plantarum (Hamon et al., 2014). There are a number of 
exopolysaccharide encoding genes with locus tags N573_RS00495, N573_RS00500 
and N573_RS00505 located between 117326 – 119653 bp, forming a cluster. L. 
fermentum 3872 also has a undecaprenyl-diphosphatase (EC 3.6.1.27) (Locus tag: 
N573_RS09665) encoding gene possibly involved in bacitracin resistance (Ghachi et 
al., 2005). L. fermentum 3872 contains genes encoding DnaK (Locus tag: 
N573_RS04975), and GroEL (Locus tag: N573_RS01895), which may be involved in 
bacterial survival during heat and hyperosmotic shock (Prasad, McJarrow and Gopal, 
2003). Homologues of both genes are also thought to play a role in mucin binding in 
Lactobacillus plantarum (Izquierdo et al., 2009). A gene encoding a translational 
elongation factor (Locus tag: N573_RS03470) protein is also present. A homologue of 
the protein is known to promote adhesion to host cells of Lactobacillus johnsonii La1 
(Granato et al., 2004). L. fermentum 3872 contains genes encoding D-Lactate 
dehydrogenase (Locus tag: N573_R S11010) and 6-phosphogluconate dehydrogenase 
(Locus tag: N573_R S10960), homologues of which are known to promote bacterial 
adhesion to mucin in Lactobacillus plantarum (Izquierdo et al., 2009). A partial gene 
potentially encoding for a mucus binding protein (Locus tag: N573_RS03620) is also 
present for L. fermentum 3872. Mucus binding protein encoding genes are also present 
for Lactobacillus fermentum strains CECT 5716, 3956 and F6. A fibronectin binding 
protein encoded by the fbpA (Locus tag: N573_RS07225) gene is likely involved in 
adhesion to ECM proteins such as fibronectin (Muñoz-Provencio, Pérez-Martínez and 
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Monedero, 2010). The gene is commonly found in other L. fermentum strains. The L. 
fermentum 3872 genome contains common antibiotic resistance genes such as four 
genes involved in in tetracycline resistance, two genes involved in beta-lactam antibiotic 
resistance, and four genes involved in fluoroquinolone resistance, along with six 
multidrug efflux pump-related genes. There are genes involved in heavy metal 
resistance with five genes involved in arsenate, six in mercury, five in cobalt-zinc-
cadmium, and six copper resistance genes. 
3.3.2 Comparative genomic analysis 
 
Figure 3.13. LASTZ comparison of the L. fermentum 3872 chromosomal sequence to 
sequences L. fermentum strain F6, CECT 5716, and IFO 3956. Default LASTZ 
parameters were used. Genomic regions that are similar among the strains used for 
comparative analysis are in blue, while red lines represent inverted areas, non-coloured 
regions are unique to L. fermentum 3872. The diagram was obtained from Lehri, 
Seddon and Karlyshev (2017a).  
LASTZ software (Harris RS, 2007) was used for comparison of the chromosomal 
sequence of L. fermentum 3872 and L. fermentum strains F6, IFO 3956, and CECT 5716 
(Figure 3.13). The software identified multiple unique genomic regions of L. fermentum 
3872. The region located between 748,875 and 919,330 bp contained hypothetical 
protein encoding genes, along with genes that encoded enterolysin A (835, 633–836, 
847 bp) and CAAX amino terminal protease self-immunity (838,683–839,366 bp). The 
latter two genes indicate the presence of a bacteriocin. BAGEL3 software (Heel et al., 
2013) confirmed that the region between 830,634 and 840,633 bp encoded a class III 
bacteriocin (Figure 3.14). A BLASTN search using the non-redundant NCBI database 
identified no valid matches to the region between 830,634 and 840,633 bp of the L. 
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fermentum 3872 genome. The region between 1,564,375 bp and 1,603,857 bp contained 
prophage-related genes not found in strains used for comparative analysis, and 
inversions of certain regions of the strains used for comparative analysis. The region 
between 1,829,274 and 1,857,186 bp was likely acquired by horizontal DNA transfer, as 
a match to Lactobacillus gasseri ATCC 33323 was identified when using a BLASTN 
search of the non-redundant NCBI database, with no matches in the genomes of L. 
fermentum strains used for comparative analysis. The region between 2,212,692 and 
2,237,160 bp contains conjugation and peptidoglycan hydrolase encoding genes. A 
BLASTN search of the latter region using the non-redundant NCBI database resulted in 
multiple matches to plasmid sequences, with the closest to plasmid pPECL-5 
(Pediococcus claussenii ATCC BAA-344) with an e value of 0.0, and a query coverage 
of 55%. The area has likely been acquired via horizontal gene transfer and was not 
identified in other L. fermentum strains used for comparative analysis. This region also 
had a gene that encoded an internalin J-like protein (InIJ) (Locus tag: N573_011130), 
which contains a mucin-binding domain (MuCBP). The region also has transposase 
encoding genes. 
L. fermentum 3872 also has an aggregation substance precursor (Locus tag: 
N573_004020) encoding gene not found in other L. fermentum strains used for 
comparative analysis. The protein encoded by the gene has been linked to both adhesion 
and aggregation (Suessmuth et al., 2000). There is an enolase-encoding gene (Locus 
tag: N573_002185), the protein encoded by the gene is known to be involved in 
adhesion to collagen (Salzillo et al., 2015). The gene is also present in other L. 
fermentum genomes. A partial cbp gene (Locus tag: N573_000435) was also identified 
in the chromosomal sequence of L. fermentum 3872. The partial CBP protein has a cell 
wall anchor domain (LPXTG), along with a B domain, but does not have an A domain 
potentially used by CBP for adhesion (Deivanayagam et al., 2000). Neither the cbp 
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gene of pLF3872 nor the chromosomal sequence of L. fermentum 3872 are present in 
other L. fermentum strains used for comparative analysis. An epsH (Locus tag: 
N573_008790) gene involved in biofilm formation (Jones et al., 2014) is also present in 
the L. fermentum 3872 genome and is absent in all the genomes of L. fermentum strains 
used for comparative analysis.  
3.3.3 Pan/Core comparative analysis  
Pan/Core analysis software (Spine/AGEnt) (Ozer, Allen and Hauser, 2014) was used to 
identify commonly found genes in L. fermentum F6, IFO 3956 and 3872, referred as 
core genes. L. fermentum CECT 5716 was excluded from the analysis as it contained 
many nucleotide ambiguities. The software was also used to identify unique genes (Pan 
genes) of L. fermentum 3872. As described in Lehri, Seddon and Karlyshev (2017a), the 
software identified 1650 genes that are common in the strains of L. fermentum that were 
tested. The software also identified 428 genes that are unique to the L. fermentum 3872 
genome. Of the unique genes present, 148 encoded hypothetical proteins, while nine 
represented CRISPRs, forty nine mobile elements, five conjugal transfer genes. Other 
genes were related to ABC transporter, bacteriocin biosynthesis, heavy metal resistance 
and prophage.
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3.3.4 Identified prophages of L. fermentum 3872 
 
Figure 3.14. LASTZ comparison 
of the chromosomal sequence of 
L. fermentum 3872 and L. 
fermentum strains F6, CECT 
5716, and IFO 3956, with 
highlighted prophage and 
bacteriocin encoding regions. 
Default LASTZ parameters were 
used. The diagram was obtained 
from Lehri, Seddon and 
Karlyshev (2017a). 
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As Pan/Core analysis found a few prophage related genes, PHAST software (Zhou et 
al., 2011) was used to identify any other L. fermentum 3872 prophages. Four regions 
that are associated with prophages were recognised, with all having a phage attachment 
(ATT) site, required for site-specific recombination. An area between 550,236 bp and 
584,763 bp of the L. fermentum 3872 chromosomal sequence had a 34.5 kb prophage 
region containing multiple phage tail protein encoding genes. Phage tail proteins are 
involved in phage attachment to host cells (Auzat et al., 2008). The region also contains 
transposase and integrase encoding genes. A 32 kb region located between 886,091 bp 
and 918,126 bp also has many transposase and integrase encoding genes. An area 
between 1,564,361 bp and 1,603,857 bp is a prophage-related 39.4 kb region. The 
region has genes that encodes phage tail, head and portal proteins. The region also has 
transposase, integrase and a protease encoding gene. PHAST software (Zhou et al., 
2011) also identified a 30.2 kb prophage region between 1,826,924 bp and 1,857,190 
bp, containing genes that encoded portal, head and capsid proteins along with terminase 
and recombinase encoding genes. This region also has a mucBP type gene, the protein 
of which contains 17 repeats of MuCBP binding domains, although there was no cell 
wall anchor domain, which is often found in cell surface proteins of Gram positive 
bacteria (Mazmanian et al., 1999). Multiple prophage-related genes were also identified 
close to the bacteriocin encoding region (830,634 bp – 840,633 bp) (Figure 3.14), 
although this region was not classified as prophage-related by PHAST software (Zhou 
et al., 2011). 
As can be seen in Figure 3.14, there were also small similarities between the prophage 
regions of L. fermentum 3872 and the L. fermentum strains used for comparative 
analysis.  
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3.4 Cloning and expression of the cbp gene 
Genome sequence analysis of L. fermentum 3872 identified a cbp gene encoding a 
collagen binding protein not found in any other strain of the species. The amino acid 
sequence of the CBP protein of pLF3872 showed that the protein had all the domains 
essential for being a functional protein. Thus, to determine whether the protein 
promoted bacterial adhesion to collagen, and consequently contributed to GIT 
colonisation, the gene was cloned in E. coli and purified for future adhesion 
experiments.  
3.4.1 Initial attempt to clone and express the cbp gene  
PCR was conducted to amplify the cbp gene of plasmid pLF3872 using primers 
CBPREV1: atgagcatgctcaatggtgatggtgatggtgaatagtaaatctacttataactactaaacc and 
CBPFOR1: aacaatctagaagaaggaggcaacagtatgagtaataaatctaggcatcgtcgac. XbaI and SphI 
restriction enzyme sites were added at the ends of the amplified cbp gene, along with a 
Shine-Dalgarno (S-D) sequence, used to aid protein expression. The cbp gene sequence 
also had an C-terminal hexa histidine tag for purification of recombinant CBP. Once 
PCR was complete, agarose gel electrophoresis was used to determine sample quality. 
 
Figure 3.15. Agarose gel electrophoresis result of amplified cbp gene with C-terminal 
hexa histidine tag and a leader peptide sequence. 1, amplified cbp gene; 2, 2-log DNA 
ladder (NEB). 
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Figure 3.15 shows that the PCR product is of expected size (3.2 kb) and that there are 
no spurious bands that may affect cloning. The PCR product was used for cloning 
experiments.  
3.4.1.1 Cloning the cbp gene  
QIAquick PCR purification kit (Qiagen) was used to purify the PCR product. The latter 
would remove PCR contaminants such as primers that may affect restriction digestion 
and ligation. The PCR product and plasmid vector pBAD33 were digested using 
enzymes XbaI and SphI, generating sticky ends for ligation. Shrimp alkaline 
phosphatase (SAP) was not used as the sticky ends were not complementary to each 
other and the samples were gel purified shortly after restriction digest. After gel 
extraction, the cbp gene insert and the pBAD33 plasmid were ligated and transformed 
on to NEB express E. coli. Clonal isolates of the transformants were grown to 
confluence, and plasmid extraction was conducted. A restriction digest and agarose gel 
electrophoresis were performed to determine if the extracted plasmid contained the cbp 
gene insert. DNA concentration readings were taken using a NanoVue 
spectrophotometer to determine if the sample was concentrated for Sanger sequencing. 
 
Figure 3.16. Agarose gel electrophoresis result confirming the presence of the cbp gene 
inserted on to the plasmid pBAD33; C represents samples that have been digested while 
UC are undigested samples (negative controls). The wells are: 1, 2 log-DNA ladder; 2, 
Sample 1; 3, Sample 2; 4, Sample 3. 
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Table 3.7. NanoVue spectrophotometer reading of samples 1 and 3 containing pBAD33 
plasmid with the cbp gene insert.  
Sample 1 Sample 3 
Concentration:  66 ng/µl concentration:  80 ng/µl 
A260/A280 1.826 A260/A280 1.785 
A260/A230 2.1 A260/A230 1.559 
 
Samples 1 and 3 have the cbp gene insert of the expected size (3,208 bp), and the 
digested pBAD33 sample is also of expected size (5.3 kb) (Figure 3.16). Sample 2 does 
not contain the cbp gene insert, as only one band is present. Table 3.7 shows that 
samples 1 and 3 are concentrated and pure enough to be sent for Sanger sequencing. 
 
Figure 3.17. NCBI BLAST result of the Sanger sequenced cbp gene with a C-terminal 
hexa histidine tag compared to the cbp gene sequence generated from Ion Torrent PGM. 
The Sanger sequenced cbp gene for both samples had no nucleotide variations, which 
can be seen in Figure 3.17. There is a 100% match (3208/3208) between the Sanger 
sequenced cbp and that sequenced by Ion Torrent PGM, with no gaps found between 
sequences. 
3.4.1.2 Expression of the CBP protein 
The recombinant CBP protein was expressed in NEB express E. coli and then purified. 
An initial small-scale protein purification was conducted using a Magne-His protein 
purification kit, in order to not waste largescale protein purification columns and 
samples. Prior to lysis, to prevent protein degradation, a cocktail of protease inhibitors 
designed for recombinant E. coli protein expression was added. At each step of the 
protein expression and purification process, small volumes of samples were taken to be 
loaded onto a polyacrylamide gel for Coomassie staining. This would help determine 
the step at which a possible issue may have occurred during protein expression.  
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Figure 3.18. Coomassie stain of the recombinant CBP protein with C-terminal hexa 
histidine tag and a leader peptide. The wells are: 1, pre-strained protein ladder (Page 
ruler plus); 2, lysate before induction; 3, lysate after induction; 4, flow through of 
lysate; 5, column wash 1; 6, column wash 2; 7, eluate 1; 8, eluate 2; 9, eluate 3. 
Coomassie staining of the gel (Figure 3.18) shows that the CBP protein is 
approximately 65 kDa, which is considerably smaller than the expected size of 111 kDa. 
The protein is not useable for adhesion experiments. 
3.4.2 Removing the leader peptide sequence of the cbp gene and adding an N-
terminal hexa histidine tag 
The previously cloned cbp gene construct resulted in a smaller protein size than 
predicted, even after using protease inhibitors. Thus, a new cbp gene construct was 
made based on previously published work that expressed an orthologue of the cbp gene 
in E. coli (Esmay et al., 2003). The leader peptide sequence was removed from the new 
cbp construct, the hexa histidine tag and S-D sequence were placed at the N-terminal of 
the CBP. Leader peptide sequences are usually removed from cell surface proteins like 
CBP by bacteria. The leader peptide sequence of the native CBP protein of L. 
fermentum 3872 may not be recognised by the E. coli translocation system, resulting in 
protein misfolding and a smaller protein size. Deciding which terminal to place the hexa 
histidine tag is also a matter of trial and error, as sometimes placing the hexa histidine 
tag in the wrong terminal may lead to protein misfolding. Thus, an N-terminal peptide 
was chosen, as was done by Esmay et al. (2003). 
PCR was conducted using primers labelled CBPREV2: 
atgagcatgctcaaatagtaaatctacttataactactaaacc, and CBPFOR2: 
atatgcttctagaagaaggaggcaacagtatgcaccatcaccatcaccatgatagcaagacaaatattactcagaacggtacg, 
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to amplify the cbp gene of pLF3872. As mentioned previously the new construct had a 
S-D sequence, XbaI and SphI restriction enzyme sites, and an N-terminal hexa histidine 
tag. The leader peptide sequence was also removed during the latter step. After 
amplification of DNA, agarose gel electrophoresis was conducted to determine sample 
quality. 
 
Figure 3.19. Agarose gel electrophoresis result of amplified cbp gene encoding for a 
protein with an N-terminal hexa histidine tag and no leader peptide sequence;1, PCR 
product; 2, 2-log DNA ladder (NEB).  
As can be seen on Figure 3.19, the PCR product is of expected size (3,094 bp). No 
spurious bands that may affect cloning are present, and thus the product was used for 
cloning experiments.   
3.4.2.1 Cloning experiment 
Once amplified, the cbp gene was purified to remove PCR contaminants. The PCR 
product and pBAD33 plasmid vector were digested using enzymes XbaI and SphI, after 
which the samples were gel purified. The insert (cbp gene) and vector (pBAD33) were 
ligated. The ligation mixture was used to transform NEB express E. coli, and the clonal 
isolates were selected and grown to confluence. To determine if transformation had 
worked, after plasmid extraction, a restriction digestion was carried out before sending 
the verified pBAD33 plasmid with the cbp gene for sample sequencing. Concentration 
and purity of the DNA were determined using a NanoVue spectrophotometer.  
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Figure 3.20. Agarose gel electrophoresis image confirming the presence of the cbp gene 
insert with the N-terminal histidine tag; C represents digested sample and UC 
undigested sample (negative control). The wells are: 1, 2-log DNA ladder (NEB); 2, 
Sample 1; 3, Sample 2. 
Table 3.8. NanoVue spectrophotometer readings of purified pBAD33 plasmid with the 
cbp gene insert used for Sanger sequencing. 
Sample 1 
 
Sample 2 
 
Concentration 
 
48 ng/µl Concentration: 60 ng/µl 
 
A260/A280 
 
1.714 A260/A280 1.690 
A260/A230  
 
2.184 A260/A230 1.967 
 
Samples 1 and 2 have the cbp gene insert that is of expected size 3094 bp. The digested 
pBAD33 plasmid is also of the expected size (5.3kb) (Figure 3.20). A band >10 kb can 
be seen for samples 1 and 2 in Figure 3.20, which is undigested sample caused by 
incomplete digestion of some of the DNA. The two samples are of good quality and 
concentrated enough (Table 3.8) for Sanger sequencing, which was used to validate the 
absence of nucleotide variations. 
 
Figure 3.21. NCBI BLASTN comparison result of Sanger sequenced cbp gene with no 
leader peptide to that sequenced using Ion Torrent PGM. 
No variations were observed for the Sanger sequenced samples, as can be seen in Figure 
3.21, with 100 % nucleotide identity to the cbp gene sequenced using Ion Torrent PGM.  
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3.4.3 Cloning and expression of a partial cbp gene  
According to a study by Deivanayagam et al (2000), in other bacteria the A domain of 
CBP is involved in adhesion. As previous attempts to express recombinant CBP led to 
degraded protein, a cbp gene construct that encoded the A domain only, was made in 
conjunction with the full cbp gene copy. The partial CBP construct lacked a leader 
peptide sequence and had an N-terminal hexa histidine tag. The gene construct also had 
XbaI and SphI restriction enzyme sites, along with an S-D sequence. PCR was 
conducted using primers CBPREV3: ctttgcatgctcaatttatagttaaactatgattatatccattag and 
CBPFOR2: 
atatgcttctagaagaaggaggcaacagtatgcaccatcaccatcaccatgatagcaagacaaatattactcagaacggtacg 
to amplify the cbp gene construct. An agarose gel electrophoresis was conducted to 
determine sample quality. 
 
Figure 3.22. Agarose gel electrophoresis result of amplified partial cbp gene;1, 2-log 
DNA ladder (NEB); 2, PCR product.  
The PCR product is of expected size (1261 bp) and does not contain any additional 
bands that may affect cloning. The sample in Figure 3.22 was used for cloning 
experiments.  
3.4.3.1 Cloning the partial cbp gene  
After PCR, the sample was purified to remove PCR contaminants. The sample and the 
pBAD33 plasmid were digested by using restriction enzymes XbaI and SphI and then 
gel purified. The purified pBAD33 and cbp samples were ligated and used to transform 
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NEB Express E. coli. Transformants were selected and grown to confluence. Plasmid 
was extracted from the confluent growth and a restriction digestion, along with agarose 
gel electrophoresis were performed, to check if the extracted sample had the cbp gene. 
 
Figure 3.23. Agarose gel electrophoresis result to confirm the presence of partial cbp 
gene insert from extracted plasmid. C represents samples that have been digested, while 
UC represents undigested samples (negative control). The wells are: 1, 2-Log DNA 
ladder (NEB); 2, Sample 1; 3, Sample 2. 
Table 3.9. NanoVue spectrophotometer reading of purified pBAD33 plasmid with 
partial cbp gene insert. 
Sample 2 
Concentration 41.0ng/µl 
A260/A280 1.640 
A260/A230 2.278 
 
Sample 2 contains the partial cbp gene insert of the expected size (1261 bp) (Figure 
3.23), and the concentration and purity are sufficient for Sanger sequencing (Table 3.9). 
Sample 1 does not contain the partial cbp gene and therefore was not sequenced.  
 
 
93 
 
 
Figure 3.24. NCBI BLASTN result comparing the Sanger sequenced partial cbp gene 
to the gene sequenced using Ion Torrent PGM. 
The NCBI BLASTN result shows that the partial cbp gene does not contain any 
nucleotide variations with a 100 % match to the cbp gene sequenced using Ion Torrent 
PGM (Figure 3.24).  
3.4.4 Expression of the cbp gene and purification of the CBP protein 
Protein expression and purification of the new cbp gene constructs that lack a leader 
peptide sequence and have an N-terminal hexa histidine tag was performed. The latter 
included expression and purification of the partial cbp gene construct, which was to be a 
backup in case the full copy of the CBP protein was degraded. Initially, a small-scale 
purification was conducted using the Magne-His Kit. This was done to allow further 
optimisation of protein expression if CBP was degraded. Small fractions of samples 
were taken at each of the protein expression and purification steps in case of experiment 
failure.  
3.4.4.1 Small scale protein purification 
 
Figure 3.25. Coomassie staining of the recombinant CBP proteins with the leader 
peptide removed and an N-terminal hexa histidine tag. The wells labelled 2–6 are 
related to partial CBP purification, while those from 7–11 are for full CBP. The wells 
are: 1, pre-strained protein ladder (Page ruler plus); 2, eluate partial CBP; 3, column 
wash 1/2/3 combined; 4, lysate flow through; 5, lysate after induction; 6, lysate before 
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induction; 7, eluate CBP; 8, column wash 1/2/3; 9, flow through; 10, lysate after 
induction; 11, lysate before induction; 12, pre-strained protein ladder (Page ruler plus).  
Figure 3.25 shows that the full copy of the CBP protein is not degraded and is 115 kDa 
in size. The protein is larger than the predicted 111 kDa, which is commonly observed 
among large cell surface proteins due to conformational properties that are not 
considered when predicting a protein’s size. Eluate (well 7) contains the CBP protein, 
with no observable spurious bands.  
The partial CBP protein is around 55 kDa and is also larger than the expected protein 
size of 47 kDa (Figure 3.25, well 2). There is also a light band below the 55 kDa band 
in well 2. This may be either non-specific protein or the CBP protein.  
 
Figure 3.26. Western blot of CBP protein without the N-terminal hexa histidine tag and 
no leader peptide sequence; 1, pre-stained protein ladder (Page ruler plus); 2, purified 
CBP protein. 
The western blot (Figure 3.26) confirmed that the CBP protein was around 115 kDa in 
size and that the CBP protein had been eluted by the Magne-His Kit. 
3.4.4.2 Large-scale protein purification 
Since small scale protein purification using the Magne-His Kit isolated CBP protein 
without indications of degradation, a large-scale protein purification was conducted. 
Samples were taken at each step of the protein expression and purification process and 
loaded into the wells of an SDS polyacrylamide gel for Coomassie staining to determine 
if the CBP protein had been purified.  
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Figure 3.27. Coomassie staining of large-scale CBP expression and purification. The 
wells labelled from 1–6 represent purification of full CBP, and wells labelled from 8–12 
represent partial CBP. The wells are: 1, lysate before induction; 2, lysate after 
induction; 3, clarified lysate; 4, column flow through; 5, CBP eluate 1; 6, CBP eluate 2; 
7, pre-stained protein ladder (Page ruler plus); 8, lysate before induction; 9, lysate after 
induction; 10, column flow through/wash mix; 11, partial CBP eluate 1; 12, partial CBP 
eluate 2.  
The clarified lysate representing E. coli after lysis using a custom lysozyme solution 
(well 3) showed that all the proteins were degraded (Figure 3.27). Degradation of 
protein was also observed for well 4 and 10, containing samples, column flow through 
representing lysate that had passed through the column. The lysates before and after 
induction had no noticeable degradation, as can be seen in wells 1, 2, 8 and 9 (Figure 
3.27). The custom lysis solution may have been contaminated with proteases, leading to 
fragmentation of the proteins as no degradation was observed before the protein 
purification step, which used NuPAGE LDS buffer for lysis. No CBP protein was 
eluted. 
3.4.4.3 Large-scale protein purification with Fastbreak Lysis solution from 
Promega 
Previous experiments with purification of recombinant CBP indicated that the lysis 
solution might have degraded the protein. Thus, the Fastbreak lysis buffer supplied by 
the Magne-His Kit (Promega) was used for large-scale protein purification. Fractions of 
the samples were taken at each step of the expression and purification protocol. Equal 
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amounts of the samples, relating to the number of cells, were loaded to each well of a 
polyacrylamide gel for Coomassie staining to help determine induction in the lysate.  
 
Figure 3.28. Coomassie staining of large scale CBP protein containing an N-terminal 
hexa histidine tag and no leader peptide. Lysis was conducted using the FastBreak 
(Promega) lysis solution. The wells labelled from 1–8 are samples from CBP protein 
expression and purification,10–12 contain partial CBP samples. The wells are: 1, lysate 
before induction; 2, lysate after induction; 3, clarified lysate; 4, column flow through; 5, 
column wash 1/2; 6, CBP eluate 1; 7, eluate 2; 8, eluate 3; 9, pre-strained protein ladder 
(Page ruler plus); 10, partial CBP eluate 1; 11, partial CBP eluate 2; 12, partial CBP 
eluate 3. The figure was obtained from Lehri, Seddon and Karlyshev (2017c).  
Both the partial and full copy of the CBP proteins were successfully purified with no 
observable spurious bands. The size of the full CBP protein was 115 kDa (well 7, 
Figure 3.28), which was larger than the predicted 111 kDa, and was similar to that 
observed during small-scale purification with the Magne-His Kit. The column flow 
through (well 4) and wash (well 5) did not contain a strong 115 kDa band. The partial 
CBP protein was also eluted and was slightly larger than 55 kDa, and bigger than that 
predicted computationally (47 kDa). Both the full CBP and partial CBP proteins were 
acceptable for downstream adhesion experiments.  
3.5 BCA assay to detect protein concentration 
After successful protein purification, a Pierce Protein BCA assay kit was used to 
determine the concentration of both the partial and full copy CBP proteins.  
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The concentration of the purified CBP was 160 µg/ml, while the concentration of the 
purified partial CBP protein was 260 µg/ml. Both proteins were concentrated enough 
for multiple adhesion experiments. 
3.6 Enzyme-linked immune absorbance assay results 
ELISA was conducted to determine whether the recombinant CBP protein could bind to 
collagen I.  
3.6.1 Optimisation of ELISA 
Initially, ELISA was carried out on 96 well UV-treated Nunclon Delta polystyrene 
plates (ThermoFisher). Test wells were coated with 0.36 µg/well collagen I (Sigma) and 
control wells were coated with 0.36 µg/well BSA (Acros Organics), 0.36 µg/well was 
used as the surface area of each well was 0.36 cm2. Control wells would help determine 
non-specific interaction between CBP and collagen I. Standard ELISA protocol was 
followed as described in section 2.15 with each well incubated with 0.36 µg of CBP. 
 
Figure 3.29. CBP adhesion to collagen I, using UV-treated Nunclon Delta plates. The 
antibodies used were 6x-His Epitope Tag monoclonal primary antibody and HRP-linked 
secondary polyclonal antibody. A single biological replicate was conducted consisting 
of three technical replicates (N = 3). 
The BSA coated wells had a higher absorbance than that for collagen I coated wells 
(Figure 3.29). The BSA (Acros Organics) used for control wells may have had 
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extracellular matrix protein (ECM) contaminants such as various types of collagen, 
fibrinogen, and fibronectin, and thus a different type of BSA may be required. Another 
reason for having a higher absorbance for control wells as opposed to test wells could 
be due to the type of plate used. Since UV treated plates have a higher binding affinity, 
as there are multiple ways in which a protein can interact with the plate, such as ionic 
and hydrophobic interactions, collagen I may have been coated in such way that 
potential collagen binding sites were not exposed on the plate.  
3.6.1.1 Further optimisation experiments 
Since the absorbance of the negative control wells for the previous experiment was 
higher than that of the test wells, further optimisation experiments were carried out. 
Two 96 well polystyrene plates from Corning were used. One was UV treated (High 
Bind Corning Costar) and the other was untreated (Med Bind Corning Costar). Treated 
and non-treated plates were used to determine whether the type of plate was causing a 
lower absorbance for test wells, as protein coating on a non-treated plate is designed for 
large molecules, such as collagen I. Two types of BSA were tested on the untreated 
plate, one of which was from Acros Organics (previously used) and the other was of 
99% purity from Sigma. For the UV treated plate, only BSA from Sigma was used. This 
would help determine whether the purity of BSA was causing an increase in absorbance 
for negative control wells. 
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Figure 3.30. Identifying optimal plates to use for future ELISA experiments. (A) UV 
treated Costar High bind plates, and (B) untreated Costar Med-Bind plate. Each plate 
was coated with collagen I and BSA, which were incubated with CBP (0.36 µg). The 
antibodies used were 6x-His Epitope Tag monoclonal primary antibody and HRP-linked 
secondary polyclonal antibody. For each experiment, one biological replicate, 
consisting of three technical replicates, was conducted (N = 3). 
As can be seen in Figure 3.30 (A), the absorbance of the control wells for the UV 
treated plate (High Bind Corning Costar) was higher than that of the test wells, even 
when using a different BSA (Sigma). The absorbance of the negative control for the 
untreated plate (Med Bind Corning Costar) was lower than that of the test wells (Figure 
3.30, B). There was also no difference in absorbance between the two types of BSA 
used for the untreated plate. Thus, the likely cause of having a higher absorbance for the 
negative control wells was the type of plate used. For future experiments, untreated 
plates were used for coating collagen I. 
3.6.1.2 Optimisation of diluent for coating wells 
As collagen I (Sigma) was initially prepared in 0.1 M acetic acid with a final pH of 3.4, 
and the recommended ELISA coating buffer has a pH of 9.6, a test ELISA experiment 
was conducted to determine whether the type of diluent used for coating plates would 
influence collagen coating and thus binding experiments. To obtain a pH of around 3.4, 
collagen I was diluted in water, while ELISA coating buffer was used as a diluent for 
comparative purposes. 
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Figure 3.31. ELISA experiment to determine the effect of collagen I coating with 
varying diluents. The antibodies used were 6x-His Epitope Tag monoclonal primary 
antibody and HRP-linked secondary polyclonal antibody. A single biological 
experiment was conducted consisting of three technical repeats (N = 3). 
The absorbance values for plates coated with ELISA coating buffer (pH 9.6) was higher 
than that of distilled water (pH 3.2) (Figure 3.31). For future experiments, ELISA 
coating buffer was used due to the increased absorbance observed at higher pH. 
3.6.2 CBP adhesion to collagen I 
After optimisation, to confirm whether the CBP protein binding to collagen I was 
concentration dependent, an ELISA-based experiment was conducted. Wells were 
coated with 0.36 µg/well of collagen I and BSA (Sigma). To determine binding to 
collagen I, a difference in absorbance between varying amounts of CBP (0.05 µg/well, 
0.1 µg/well, 0.2 µg/well and 0.36 µg/well) was used. To differentiate between actual 
and non-specific interactions, BSA (Sigma) coated wells were used as a negative 
control.  
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3.6.2.1 CBP binding assay 
 
Figure 3.32. Determining CBP concentration dependency in binding to collagen I. The 
antibodies used were 6x-His Epitope Tag monoclonal primary antibody and HRP-linked 
secondary polyclonal antibody. The data contains two biological repeats with three 
technical repeats (N = 6). The figure was obtained from Lehri, Seddon and Karlyshev 
(2017c).  
As mentioned in Lehri, Seddon and Karlyshev’s (2017c) article, the CBP protein binds 
to collagen I in a concentration dependent manner (Figure 3.32). The absorbance when 
using 0.1 µg/well of CBP is higher than that of 0.05 µg/well. No difference in 
absorbance was observed between concentrations of 0.1 µg/well to 0.36 µg/well of 
CBP.  
3.6.2.2 C. jejuni binding assay 
Binding experiments were conducted to discover whether C. jejuni 11168H and 81–176 
strains attached to collagen I. Varying amounts of C. jejuni were added to each well, 2 x 
108, 2 x 107 and 2 x 106 CFU/well to see if there was concentration dependency and to 
find the most useful amount of C. jejuni to use for competition experiments. 
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Figure 3.33. Identifying C. jejuni strains 81–176 (A) and 11168H (B) concentration 
dependency in binding to collagen I. The antibodies used were C. jejuni monoclonal 
primary antibody and goat anti-mouse polyclonal secondary antibody. The data consists 
of two biological repeats, each having three technical repeats (N = 6) except for (A), 2 x 
10^8 where N = 5. The figure was obtained from Lehri, Seddon and Karlyshev (2017c).  
Figure 3.33 shows that both C. jejuni 11168H and 81–176 bind to collagen I in a 
concentration dependent manner. For future competition experiments, 2 x 107 CFU/well 
of C. jejuni were used, as this utilised a minimal number of cells yet had a high enough 
absorbance to detect changes. Using 2 x 107 CFU/well of C. jejuni cells would also be 
useful for obtaining the required ratios of C. jejuni to L. fermentum 3872 of 2:1, 1:1, 
1:5, 1:10 for whole cell competition assay experiments. 
3.7 Competition assay 
3.7.1 Reduction of C. jejuni adhesion to collagen I in the presence of CBP 
Binding experiments showed that both the CBP protein and C. jejuni 11168H and 81–
176 strains bind to collagen I. Thus, competition experiments were carried out to 
determine if the CBP protein could inhibit C. jejuni strains 11168H and 81–76 binding 
to collagen I. 
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Figure 3.34. ELISA experiment showing the effect of CBP on C. jejuni 11168H and 
81–176 binding to collagen I. The bars labelled 81–176 and 11168H only contain C. 
jejuni strains 11168H (B and D) and 81–176 (A and C) of 2 X 107 CFU/well. The bars 
labelled 0.36 µg and 2 µg contain a mixture of 0.36 µg or 2 µg CBP and either C. jejuni 
11168H (B, D) or 81176 (A, C). The antibodies used were C. jejuni monoclonal 
primary antibody and goat anti-mouse polyclonal secondary antibody. Graphs A and B 
have data from two biological repeats each with three technical repeats (N = 6), while C 
and D consists of three biological repeats, each with three technical repeats (N = 9). The 
figure was obtained from Lehri, Seddon and Karlyshev (2017c) with additional graphs 
(A) and (B) added. 
An amount of 0.36 µg/well of CBP does not reduce absorbance of C. jejuni 11168H and 
81–176 (Figure 3.34; A and B). Increasing the amount of CBP to 2 µg/well causes a 
decrease in C. jejuni 11168H and 81–176 absorbance, inhibiting C. jejuni binding to 
collagen I (Figure 3.34; C and D). 
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3.7.2 Reduction in C. jejuni adhesion to collagen I in the presence of L. fermentum 
3872 
As competition experiment between CBP and C. jejuni strains 11168H and 81–176 
showed inhibition of C. jejuni binding to collagen I, a competition experiment was also 
carried out to determine whether L. fermentum 3872 whole cells could inhibit C. jejuni 
11168H and 81–176 binding to collagen I.  
 
Figure 3.35. Whole cell competition experiments between L. fermentum 3872 and C. 
jejuni strains 81-176 (A) and 11168H (B) in binding to collagen I. Bars labelled Control 
have 2 x 107 CFU/well C. jejuni strains 11168H or 81–176. The cell to cell ratios shown 
on the graph are after adding a suspension mixture of bacteria to each well. The 
antibodies used were C. jejuni (PEB1) polyclonal primary antibody and goat-anti-rabbit 
IgG polyclonal HRP conjugated secondary antibody. Two biological repeats were 
conducted, each with three technical repeats (N = 6), apart from control (B) and 1:10 
(B), for which three biological repeats were conducted, each with three technical repeats 
(N = 9). The figure was obtained from Lehri, Seddon and Karlyshev (2017c). 
The absorbance observed for the C. jejuni 11168H and 81–176 wells increases when a 
ratio of C. jejuni to L. fermentum 3872 of 2:1 is used (Figure 3.35). The increase in 
absorbance may be a result of aggregation (further described in the discussion section), 
although more research is needed to adequately prove the cause of the increased 
absorbance. When increasing the amount of L. fermentum 3872, a decrease in 
absorbance is seen for C. jejuni 11168H and 81–176 wells (Figure 3.35). 
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3.8 Identifying proteins contributing to collagen I adhesion for C. jejuni strains 
11168H and 81-176  
Genome sequencing identified multiple genes potentially involved in adhesion for L. 
fermentum 3872, including those involved in collagen binding. For C. jejuni strains 
11168H and 81–176, genome sequence analysis could not identify collagen binding 
proteins. Therefore, to determine the type of proteins utilised by C. jejuni strains 
11168H and 81–176 for adhesion to collagen I, a Co-IP was conducted with the lysates 
of C. jejuni strains, followed by mass spectrometry analysis. 
3.8.1 Coomassie staining of the Co-IP eluates 
Initially, Coomassie was used to stain the eluted proteins of C. jejuni strains 11168H 
and 81–176 that interacted with collagen I coated beads. 
 
Figure 3.36. Coomassie stained gel picture of C. jejuni strains 11168H and 81–176 Co-
IP eluates; 1, pre-stained ladder (Page ruler plus); 2, 81–176 column flow through; 3, 
81–176 lysate; 4, 81–176 Co-IP eluate; 5, 11168H column flow through; 6, 11168H 
lysate; 7, 11168H eluate; 9, pre-stained ladder (Page ruler plus). 
No bands were detected for the Co-IP eluates of C. jejuni strains 11168H and 81–176 
(wells 4 and 7; Figure 3.36). The lysate and flow through wells showed that the proteins 
were not degraded. Either no protein was present in the eluates, or Coomassie staining 
was not sensitive enough to detect the minute quantity of eluted protein. The Co-IP 
protocol suggested using a more sensitive protein staining approach. 
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3.8.2 Silver staining of the Co-IP eluates 
Silver staining was used to determine if there was any detectable protein eluted from 
collagen I coated beads, incubated with the lysates of C. jejuni strains 11168H and 81–
176. Silver staining is far more sensitive than Coomassie staining in detecting minute 
quantities of protein. 
 
Figure 3.37. Silver stain of C. jejuni 11168H and 81–176 Co-IP eluates; 1, pre-stained 
ladder (Page ruler plus); 2, 11168H eluate after one hour of incubation; 3, 11168H 
eluate after three hours’ incubation; 4, 81–176 eluate after one hour of incubation; 5, 
81–176 eluate after three hours’ incubation. The figure was obtained from Lehri, 
Seddon and Karlyshev (2017c). 
The silver stain analysis detected two major bands for both C. jejuni strains 11168H and 
81–176 at around 65 kDa and 15 kDa (Figure 3.37). The Co-IP experiment was 
repeated twice with similar results. There were also light bands for the C. jejuni strains 
tested, namely after a three-hour incubation, which was likely caused by nonspecific 
interactions during Co-IP experiment. Nonspecific interactions are common in Co-IP 
experiments, particularly for long-term incubations, as stated in the manufacturer's 
protocol. The two most apparent bands, at 65 kDa and 15 kDa, were extracted and sent 
for mass spectrometry analysis (LC-MS/MS).  
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Figure 3.38. Screenshots of Mascot software hits for mass spectrometry (LC-MS/MS) 
data output. The data shows the major hits for the 65 kDa protein eluted during Co-IP 
for C. jejuni strains 81–176 (A), 11168H (B). The figure was obtained from Lehri, 
Seddon and Karlyshev (2017c). 
Analysis of mass spectrometry data revealed that, for both C. jejuni strains 11168H and 
81–176, the 65 kDa band was affiliated with flagellin subunits FlaA and FlaB (Figure 
3.38). The estimated size of FlaA and FlaB was smaller (60 kDa) than the silver stain 
result (Figure 3.37). This is likely a result of O-linked glycosylation of the protein in 
Campylobacter, which can alter the mobility of protein in SDS gels (Hitchen et al., 
2010). Mass spectrometry data analysis of the 15 kDa protein using Mascot software 
had partial amino acid hits to FlaA and FlaB proteins of C. jejuni strains 11168H and 
81–76. The proteins of 15 kDa in size may potentially be fragmented FlaA and FlaB 
proteins.  
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3.9 Inhibition of C. jejuni 11168H and 81-176 growth by L. fermentum 3872 
supernatant  
An agar well diffusion assay was conducted to determine whether L. fermentum 3872 
produces antimicrobials that may inhibit C. jejuni strains 11168H and 81–176 growth in 
vitro.  
 
Figure 3.39. Agar well diffusion assay result for C. jejuni 11168H and 81–176 grown in 
the presence of L. fermentum 3872 cell free culture supernatant; 1, M.R.S broth 
(control); 2–4, L. fermentum 3872 cell free supernatant; 2, untreated; 3, heat treated; 4, 
pH adjusted. The figure was obtained from Lehri, Seddon and Karlyshev (2017c). 
C. jejuni growth inhibition was observed in wells with low pH (Figure 3.39). The 
diameter of the zone of inhibition for C. jejuni 11168H with L. fermentum 3872 cell free 
supernatant was 21 mm (SD±1), and was 21 mm (SD± 0.5) for C. jejuni 81–176. After 
boiling L. fermentum 3872, the zone of inhibition for C. jejuni 11168H was 21 mm (SD 
±0.5) and for C. jejuni 81–176 was 21 (SD± 0.4). No growth inhibition was observed in 
control wells or in wells where the pH of the L. fermentum 3872 supernatant was 
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adjusted to that of the control wells. There was no difference in the diameter of zones of 
inhibition between the C. jejuni strains tested and between boiled and not boiled L. 
fermentum 3872 supernatants.  
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Chapter 4: Discussion 
4.1 Genome sequencing issues and possible solutions 
During the completion of the genome sequence for L. fermentum 3872, it was 
determined that multiple assembly errors could not be successfully identified due to an 
over reliance on read mapping as a quality indicator. This can be a major issue for many 
draft genome assemblies deposited in databanks, and for comparative genomic studies 
that assume good genome quality. For unpaired reads generated by the Ion Torrent 
PGM, assembly verification can be conducted using sequence scaffolding tools such as 
Contiguator (Galardini et al., 2011), given that there is minimal genotypic variation 
between the query and reference sequence. This method is also dependent on the quality 
of the reference sequence assembly. As an example, during this study, Contiguator 
(Galardini et al., 2011) detected multiple alignment variations between the query 
sequence (L. fermentum 3872) and that of the reference sequence (L. fermentum IFO 
3956) thus indicating a misassembly of the query sequence (Figure 3.5). When splitting 
the correctly assembled L. fermentum 3872 chromosomal sequence at 100,000 bp 
points, Contiguator alignment to the reference sequence had improved, indicating a 
better assembly (Figure 3.11). Furthermore, the Ion Torrent PGM is able to generate 
mate pair reads, which are capable of sequencing two ends of a fragmented DNA of 400 
bp in length, with a 20kb sequence gap between the sequenced ends. Mate pair read 
data, in combination with unpaired reads, would enable identification of contig location 
for scaffolding and genome sequence completion. The drawback of this technique is 
that the cost of generating mate pair reads is higher than that of a PacBio RSII 
sequencing run, which can sequence nucleotide fragments of >14kb in length without 
gaps (Reuter, Spacek and Snyder, 2015). Furthermore, combining mate pair and 
unpaired read data requires much more computational effort than combining long 
PacBio RSII generated reads with short reads.  
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Analysis of the misassembled contigs indicated that assembly errors could be dependent 
on the type of de novo assembly tool used, as certain de novo assemblers had more 
assembly errors than others (Table 3.4). The sequencing region being assembled may 
also give rise to misassembly as certain sequenced regions were misassembled 
regardless of the de novo assembly tools used. Misassembly predominantly happened 
within or near repetitive regions (for example, transposons or RNA encoding regions), 
as shown in Figure 3.7. Many de novo assemblers do not extend a sequence beyond 
repetitive elements, given short reads are being used. Thus, it would be useful not to fill 
in sequencing gaps unless information on the contig’s location/orientation in relation to 
other contigs is known, along with the information on the gap size between contigs. If 
such information is known and the gap size is not large, then BLASTN extension, or 
preferably Sanger sequencing, may be used to fill in sequencing gaps.  
An optical map can be a useful sequence assembly validation tool. The optical map of 
the genome is independent of nucleotide sequence data, which removes sequencing bias 
and thus provides greater confidence in the assembly quality. As described previously, 
all de novo assemblers had difficulty assembling specific genomic sequence regions, 
and thus an assembler that utilises optical map data to guide sequence assembly could 
be useful in accurate genome assembly (Lin et al., 2012). Optical maps are currently 
helpful in genome sequences of over 30 kb in size, which could be improved by 
introducing more restriction enzymes and thus improving the resolution of the map 
generated. Furthermore, as genome sequencing technology is focusing on large, low-
quality read data, an optical map would be useful in differentiating between contigs and 
reads that have artefactually been categorised as contigs by de novo assemblers, which 
was the case with the remaining five sequences of the PacBio RSII output. A major 
issue with bacterial genome sequencing is that bacterial colonies tend to have genotypic 
variation, which makes it difficult to determine whether the sequenced clonal isolate is 
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truly representative of the microbe being administered for probiotic use (Walsh et al., 
2016). For this study, two clonal isolates were sequenced at confluence and no 
variations were found. Nonetheless, re-sequencing after administration of L. fermentum 
3872 to a host or after prolonged storage would be advisable to determine any genotypic 
change. 
4.2 The chromosomal sequence of L. fermentum 3872 
As mentioned in the results section, the chromosomal sequence of L. fermentum 3872 
consisted of multiple vitamin B coding genes. These genes may be useful for infants, as 
the bacteria was isolated from a healthy human female’s milk (Abramov et al., 2014). 
There are several genes and metabolic pathways for pH adjustment and acid tolerance 
that could play a role in L. fermentum 3872 survival within the acidic environment of 
the GIT. Acid tolerance would enable the probiotic to be ingested and to reach its 
destined site of action, as well as to colonise the host to provide its desired effect. The 
L. fermentum 3872 genome also contains a group of genes involved in 
exopolysaccharides (EPS) synthesis. In other lactic acid bacteria, EPS are involved in 
bacterial protection against toxic compounds and desiccation, thus playing an important 
role in bacterial survival (Patel, Majumder and Goyal, 2009). EPS also have host 
cholesterol-lowering properties and have been known to promote bacterial adhesion and 
biofilm formation (Mozzi et al., 2009).  
Another gene located near a cluster of EPS genes is epsH, which is not found in other L. 
fermentum strains used for comparative analysis. A study conducted by Jones et al. 
(2014) showed that the protein encoded by epsH plays a role in protection against 
inflammation induced by Citrobacter rodentium in mice. The study stated that the EpsH 
protein may reduce inflammation and help combat colitis induced by enteric pathogens 
via immunomodulation by affecting TLR4 (Jones et al., 2014). Thus, L. fermentum 
3872 may be a candidate for studies involving inflammatory bowel diseases.  
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Other survival genes that encode DnaK and GroEL have also been associated with 
osmotic and heat shock resistance (Prasad, McJarrow and Gopal, 2003), and have been 
known to be overly expressed in the cell wall region of bacteria that bind to mucin 
(Izquierdo et al., 2009). The GroEL encoding gene of Lactobacilllis johsonii La1 is 
known to cause H. pylori aggregation, which in turn may aid in the clearance of H. 
pylori, mediated by mucus flushing (Bergonzelli et al., 2006). Genes that encode D-
Lactate dehydrogenase, and 6-phosphogluconate dehydrogenase, have also been known 
to be overexpressed in Lactobacillus species that bind to mucin (Izquierdo et al., 2009). 
The mucus binding protein of L. fermentum 3872 has been annotated as partial, this is 
due to the fact that the protein has a leucin start codon as opposed to the more 
commonly used methionine, thus verification is needed to determine whether the 
protein is truly partial. As mentioned in the result section a gene that encodes the 
internalin J-like precursor (inlJ) has a mucin binding (MucBP) domain and may 
promote bacterial adhesion to mucin (Sabet et al., 2005; Juge, 2012). A Translational 
elongation factor gene similar to that found for L. fermentum 3872 has also been known 
to contribute in adhesion to intestinal Caco-2 cells under low pH (Granato et al., 2004). 
The above mentioned adhesion genes may be useful candidates for future adhesion and 
competitive exclusion studies. Proteins that bind to mucin are important in that mucin is 
found in the lining of the GIT and is often one of the first points of contact for many 
pathogenic bacteria for GIT colonisation of the host (Oelschlaeger, 2010). L. fermentum 
3872 also has a gene that encodes an aggregation substance precursor protein, which has 
been associated with bacterial aggregation and adhesion (Suessmuth et al., 2000), and 
thus may be useful for competitive exclusion studies. An enolase encoding gene is 
known to promote adhesion to collagen (Salzillo et al., 2015) and may potentially work 
synergistically with the CBP protein. As mentioned in the results section a gene 
encoding a fibronectin binding protein was also found. The protein may promote L. 
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fermentum 3872 adhesion to fibronectin (Muñoz-Provencio, Pérez-Martínez and 
Monedero, 2010), an ECM protein much like collagen. These genes may play a role in 
L. fermentum 3872 host colonisation, survival, and be potential candidates for future 
competition experiments. There are also genes present for iron acquisition, which may 
play a role in inhibiting the growth of other bacteria as iron acquisition is important for 
bacterial growth (Oelschlaeger, 2010). Many of the antibiotic-resistance genes 
identified in L. fermentum 3872 are commonly found in other bacteria, such as genes 
involved in beta-lactamase resistance, tetracycline resistance, and fluoroquinolone 
resistance. Thus L. fermentum 3872 can be widely used against pathogens with minimal 
concern about antibiotic-resistance gene transfer.  
Comparative genomic analysis revealed that many of the unique regions of L. 
fermentum 3872 have large areas consisting of prophage-related genes, which was 
confirmed by PHAST software (Zhou et al., 2011) identifying four intact prophage-
related regions. The regions seem to be newly incorporated due to the sudden G+C 
change compared to that of the surrounding genomic area and is a result of horizontal 
gene transfer. Prophages can be induced under specific conditions to produce 
bacteriophages that may be utilised to tackle pathogenic bacteria. As mentioned in the 
introduction, the use of bacteriophages is promising in reducing C. jejuni numbers in 
poultry, but C. jejuni can become resistant to bacteriophage therapy (Kaakoush et al., 
2015). Thus, a combination of antimicrobials or phages may be useful for combating C. 
jejuni infections.  
A class III bacteriocin unique to L. fermentum 3872 was also identified. Class III 
bacteriocins tend to be large, thermolabile and have a broad antimicrobial spectrum 
(Ben Lagha et al., 2017). They are divided into two subclasses: type IIIa and type IIIb 
(Ben Lagha et al., 2017), type IIIa is bacteriolytic and catalyses the hydrolysis of 
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peptidoglycan. Type IIIb bacteriocins are non-lytic but may cause membrane leakage, 
prevent sugar uptake or inhibit DNA synthesis (Ben Lagha et al., 2017). According to 
BAGEL3 and BACTIBASE software, the closest match to the bacteriocin of L. 
fermentum 3872 was enterolysin A from Enterococcus faecalis, with a query coverage 
of 40% and identity of 14%. A study has shown that enterolysin A isolated from E. 
faecalis LMG 2333 is bacteriolytic and may inhibit growth of particular Enterococci, 
Lactococci, Lactobacilli and Pediococci bacteria (Nilsen, Nes and Holo, 2003). Based 
on similarity to enterolysin A, the bacteriocin from L. fermentum 3872 may also be a 
class IIIa bacteriocin. 
4.3 Information on the plasmid pLF3872  
The G+C content of the plasmid pLF3872 is lower (40.1%) than that of the 
chromosomal sequence of L. fermentum 3872 (50.1%), indicating that pLF3872 has 
recently been acquired. The presence of multiple conjugation genes mentioned 
previously suggests that the plasmid has conjugative ability, and that conjugation may 
be a possible means of plasmid acquisition. Conjugation may pose a risk in transfer of 
genes such as cbp to other microbes. The presence of toxin-antitoxin genes (eatL-zetL) 
may ensure stable maintenance of pLF3872 in L. fermentum 3872. To date, there are 
several plasmids identified in some L. fermentum strains (i.e. L. fermentum MTCC 8711 
contains seven plasmids), none of which are similar to pLF3872. As previously 
mentioned, there are three closely related plasmids identified in other species of 
Lactobacillus, namely plca36 (L. casei Zhang), pWCFS103 (L. plantarum WCFS1) and 
plasmid 1(L. paracasei subsp). As mentioned in the results section plasmid pLF3872 
consists of a cbp gene not found in any other strain of L. fermentum sequenced to date. 
An orthologue of the gene has been identified in Lactobacillus plantarum 91. The CBP 
protein expressed by L. plantarum 91 has shown antagonistic properties against 
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pathogen E. coli O157: H7 via competitive exclusion of adhesion ligands (Yadav et al., 
2013), which may be of interest for future L. fermentum 3872 experiments.  
4.4 Competition and inhibition experiments 
As genomic analysis identified a putative cbp gene, the CBP protein was expressed and 
analysed for competitive exclusion against enteric pathogen C. jejuni. Binding 
experiments showed that CBP may be utilised by L. fermentum 3872 for collagen I 
adhesion. The study also demonstrated that C. jejuni strains 11168H and 81–176 attach 
to collagen I. Adhesion can be important for bacterial colonisation, the CBP protein 
may play a role in L. fermentum 3872 growth and survival within a host, increasing the 
possibility of L. fermentum 3872 providing its probiotic effect through other 
mechanisms. Adhesion to collagen I may also increase C. jejuni virulence and potential 
for infection. Co-IP and mass spectrometry data suggested that C. jejuni strains 11168H 
and 81-176 may utilise flagella components (FlaA and FlaB) for binding collagen I. 
Studies have shown that C. jejuni deficient of flagella have a lower adhesion to 
intestinal epithelia (Haiko and Westerlund-Wikstrom, 2013; Newell, McBride and 
Dolby, 1985), but this is the first instance that the proteins have been directly affiliated 
with collagen adhesion.  
In vitro experiments showed that the CBP protein prevents C. jejuni 11168H and 81–
176 attachment to collagen I. Collagen I binding of C. jejuni strains 11168H and 81–
176 was also inhibited in the presence of L. fermentum 3872. This competition may 
directly be against flagellar components (FlaA and FlaB) of C. jejuni 11168H and 81–
176. The competition assay results demonstrate a way to use L. fermentum 3872 to 
reduce C. jejuni in the host via competitive exclusion. ELISA-based whole cell 
competition experiments also showed an increase in absorbance when mixing low 
amounts of L. fermentum 3872 to C. jejuni. The reasoning behind the increase in 
absorbance needs to be determined in future studies, a potential theory of the result may 
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be that either L. fermentum 3872 is causing auto-aggregation of C. jejuni strains 11168H 
and 81–176 or there is co-aggregation between the C. jejuni strains tested to L. 
fermentum 3872. Previous studies have shown co-aggregation between Lactobacillus 
and C. jejuni (Nishiyama et al., 2014), as described in the introduction. The agar well 
diffusion assay showed that growth of C. jejuni strains 11168H and 81-176 was 
inhibited by the low pH of the L. fermentum 3872 cell-free supernatant. The low pH 
environment, in combination with co-aggregation, could work synergistically in 
combating C. jejuni infection as the distance between the two bacteria would reduce 
(Tareb et al., 2013). Using numerous ways to combat pathogenic bacteria would also be 
advantageous in that the pathogen would have to evolve in many ways to survive.  
4.5 Conclusion  
With increasing interest in OMIC technologies, especially in the field of genomics, and 
an ever-growing abundance of data generated by the technology, emphasis needs to be 
on the quality of data generated, particularly for probiotic research, which is becoming 
heavily reliant on genomic data for characterising probiotics regarding safety, stability, 
and potential use (Papadimitriou et al., 2015; Johnson and Klaenhammer, 2014; Walsh 
et al., 2016). As previously mentioned, many genomic studies leave sequences as draft 
assemblies, making it difficult to build a complete profile of the organism in question 
(Land et al., 2014). Having a complete genomic profile of a probiotic is important as 
certain probiotic traits can be overlooked due to their strain-specific nature (Islam, 
2015). An example of the importance of a complete genome sequence was 
demonstrated with L. fermentum 3872, where previously, a partial cbp gene was 
identified when L. fermentum 3872 was in a draft state. The full copy of the cbp gene 
was only identified during the genome completion project, enabling the determination 
of essential CBP components, such as its leader peptide sequence. Identifying the leader 
peptide sequence may have been important for the expression of the recombinant CBP 
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protein for functional genomic analysis, as before its removal, the recombinant protein 
was degraded. The genome completion project also demonstrated that the cbp gene was 
present in a newly identified plasmid pLF3872, consisting of many conjugative genes. 
The conjugative genes may be problematic in that the plasmid may transfer genes to 
pathogenic bacteria. Nonetheless, pathogens such as C. jejuni tend to accept DNA only 
readily from their own species (Johnson, Shank and Johnson, 2017). Many survival and 
adhesion genes were identified, which may enable L. fermentum 3872 to survive the 
harsh GIT environment. Both the survival and adhesion genes helped build a profile of 
the probiotic in that it could potentially be administered orally and be useful in the GIT 
region. The presence of the adhesion genes may also be the reason for L. fermentum 
3872 having strong adhesion to HeLa and Buccal cells compared to other Lactobacillus 
strains tested during experiments conducted for patent application (Abramov et al., 
2014). To obtain a complete profile of the genetic makeup of L. fermentum 3872, the 
hypothetical proteins need to be functionally identified. As an antimicrobial tool, L. 
fermentum 3872 may be useful in combating enteric pathogens via competitive 
exclusion due to the multiple adhesion genes present. One such gene analysed during 
this study was a putative cbp, which encoded a CBP protein. The protein successfully 
inhibited C. jejuni strains 11168H and 81–176 attachment to collagen I. Furthermore, 
the combination of low pH and competitive exclusion may further reduce the 
survivability of C. jejuni in the presence of L. fermentum 3872, making it difficult for 
the pathogen to evolve and be resistant to the antagonistic effects of L. fermentum 3872. 
Nonetheless, as discussed in the future work section, in vivo experiments need to be 
conducted to determine whether L. fermentum 3872 is effective in combating C. jejuni 
in animal or human models. With C. jejuni being an important cause of gastroenteritis 
(Kaakoush et al., 2015), and travellers’ diarrhoea (Kaakoush et al., 2015), L. fermentum 
3872 may be used as an adjunct to rehydration therapy or as a prophylactic during 
119 
 
travels to high infection risk countries. If found to be effective in reducing the duration 
of gastroenteritis, the use of L. fermentum 3872, and perhaps a selection of probiotics 
with similar modes of actions, may reduce the incidence of C. jejuni affiliated IBD and 
IBS as the risk of developing the latter two conditions is dependent on the duration of 
the C. jejuni infection (Ericsson, Hatz and DuPont, 2008). 
A summary of the major findings of the current study are listed below: 
1. The genome sequence of L. fermentum 3872 was completed and a plasmid 
pLF3872 was discovered. Potential genes that may be of interest for future 
studies contributing to probiotic activity were highlighted.  
2.  The study demonstrated that read mapping, a commonly used genome 
sequence quality assessment tool could fail to detect sequence missassemblies.   
3. The results showed that putative CBP isolated from L. fermentum 3872 and C. 
jejuni strains 11168H and 81-176, bind to collagen I. The C. jejuni strains 
utilise flagellar proteins FlaA and FlaB for collagen I adhesion.  
4. The CBP protein inhibits C. jejuni 11168H and 81-176 binding to collagen I. L. 
fermentum 3872 also inhibits C. jejuni 11168H and 81-176 adhesion to collagen 
I. 
5. L. fermentum 3872 is able to inhibit C. jejuni 11168H and 81-176 growth by 
lowering the pH environment. 
4.6 Future experiments and limitations  
While sequencing the genome of L. fermentum 3872, read mapping was unable to detect 
sequence misassembly. The Ion Torrent PGM used for this project only generates 
unpaired reads, and thus it would be interesting to determine whether paired end reads 
would produce similar results to unpaired reads. Paired end reads are similar to mate 
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pair reads in that two ends of a DNA fragment is sequenced but the region between the 
sequenced ends are smaller in size e.g. hundreds of bases rather than kilobases, and thus 
requires less laboratory work. Paired end reads have more software support that can be 
utilised for sequence gap closure, improvement of nucleotide and assembly errors. 
Tools such as iterative mapping and assembly for gap elimination (IMAGE) (Tsai, Otto 
and Berriman, 2010) can be utilised for automated gap closure, iterative correction of 
reference nucleotides (ICORN) (Otto et al., 2010) can be used to correct small 
nucleotide errors, and recognition of errors in assemblies using paired end reads 
(REAPR) (Hunt et al., 2013) can be used for assembly error correction. IMAGE, 
ICORN and REAPR tools do not require a reference genome, which can mitigate a 
carryover of potential assembly errors introduced by a reference genome sequence.  
Future studies could also determine whether the CBP protein can inhibit adhesion of 
other pathogenic bacteria that are heavily reliant on collagen I attachment, such as 
Staphylococcus aureus (Ponnuraj et al., 2003). Competitive exclusion studies can also 
be conducted against E. coli O157: H7 as previous in vitro experiments have shown a 
reduction in attachment to collagen I in the presence of the CBP protein expressed by L. 
plantarum 91 (Yadav et al., 2013). cbp gene knockout experiments for L. fermentum 
3872 can also be conducted to determine the extent to which the protein plays a role in 
L. fermentum 3872 adhesion to collagen I. Experiments with various other collagen 
types can be carried out to determine whether the CBP protein can promote attachment 
to collagens such as collagen IV, present in the basement membrane of the GIT 
(Verbeke et al., 2001). The current study did not directly demonstrate L. fermentum 
3872 attachment to collagen I due to non-availability of L. fermentum specific 
antibodies. The already expressed recombinant CBP protein can be used as an antigen 
for the development of polyclonal antibodies for confocal microscopy to visually 
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observe the CBP protein. The antibodies may also be used for ELISA experiments to 
confirm L. fermentum 3872 attachment to collagen I and perhaps other ECM proteins.  
There were many other putative genes identified relating to L. fermentum 3872 adhesion 
to the GIT, such as those that promote binding to mucin and intestinal epithelia. It 
would be interesting to determine whether the genes play a role in the prevention of 
enteric pathogen attachment to GIT proteins. ELISA experiments between L. fermentum 
3872 and C. jejuni indicated aggregation. Confocal microscopy could be used to 
observe if C. jejuni aggregation or co-aggregation is occurring in the presence of L. 
fermentum 3872. Moreover, previous studies that reported co-aggregation between 
Lactobacillus and C. jejuni found that the introduction of proteinase K resulted in no 
aggregation (Nishiyama et al., 2014), suggesting that a protein was involved in the 
phenotypic effect. An ELISA could be repeated with the introduction of proteinase K to 
determine whether a protein is the causative agent of the aggregation effect. The 
putative bacteriocin of L. fermentum 3872 may also be expressed. A study has shown 
that Enterolysin A production in MRS was optimal at a constant pH of 6.5 but 
decreased as the pH lowered (Nilsen, Nes and Holo, 2003). Thus, L. fermentum 3872 
could be grown in MRS broth with a constantly adjusted pH to isolate the bacteriocin, 
to determine whether the protein has an antagonistic effect on other bacteria.  
The current study demonstrated that L. fermentum 3872 may utilise competitive 
exclusion and acidification of the environment to combat C. jejuni infection in vitro. 
The in vitro experiments need to be followed by in vivo experiments to determine 
whether L. fermentum 3872 can truly be used as a tool against C. jejuni infections in 
hosts. This is because certain in vitro studies have shown good antagonistic effects on 
C. jejuni but have failed to show similar effects in vivo (Johnson, Shank and Johnson, 
2017), although many other studies have had positive correlations between in vitro and 
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in vivo models (Kaakoush et al., 2015). As L. fermentum 3872 was isolated from a 
healthy human and utilised in its natural GIT environment, a randomised control trial 
could be undertaken. The trial may provide L. fermentum 3872 as an adjunct to 
rehydration therapy for individuals suffering from C. jejuni induced gastroenteritis. For 
the study, the time it takes for symptoms of gastroenteritis to be resolved could be 
measured for both case and control groups. This would provide an indication of whether 
the introduction of L. fermentum 3872 has a beneficial effect in the treatment of C. 
jejuni induced gastroenteritis. A follow-up study may also be conducted to determine 
future incidences of colitis and other post C. jejuni infection-related conditions. A 
cocktail of probiotics that are known to inhibit C. jejuni can also be used to determine 
whether there is a further reduction in the duration of C. jejuni infection symptoms.  
Studies on the use of L. fermentum 3872 as a prophylactic in individuals travelling 
abroad could also be conducted to determine if the incidence of travellers’ diarrhoea can 
be reduced. In vivo experiments on poultry could be conducted to determine whether L. 
fermentum 3872 can reduce C. jejuni in chickens, much like that carried out by 
Nishiyama et al. (2014). This would help identify whether L. fermentum 3872 can be 
used against a major vector for human C. jejuni infection (Kaakoush et al., 2015). There 
may be a benefit in using probiotics isolated from humans in poultry as the risk of the 
bacterium being pathogenic to a human would be unlikely. The L. fermentum 3872 
growth condition could also be varied for the agar well diffusion assay to determine 
whether there are any proteins induced that have an antagonistic effect on C. jejuni 
during varying L. fermentum 3872 growth conditions.  
 
 
 
 
123 
 
Publications 
During the course of this study the publications listed below were reported. 
Lehri, B., Seddon, A. M. and Karlyshev, A. V. (2015) 'Lactobacillus fermentum 3872 
genome sequencing reveals plasmid and chromosomal genes potentially involved in a 
probiotic activity', FEMS Microbiology Letters, 362 (11), doi: 10.1093/femsle/fnv068. 
Lehri, B., Seddon, A. M. and Karlyshev, A. V. (2017) 'Potential probiotic-associated 
traits revealed from completed high quality genome sequence of Lactobacillus 
fermentum 3872', Standards in Genomic Sciences, 12 (1), pp. 19. 
Lehri, B., Seddon, A. M. and Karlyshev, A. V. (2017a) 'The hidden perils of read 
mapping as a quality assessment tool in genome sequencing', Scientific Reports, 7, doi: 
10.1038/srep43149. 
Lehri, B., Seddon, A. M. and Karlyshev, A. V. (2017b) 'Lactobacillus fermentum 3872 
as a potential tool for combatting Campylobacter jejuni infections', Virulence, pp. 00-
00, doi: 10.1080/21505594.2017.1362533. 
Lehri, B., Kukreja, K., Vieira, A., Zaremba, M., Bonney, K., & Karlyshev, A. V. 
(2015). Specific genetic features of campylobacter jejuni strain G1 revealed by genome 
sequencing. FEMS Microbiology Letters, 362(4), 1-3.  
 
 
 
 
 
 
124 
 
References  
Abramov VM, Khlebnikov VS, Pchelintsev SJ, Kosarev IV, Karlyshev AV, Vasilenko 
RN, Melnikov VG. (2014) ‘Strain Lactobacillus fermentum having broad spectrum of 
antagonistic activity and probiotic lactobacterium consortium for manufacturing 
bacterial preparations RU 2528862 C1’, Russia. Patent. Application Number: 
2013118084/10, Application Date: 19.04.2013, Publication Number: 0002528862.  
Acheson, D. and Allos, B. M. (2001) 'Campylobacter jejuni Infections: Update on 
Emerging Issues and Trends', Clinical Infectious Diseases, 32 (8), pp. 1201-1206. 
Ajene, A. N., Walker, C. L. F. and Black, R. E. (2013) 'Enteric Pathogens and Reactive 
Arthritis: A Systematic Review of Campylobacter, Salmonella and Shigella-associated 
Reactive Arthritis', Journal of Health, Population, and Nutrition, 31 (3), pp. 299-307. 
Allen, S. J., Martinez, E. G., Gregorio, G. V. and Dans, L. F. (2010) 'Probiotics for 
treating acute infectious diarrhoea', The Cochrane Library, CD003048 (11), doi: 
10.1002/14651858.CD003048.pub3. 
Alok, A., Singh, I. D., Singh, S., Kishore, M., Jha, P. C. and Iqubal, M. A. (2015) 
'Probiotics: A New Era of Biotherapy', Advanced Biomedical Research, 6 pp. 31. 
Amour, C., Gratz, J., Mduma, E., Svensen, E., Rogawski, E. T., McGrath, M., Seidman, 
J. C., McCormick, B. J. J., Shrestha, S., Samie, A., Mahfuz, M., Qureshi, S., Hotwani, 
A., Babji, S., Trigoso, D. R., Lima, A. A. M., Bodhidatta, L., Bessong, P., Ahmed, T., 
Shakoor, S., Kang, G., Kosek, M., Guerrant, R. L., Lang, D., Gottlieb, M., Houpt, E. R., 
Platts-Mills, J. (2016) 'Epidemiology and Impact of Campylobacter Infection in 
Children in 8 Low-Resource Settings: Results From the MAL-ED Study', Clinical 
Infectious Diseases, 63 (9), pp. 1171-1179. 
125 
 
Anderson, R. C., Young, W., Clerens, S., Cookson, A. L., McCann, M. J., Armstrong, 
K. M. and Roy, N. C. (2013) 'Human Oral Isolate Lactobacillus fermentum AGR1487 
Reduces Intestinal Barrier Integrity by Increasing the Turnover of Microtubules in 
Caco-2 Cells', Plos One, 8 (11), pp. e78774. 
Angiuoli, S. V., Gussman, A., Klimke, W., Cochrane, G., Field, D., Garrity, G. M., 
Kodira, C. D., Kyrpides, N., Madupu, R., Markowitz, V., Tatusova, T., Thomson, N. 
and White, O. (2008) 'Toward an Online Repository of Standard Operating Procedures 
(SOPs) for (Meta) genomic Annotation', OMICS : A Journal of Integrative Biology, 12 
(2), pp. 137-141. 
Antipov, D., Korobeynikov, A., McLean, J. S. and Pevzner, P. A. (2016) 
'hybridSPAdes: an algorithm for hybrid assembly of short and long reads', 
Bioinformatics, 32 (7), pp. 1009-1015. 
Auzat, I., Dröge, A., Weise, F., Lurz, R. and Tavares, P. (2008) 'Origin and function of 
the two major tail proteins of bacteriophage SPP1', Molecular Microbiology, 70 (3), pp. 
557-569. 
Bankevich, A., Nurk, S., Antipov, D., Gurevich, A. A., Dvorkin, M., Kulikov, A. S., 
Lesin, V. M., Nikolenko, S. I., Pham, S., Prjibelski, A. D., Pyshkin, A. V., Sirotkin, A. 
V., Vyahhi, N., Tesler, G., Alekseyev, M. A. and Pevzner, P. A. (2012) 'SPAdes: A 
New Genome Assembly Algorithm and Its Applications to Single-Cell Sequencing', 
Journal of Computational Biology, 19 (5), pp. 455-477. 
Ben Lagha, A., Haas, B., Gottschalk, M. and Grenier, D. (2017) 'Antimicrobial potential 
of bacteriocins in poultry and swine production', Veterinary Research, 48 (1), pp. 22. 
Bergonzelli, G. E., Granato, D., Pridmore, R. D., Marvin-Guy, L. F., Donnicola, D. and 
Corthésy-Theulaz, I. E. (2006) 'GroEL of Lactobacillus johnsonii La1 (NCC 533) Is 
126 
 
Cell Surface Associated: Potential Role in Interactions with the Host and the Gastric 
Pathogen Helicobacter pylori', Infection and Immunity, 74 (1), pp. 425-434. 
Bermudez-Brito, M., Plaza-Diaz, J., Munoz-Quezada, S., Gomez-Llorente, C. and Gil, 
A. (2012) 'Probiotic Mechanisms of Action', Annals of Nutrition and Metabolism, 61 
(2), pp. 160-174. 
Berstad, A., Raa, J., Midtvedt, T. and Valeur, J. (2016) 'Probiotic lactic acid bacteria -
the fledgling cuckoos of the gut?', Microbial Ecology in Health and Disease, 27, doi: 
10.3402/mehd.v27.31557. 
Bull, M. J., Jolley, K. A., Bray, J. E., Aerts, M., Vandamme, P., Maiden, M. C. J., 
Marchesi, J. R. and Mahenthiralingam, E. (2014) 'The domestication of the probiotic 
bacterium Lactobacillus acidophilus', 4 (1). 
Butel, M.J. (2014) 'Probiotics, gut microbiota and health', Medicine Et Maladies 
Infectieuses, 44 (1), pp. 1-8. 
Carver, T. J., Rutherford, K. M., Berriman, M., Rajandream, M., Barrell, B. G. and 
Parkhill, J. (2005) 'ACT: the Artemis comparison tool', Bioinformatics, 21 (16), pp. 
3422-3423. 
Castillo, N. A., Perdigon, G. and de Moreno, d. L. (2011) 'Oral administration of a 
probiotic Lactobacillus modulates cytokine production and TLR expression improving 
the immune response against Salmonella enterica serovar Typhimurium infection in 
mice', BMC Microbiology, 11 (1), pp. 177. 
Chevreux, B., Pfisterer, T., Drescher, B., Driesel, A. J., Muller, W. E. G., Wetter, T. and 
Suhai, S. (2004) 'Using the miraEST Assembler for Reliable and Automated mRNA 
Transcript Assembly and SNP Detection in Sequenced ESTs', Genome Research, 14 
(6), pp. 1147-1159. 
127 
 
Claesson, M. J., Sinderen, D. V. and O'Toole, P. W. (2007) ‘The genus Lactobacillus--a 
genomic basis for understanding its diversity’, FEMS Microbiology Letters, 269(1), pp. 
8-22.  
Corr, S. C., Li, Y., Riedel, C. U., O'Toole, P. W., Hill, C. and Gahan, C. G. M. (2007) 
'Bacteriocin production as a mechanism for the anti-infective activity of Lactobacillus 
salivarius UCC118', Proceedings of the National Academy of Sciences, 104 (18), pp. 
7617-7621. 
Cotter, P. D., Hill, C. and Ross, R. P. (2005) 'Bacteriocins: developing innate immunity 
for food', Nature Reviews Microbiology, 3(10), pp. 777-788. 
Cozma-Petrut, A., Loghin, F., Miere, D. and Dumitrascu, D. L. (2017) 'Diet in irritable 
bowel syndrome: What to recommend, not what to forbid to patients!', World Journal of 
Gastroenterology, 23 (21), pp. 3771-3783. 
Davies, J. R., Svensäter, G. and Herzberg, M. C. (2009) 'Identification of novel 
LPXTG-linked surface proteins from Streptococcus gordonii', Microbiology, 155 (6), 
pp. 1977-1988. 
De Mattos, B.,Rafael Ramos, Garcia, M. P. G., Nogueira, J. B., Paiatto, L. N., 
Albuquerque, C. G., Souza, C. L., Fernandes, L. G. R., Tamashiro, W.M., and Simioni, 
P. U. (2015) 'Inflammatory Bowel Disease: An Overview of Immune Mechanisms and 
Biological Treatments', Mediators of Inflammation, 2015, pp. 1-11. 
Deivanayagam, C. C., Rich, R. L., Carson, M., Owens, R. T., Danthuluri, S., Bice, T., 
Höök, M. and Narayana, S. V. (2000) 'Novel fold and assembly of the repetitive B 
region of the Staphylococcus aureus collagen-binding surface protein', Structure, 8 (1), 
pp. 67-78. 
128 
 
Dobson, A., Cotter, P. D., Ross, R. P. and Hill, C. (2012) 'Bacteriocin Production: a 
Probiotic Trait?', Applied and Environmental Microbiology, 78 (1), pp. 1-6. 
Doron, S. and Snydman, D. R. (2015) 'Risk and Safety of Probiotics', Clinical Infectious 
Diseases, 60 (2) pp. S129-S134. 
Drissi, F., Merhej, V., Angelakis, E., El Kaoutari, A., Carriere, F., Henrissat, B. and 
Raoult, D. (2014) 'Comparative genomics analysis of Lactobacillus species associated 
with weight gain or weight protection', 4 (2), pp. e109. 
EFSA Panel on Biological Hazards. (2011) 'Scientific Opinion on Campylobacter in 
broiler meat production: control options and performance objectives and/or targets at 
different stages of the food chain', EFSA Journal, 9 (4), pp. 2105. 
Ekblom, R. and Wolf, J. B. W. (2014) 'A field guide to whole-genome sequencing, 
assembly and annotation', Evolutionary Applications, 7 (9), pp. 1026-1042. 
Ericsson, C. D., Hatz, C. and DuPont, A. W. (2008) 'Postinfectious Irritable Bowel 
Syndrome', Clinical Infectious Diseases, 46 (4), pp. 594-599. 
Esmay, P. A., Billington, S. J., Link, M. A., Songer, J. G. and Jost, B. H. (2003) 'The 
Arcanobacterium pyogenes Collagen-Binding Protein, CbpA, Promotes Adhesion to 
Host Cells', Infection and Immunity, 71 (8), pp. 4368-4374. 
European Food Safety Authority and European Centre for Disease Prevention and 
Control. (2016) 'The European Union summary report on antimicrobial resistance in 
zoonotic and indicator bacteria from humans, animals and food in 2014', EFSA Journal, 
14 (2), pp. 4380. 
Evivie, S., Huo, G., Igene, J. and Bian, X. (2017) ‘Some current applications, 
limitations and future perspectives of lactic acid bacteria as probiotics’, Food & 
Nutrition Research, 61 (1), pp.1318034. 
129 
 
Fiocchi, A., Pawankar, R., Cuello-Garcia, C., Ahn, K., Al-Hammadi, S., Agarwal, A., 
Beyer, K., Burks, W., Canonica, G. W., Ebisawa, M., Gandhi, S., Kamenwa, R., Lee, B. 
W., Li, H., Prescott, S., Riva, J. J., Rosenwasser, L., Sampson, H., Spigler, M., 
Terracciano, L., Vereda-Ortiz, A., Waserman, S., Yepes-Nunez, J. J., Brozek, J. L. and 
Schunemann, H. J. (2015) 'World Allergy Organization-McMaster University 
Guidelines for Allergic Disease Prevention (GLAD-P): Probiotics', World Allergy 
Organization Journal, 8 (1), pp. 1-13. 
Flanagan, R. C., Neal-McKinney, J., Dhillon, A. S., Miller, W. G. and Konkel, M. E. 
(2009) 'Examination of Campylobacter jejuni Putative Adhesins Leads to the 
Identification of a New Protein, Designated FlpA, Required for Chicken Colonization', 
Infection and Immunity, 77 (6), pp. 2399-2407. 
Ford, A. C., Quigley, E. M., Lacy, B. E., Lembo, A. J., Saito, Y. A., Schiller, L. R., 
Soffer, E. E., Spiegel, B. M. and Moayyedi, P. (2014) 'Efficacy of prebiotics, probiotics, 
and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: 
systematic review and meta-analysis', The American Journal of Gastroenterology, 109 
(10), pp. 1547-1561. 
Galardini, M., Biondi, E. G., Bazzicalupo, M. and Mengoni, A. (2011) 'CONTIGuator: 
a bacterial genome finishing tool for structural insights on draft genomes', Source Code 
for Biology and Medicine, 6 (1) pp. 11. 
Gautret, P., Cramer, J. P., Field, V., Caumes, E., Jensenius, M., Gkrania-Klotsas, E., de 
Vries, P. J., Grobusch, M. P., Lopez-Velez, R., Castelli, F., Schlagenhauf, P., Hervius 
Askling, H., von Sonnenburg, F., Lalloo, D. G., Loutan, L., Rapp, C., Basto, F., Santos 
O'Connor, F., Weld, L., Parola, P. and EuroTravNet Network. (2012) 'Infectious 
diseases among travellers and migrants in Europe, EuroTravNet 2010', Euro 
130 
 
Surveillance: Bulletin Europeen Sur Les Maladies Transmissibles, European 
Communicable Disease Bulletin, 17 (26), pp. 20205. 
Ghachi, M. E., Derbise, A., Bouhss, A. and Mengin-Lecreulx, D. (2005) 'Identification 
of Multiple Genes Encoding Membrane Proteins with Undecaprenyl Pyrophosphate 
Phosphatase (UppP) Activity in Escherichia coli', Journal of Biological Chemistry, 280 
(19), pp. 18689-18695. 
Granato, D., Bergonzelli, G. E., Pridmore, R. D., Marvin, L., Rouvet, M. and Corthésy-
Theulaz, I. E. (2004) 'Cell Surface-Associated Elongation Factor Tu Mediates the 
Attachment of Lactobacillus johnsonii NCC533 (La1) to Human Intestinal Cells and 
Mucins', Infection and Immunity, 72 (4), pp. 2160-2169. 
Guzman, L. M., Belin, D., Carson, M. J. and Beckwith, J. (1995) 'Tight regulation, 
modulation, and high-level expression by vectors containing the arabinose PBAD 
promoter.', Journal of Bacteriology, 177 (14), pp. 4121-4130. 
Haiko, J. and Westerlund-Wikstrom, B. (2013) 'The Role of the Bacterial Flagellum in 
Adhesion and Virulence', Biology, 2 (4), pp. 1242-1267. 
Hamon, E., Horvatovich, P., Marchioni, E., Aoudé-Werner, D. and Ennahar, S. (2014) 
'Investigation of potential markers of acid resistance in Lactobacillus plantarum by 
comparative proteomics', Journal of Applied Microbiology, 116 (1), pp. 134-144. 
Hampton, T. (2013) 'Report reveals scope of US antibiotic resistance threat', Jama, 310 
(16), pp. 1661-1663. 
Han, K., Jang, S. S., Choo, E., Heu, S. and Ryu, S. (2007) ‘Prevalence, genetic 
diversity, and antibiotic resistance patterns of Campylobacter jejuni from retail raw 
chickens in Korea. International Journal of Food Microbiology, 114 (1), pp. 50-59. 
131 
 
Harris RS. (2007) ‘Improved pairwise alignment of genomic DNA’. PhD Thesis. The 
Pennsylvania State University. 
Heel, A. J., Jong, A., Montalban-Lopez, M., Kok, J. and Kuipers, O. P. (2013) 
'BAGEL3: automated identification of genes encoding bacteriocins and non-bactericidal 
post translationally modified peptides', Nucleic Acids Res, 41(W1), pp. W448-W453. 
Hevia, A., Delgado, S., Margolles, A. and Sánchez, B. (2015) 'Application of density 
gradient for the isolation of the fecal microbial stool component and the potential use 
thereof', Scientific reports, 5 (1), doi:10.1038/srep16807. 
Hitchen, P., Brzostek, J., Panico, M., Butler, J. A., Morris, H. R., Dell, A. and Linton, 
D. (2010) 'Modification of the Campylobacter jejuni flagellin glycan by the product of 
the Cj1295 homopolymeric-tract-containing gene', Microbiology, 156 (7) pp. 1953-
1962. 
Ho, N. and Prasad, V. (2013) 'Probiotics, prebiotics, synbiotics and naturally fermented 
foods: why more may be more', Annals of Gastroenterology : Quarterly Publication of 
the Hellenic Society of Gastroenterology, 26 (3), pp. 277-278. 
Homan, M. and Orel, R. (2015) 'Are probiotics useful in Helicobacter pylori 
eradication?', World Journal of Gastroenterology: WJG, 21 (37), pp. 10644-10653. 
Horgan, R. P. and Kenny, L. C. (2011) '‘Omic’ technologies: genomics, transcriptomics, 
proteomics and metabolomics', The Obstetrician & Gynaecologist, 13 (3), pp. 189-195. 
Hoveyda, N., Heneghan, C., Mahtani, K. R., Perera, R., Roberts, N. and Glasziou, P. 
(2009) 'A systematic review and meta-analysis: probiotics in the treatment of irritable 
bowel syndrome', BMC Gastroenterology, 9 (1), pp. 15. 
132 
 
Hsiao, W. W. and Fraser-Liggett, C. M. (2009) 'Human Microbiome Project--paving the 
way to a better understanding of ourselves and our microbes', Drug Discovery Today, 
14 (7-8), pp. 331-333. 
Hu, L. and Kopecko, D. J. (1999) 'Campylobacter jejuni 81-176 Associates with 
Microtubules and Dynein during Invasion of Human Intestinal Cells', Infection and 
Immunity, 67 (8), pp. 4171-4182. 
Hu, Y., Benedik, M. J. and Wood, T. K. (2012) 'Antitoxin DinJ influences the general 
stress response through transcript stabilizer CspE', Environmental Microbiology, 14 (3), 
pp. 669-679. 
Huang, X. and Madan, A. (1999) 'CAP3: A DNA Sequence Assembly Program', 
Genome Research, 9 (9), pp. 868-877. 
Hunt, M., Kikuchi, T., Sanders, M., Newbold, C., Berriman, M. and Otto, T. D. (2013) 
'REAPR: a universal tool for genome assembly evaluation', Genome Biology, 14 (5), pp. 
R47. 
Islam, S. U. (2015) 'Clinical Uses of Probiotics', Medicine, 95 (5), pp. e2658. 
Izquierdo, E., Horvatovich, P., Marchioni, E., Aoude-Werner, D., Sanz, Y. and 
Ennahar, S. (2009) '2-DE and MS analysis of key proteins in the adhesion of 
Lactobacillus plantarum, a first step toward early selection of probiotics based on 
bacterial biomarkers', Electrophoresis, 30 (6), pp. 949-956. 
Jandhyala, S. M., Talukdar, R., Subramanyam, C., Vuyyuru, H., Sasikala, M. and 
Reddy, D. N. (2015) 'Role of the normal gut microbiota', World Journal of 
Gastroenterology : WJG, 21 (29), pp. 8787-8803. 
133 
 
Johansson, M. A., Sjogren, Y. M., Persson, J., Nilsson, C. and Sverremark-Ekstrom, E. 
(2011) 'Early Colonization with a Group of Lactobacilli Decreases the Risk for Allergy 
at Five Years of Age Despite Allergic Heredity', Plos One, 6 (8), pp. e23031. 
Janssen, R., Krogfelt, K. A., Cawthraw, S. A., van Pelt, W., Wagenaar, J. A. and Owen, R. J. 
(2008) 'Host-Pathogen Interactions in Campylobacter Infections: the Host Perspective', Clinical 
Microbiology Reviews, 21 (3), pp. 505-518.  
Johnson, B. R. and Klaenhammer, T. R. (2014) 'Impact of genomics on the field of 
probiotic research: historical perspectives to modern paradigms', Antonie Van 
Leeuwenhoek, 106 (1), pp. 141-156. 
Johnson, T. J., Shank, J. M. and Johnson, J. G. (2017) ‘Current and Potential 
Treatments for Reducing Campylobacter Colonization in Animal Hosts and Disease in 
Humans’ Frontiers in Microbiology, 8, doi: org/10.3389/fmicb.2017.00487.  
Jones, S. E., Paynich, M. L., Kearns, D. B. and Knight, K. L. (2014) 'Protection from 
intestinal inflammation by bacterial exopolysaccharides', Journal of Immunology 
(Baltimore, Md.: 1950), 192 (10), pp. 4813-4820. 
Jorgensen, F., Charlett, A., Arnold, E., Swift, C., Madden, B. and C Elviss, N. (2017) 
‘A microbiological survey of Campylobacter contamination in fresh whole UK -
produced chilled chickens at retail sale’, Public Health England and UK Food 
Standards Agency. Available at: https://www.food.gov.uk/sites/default/files/fsa-project-
fs102121-year-2-report.pdf (Accessed: 20 June 2017). 
Juge, N. (2012) 'Microbial adhesins to gastrointestinal mucus', Trends in Microbiology, 
20 (1), pp. 30-39. 
134 
 
Kaakoush, N. O., Castano-Rodriguez, N., Mitchell, H. M. and Man, S. M. (2015) 
'Global Epidemiology of Campylobacter Infection', Clinical Microbiology Reviews, 28 
(3), pp. 687-720. 
Karlyshev, A. V., Linton, D., Gregson, N. A. and Wren, B. W. (2002) 'A novel 
paralogous gene family involved in phase-variable flagella-mediated motility in 
Campylobacter jejuni', Microbiology, 148 (2), pp. 473-480. 
Kawai, F., Paek, S., Choi, K., Prouty, M., Kanipes, M. I., Guerry, P. and Yeo, H. (2012) 
'Crystal structure of JlpA, a surface-exposed lipoprotein adhesin of Campylobacter 
jejuni', Journal of Structural Biology, 177 (2), pp. 583-588. 
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, 
S., Cooper, A., Markowitz, S., Duran, C., Thierer, T., Ashton, B., Meintjes, P and 
Drummond, A. (2012) 'Geneious Basic: An integrated and extendable desktop software 
platform for the organization and analysis of sequence data', Bioinformatics, 28 (12), 
pp. 1647-1649. 
Kline, K. A., Fälker, S., Dahlberg, S., Normark, S. and Henriques-Normark, B. (2009) 
‘Bacterial Adhesins in Host-Microbe Interactions’, Cell Host & Microbe, 5 (6), pp. 580-
592. 
Konkel, M. E., Larson, C. L. and Flanagan, R. C. (2010) 'Campylobacter jejuni FlpA 
Binds Fibronectin and Is Required for Maximal Host Cell Adherence', Journal of 
Bacteriology, 192 (1), pp. 68-76. 
Kuusela, P., Moran, A. P., Vartio, T. and Kosunen, T. U. (1989) 'Interaction of 
Campylobacter jejuni with extracellular matrix components', Biochimica Et Biophysica 
Acta (BBA) - General Subjects, 993 (2–3), pp. 297-300. 
135 
 
Lahtinen, S. J. (2012) 'Probiotic viability - does it matter?', Microbial Ecology in Health 
and Disease, 23, doi: 10.3402/mehd.v23i0.18567. 
Land, M., Hyatt, D., Jun, S., Kora, G., Hauser, L., Lukjancenko, O and Ussery, D. 
(2014) 'Quality scores for 32,000 genomes', Standards in Genomic Sciences, 9 (1), pp. 
20. 
Lee, K., Pi, K., Kim, E. B., Rho, B., Kang, S. and Lee, H. G. (2010) 'Glutathione-
mediated response to acid stress in the probiotic bacterium, Lactobacillus salivarius', 
Biotechnology Letters, 32 (7), pp. 969-972. 
Lehri, B., Seddon, A. M. and Karlyshev, A. V. (2015) 'Lactobacillus fermentum 3872 
genome sequencing reveals plasmid and chromosomal genes potentially involved in a 
probiotic activity', FEMS Microbiology Letters, 362 (11), doi: 10.1093/femsle/fnv068. 
Lehri, B., Seddon, A. M. and Karlyshev, A. V. (2017a) 'Potential probiotic-associated 
traits revealed from completed high quality genome sequence of Lactobacillus 
fermentum 3872', Standards in Genomic Sciences, 12 (1), pp. 19. 
Lehri, B., Seddon, A. M. and Karlyshev, A. V. (2017b) 'The hidden perils of read 
mapping as a quality assessment tool in genome sequencing', Scientific Reports, 7, doi: 
10.1038/srep43149. 
Lehri, B., Seddon, A. M. and Karlyshev, A. V. (2017c) 'Lactobacillus fermentum 3872 
as a potential tool for combatting Campylobacter jejuni infections', Virulence, pp. 00-
00, doi: 10.1080/21505594.2017.1362533. 
Lesbros-Pantoflickova, D., Corthesy-Theulaz, I. and Blum, A. L. (2007) 'Helicobacter 
pylori and probiotics', The Journal of Nutrition, 137 (3), pp. 812S-8S. 
136 
 
Lichtenstein, L., Avni-Biron, I. and Ben-Bassat, O. (2016) ‘Probiotics and prebiotics in 
Crohn's disease therapies’, Best Practice & Research Clinical Gastroenterology, 30 (1), 
pp. 81-88.  
Lilly, D. M. and Stillwell, R. H. (1965) 'Probiotics: Growth-Promoting Factors 
Produced by Microorganisms', Science, 147 (3659), pp. 747-748. 
Lin, H. C., Goldstein, S., Mendelowitz, L., Zhou, S., Wetzel, J., Schwartz, D. C. and 
Pop, M. (2012) ‘AGORA: Assembly Guided by Optical Restriction Alignment’, BMC 
Bioinformatics, 13 (1), pp. 189.  
Lin, S. and Liao, Y. (2013) 'CISA: Contig Integrator for Sequence Assembly of 
Bacterial Genomes', Plos One, 8 (3), pp. e60843.   
Mack, D. R., Ahrne, S., Hyde, L., Wei, S. and Hollingsworth, M. A. (2003) 
'Extracellular MUC3 mucin secretion follows adherence of Lactobacillus strains to 
intestinal epithelial cells in vitro', Gut, 52 (6), pp. 827-33. 
Mackowiak, P. A. (2013) 'Recycling Metchnikoff: Probiotics, the Intestinal Microbiome 
and the Quest for Long Life', Frontiers in Public Health, 1 (52), doi: 
10.3389/fpubh.2013.00052. 
Mahdavi, J., Pirinccioglu, N., Oldfield, N. J., Carlsohn, E., Stoof, J., Aslam, A., Self, T., 
Cawthraw, S. A., Petrovska, L., Colborne, N., Sihlbom, C., Boren, T., Wooldridge, K. 
G. and Ala'Aldeen, D. A. A. (2014) 'A novel O-linked glycan modulates Campylobacter 
jejuni major outer membrane protein-mediated adhesion to human histo-blood group 
antigens and chicken colonization', Open Biology, 4 (1), pp. 130202. 
Mazmanian, S. K., Liu, G., Ton-That, H. and Schneewind, O. (1999) 'Staphylococcus 
aureus sortase, an enzyme that anchors surface proteins to the cell wall', 285 (5428), pp. 
760-763. 
137 
 
Mendelowitz, L., Pop, M. (2014) ‘Computational methods for optical mapping’, 
GigaScience, 3 (1), doi: https://doi.org/10.1186/2047-217X-3-33. 
MetaHIT (2017). Available at: http://www.metahit.eu/index.php?id=410 (Accessed: 21 
June 2017). 
Moal, V. L. and Servin, A. L. (2014) 'Anti-Infective Activities of Lactobacillus Strains 
in the Human Intestinal Microbiota: from Probiotics to Gastrointestinal Anti-Infectious 
Biotherapeutic Agents', Clinical Microbiology Reviews, 27 (2), pp. 167-199. 
Moore, J. E., Wilson, T. S., Wareing, D. R., Humphrey, T. J. and Murphy, P. G. (2002) 
'Prevalence of thermophilic Campylobacter spp. in ready-to-eat foods and raw poultry 
in Northern Ireland', Journal of Food Protection, 65 (8), pp. 1326-1328. 
Mozzi, F., Gerbino, E., Font de Valdez, G. and Torino, M. I. (2009) 'Functionality of 
exopolysaccharides produced by lactic acid bacteria in an in vitro gastric system', 
Journal of Applied Microbiology, 107 (1), pp. 56-64. 
Muñoz-Provencio, D., Pérez-Martínez, G. and Monedero, V. (2010) 'Characterization of 
a fibronectin-binding protein from Lactobacillus casei BL23', Journal of Applied 
Microbiology, 108 (3), pp. 1050-1059. 
Myers, E. W., Sutton, G. G., Delcher, A. L., Dew, I. M., Fasulo, D. P., Flanigan, M. J., 
Kravitz, S. A., Mobarry, C. M., Reinert, K. H., Remington, K. A., Anson, E. L., 
Bolanos, R. A., Chou, H. H., Jordan, C. M., Halpern, A. L., Lonardi, S., Beasley, E. M., 
Brandon, R. C., Chen, L., Dunn, P. J., Lai, Z., Liang, Y., Nusskern, D. R., Zhan, M., 
Zhang, Q., Zheng, X., Rubin, G. M., Adams, M. D. and Venter, J. C. (2000) 'A whole-
genome assembly of Drosophila', Science (New York, N.Y.), 287 (5461), pp. 2196-2204. 
Mynewgut (2017). Available at: http://www.mynewgut.eu/ (Accessed: 21 June 2017). 
138 
 
Neal-McKinney, J., Lu, X., Duong, T., Larson, C. L., Call, D. R., Shah, D. H. and 
Konkel, M. E. (2012) 'Production of Organic Acids by Probiotic Lactobacilli Can Be 
Used to Reduce Pathogen Load in Poultry', Plos One, 7 (9), pp. e43928. 
Newell, D. G., McBride, H. and Dolby, J. M. (1985) 'Investigations on the role of 
flagella in the colonization of infant mice with Campylobacter jejuni and attachment of 
Campylobacter jejuni to human epithelial cell lines', The Journal of Hygiene, 95 (2), pp. 
217-227. 
Nichols, G. L., Richardson, J. F., Sheppard, S. K., Lane, C. and Sarran, C. (2012) 
'Campylobacter epidemiology: a descriptive study reviewing 1 million cases in England 
and Wales between 1989 and 2011', BMJ Open, 2 (4), pp. e001179.  
Nielsen, H., Hansen, K. K., Gradel, K. O., Kristensen, B., Ejlertsen, T., Ostergaard, C. 
and Schonheyder, H. C. (2010) 'Bacteraemia as a result of Campylobacter species: a 
population-based study of epidemiology and clinical risk factors', Clinical Microbiology 
and Infection, 16 (1), pp. 57-61. 
Nilsen, T., Nes, I. F. and Holo, H. (2003) 'Enterolysin A, a Cell Wall-Degrading 
Bacteriocin from Enterococcus faecalis LMG 2333', Applied and Environmental 
Microbiology, 69 (5), pp. 2975-2984. 
Nishiyama, K., Seto, Y., Yoshioka, K., Kakuda, T., Takai, S., Yamamoto, Y. and 
Mukai, T. (2014) 'Lactobacillus gasseri SBT2055 Reduces Infection by and 
Colonization of Campylobacter jejuni', Plos One, 9 (9), pp. e108827, doi: 
10.1371/journal.pone.0108827. 
Ó Cróinín, T. and Backert, S. (2012) 'Host Epithelial Cell Invasion by Campylobacter 
jejuni: Trigger or Zipper Mechanism?', Frontiers in Cellular and Infection 
Microbiology, 2, doi: 10.3389/fcimb.2012.00025. 
139 
 
Oakland, M., Jeon, B., Sahin, O., Shen, Z. and Zhang, Q. (2011) 'Functional 
Characterization of a Lipoprotein-Encoding Operon in Campylobacter jejuni', Plos One, 
6 (5), pp. e20084. doi: 10.1371/journal.pone.0020084. 
Oelschlaeger, T. A. (2010) 'Mechanisms of probiotic actions – A review', International 
Journal of Medical Microbiology, 300 (1), pp. 57-62. 
OpGen (2017). Available at: http://www.opgen.com/sequencing/ (Accessed: 19 Oct. 
2017). 
Otto, T. D., Sanders, M., Berriman, M. and Newbold, C. (2010) 'Iterative Correction of 
Reference Nucleotides (iCORN) using second generation sequencing technology', 
Bioinformatics, 26 (14), pp. 1704-1707. 
Overbeek, R., Olson, R., Pusch, G. D., Olsen, G. J., Davis, J. J., Disz, T., Edwards, R. 
A., Gerdes, S., Parrello, B., Shukla, M., Vonstein, V., Wattam, A. R., Xia, F. and 
Stevens, R. (2014) 'The SEED and the Rapid Annotation of microbial genomes using 
Subsystems Technology (RAST)', Nucleic Acids Research, 42 (1), pp. D206-D214. 
Ozer, E., Allen, J. and Hauser, A. (2014) 'Characterization of the core and accessory 
genomes of Pseudomonas aeruginosa using bioinformatic tools Spine and AGEnt', BMC 
Genomics, 15 (1), pp. 737. 
Papadimitriou, K., Zoumpopoulou, G., Foligne, B., Alexandraki, V., Kazou, M., Pot, B. 
and Tsakalidou, E. (2015) 'Discovering probiotic microorganisms: in vitro, in vivo, 
genetic and omics approaches', Frontiers in Microbiology, 6 pp. 58. 
Parkhill, J., Wren, B. W., Mungall, K., Ketley, J. M., Churcher, C., Basham, D., 
Chillingworth, T., Davies, R. M., Feltwell, T., Holroyd, S., Jagels, K., Karlyshev, A. V., 
Moule, S., Pallen, M. J., Penn, C. W., Quail, M. A., Rajandream, M. A., Rutherford, K. 
M., van Vliet, A. H., Whitehead, S. and Barrell, B. G. (2000) 'The genome sequence of 
140 
 
the food-borne pathogen Campylobacter jejuni reveals hypervariable sequences', 
Nature, 403 (6770), pp. 665-668. 
Patel, S., Majumder, A. and Goyal, A. (2009) 'Potentials of Exopolysaccharides from 
Lactic Acid Bacteria', Indian Journal of Microbiology, 52 (1), pp. 3-12. 
Penner, R. M. and Fedorak, R. N. (2005) 'Probiotics in the Management of 
Inflammatory Bowel Disease', Medscape General Medicine, 7 (3), pp. 19-19. 
Pessione, E. (2012) 'Lactic acid bacteria contribution to gut microbiota complexity: 
lights and shadows', Frontiers in Cellular and Infection Microbiology, 2 pp. 86. 
Pietrocola, G., Valtulina, V., Rindi, S., Jost, B. H. and Speziale, P. (2007) 'Functional 
and structural properties of CbpA, a collagen-binding protein from Arcanobacterium 
pyogenes', Microbiology, 153 (10), pp. 3380-3389. 
Platts-Mills, J. and Kosek, M. (2014) 'Update on the burden of Campylobacter in 
developing countries', Current Opinion in Infectious Diseases, 27 (5), pp. 444-450. 
Ponnuraj, K., Bowden, M. G., Davis, S., Gurusiddappa, S., Moore, D., Choe, D., Xu, 
Y., Hook, M. and Narayana, S. V. L. (2003) 'A “dock, lock, and latch” Structural Model 
for a Staphylococcal Adhesin Binding to Fibrinogen', Cell, 115 (2), pp. 217-228. 
Prasad, J., McJarrow, P. and Gopal, P. (2003) 'Heat and Osmotic Stress Responses of 
Probiotic Lactobacillus rhamnosus HN001 (DR20) in Relation to Viability after 
Drying', Applied and Environmental Microbiology, 69 (2), pp. 917-925. 
Public Health England (2017) Campylobacter data 2006 to 2015. Public Health 
England (Campylobacter: guidance, data and analysis), pp. 1-9. Available at: 
https://www.gov.uk/government/publications/campylobacter-cases-2000-to-2012 
(Accessed: 8 August 2017). 
141 
 
Rautava, S., Kalliomaki, M. and Isolauri, E. (2002) 'Probiotics during pregnancy and 
breast-feeding might confer immunomodulatory protection against atopic disease in the 
infant', Journal of Allergy and Clinical Immunology, 109 (1), pp. 119-121. 
Renz-Polster, H., David, M. R., Buist, A. S., Vollmer, W. M., O'Connor, E. A., Frazier, 
E. A. and Wall, M. A. (2005) 'Caesarean section delivery and the risk of allergic 
disorders in childhood', Clinical & Experimental Allergy, 35 (11), pp. 1466-1472. 
Reuter, J. A., Spacek, D. and Snyder, M. P. (2015) 'High-Throughput Sequencing 
Technologies', Molecular Cell, 58 (4), pp. 586-597. 
Riddle, M. S., Murray, J. A., Cash, B. D., Pimentel, M. and Porter, C. K. (2013) 
'Pathogen-Specific Risk of Celiac Disease Following Bacterial Causes of Foodborne 
Illness: A Retrospective Cohort Study', Digestive Diseases and Sciences, 58 (11), pp. 
3242-3245. 
Rubinchik, S., Seddon, A. and Karlyshev, A. V. (2012) 'Molecular mechanisms and 
biological role of Campylobacter jejuni attachment to host cells', European Journal of 
Microbiology & Immunology, 2 (1), pp. 32-40. 
Ruggiero, P. (2014) 'Use of probiotics in the fight against Helicobacter pylori', World 
Journal of Gastrointestinal Pathophysiology, 5 (4), pp. 384-391. 
Sánchez , B., Delgado, S., Blanco-Miguez, A., Lourenco, A., Gueimonde, M. and 
Margolles, A. (2017) 'Probiotics, gut microbiota, and their influence on host health and 
disease', Molecular Nutrition & Food Research, 61 (1), pp. 1613-4133. 
Sabet, C., Lecuit, M., Cabanes, D., Cossart, P. and Bierne, H. (2005) 'LPXTG Protein 
InlJ, a Newly Identified Internalin Involved in Listeria monocytogenes Virulence', 
Infection and Immunity, 73 (10), pp. 6912-22. 
142 
 
Salari, P., Nikfar, S. and Abdollahi, M. (2012) 'A meta-analysis and systematic review 
on the effect of probiotics in acute diarrhea', Inflammation & Allergy Drug Targets, 11 
(1), pp. 3-14. 
Salzillo, M., Vastano, V., Capri, U., Muscariello, L., Sacco, M. and Marasco, R. (2015) 
'Identification and characterization of enolase as a collagen-binding protein in 
Lactobacillus plantarum', Journal of Basic Microbiology, 55 (7), pp. 890-897. 
Sanders, M. E. (2008) 'Probiotics: Definition, Sources, Selection, and Uses', Clinical 
Infectious Diseases, 46 (1) pp. S58-S61. 
Scheurwater, E., Reid, C. W. and Clarke, A. J. (2008) 'Lytic transglycosylases: Bacterial 
space-making autolysins', The International Journal of Biochemistry & Cell Biology, 40 
(4), pp. 586-591. 
Schwille-Kiuntke, J., Enck, P., Zendler, C., Krieg, M., Polster, A. V., Klosterhalfen, S., 
Autenrieth, I. B., Zipfel, S. and Frick, J. (2011) 'Postinfectious irritable bowel 
syndrome: follow-up of a patient cohort of confirmed cases of bacterial infection with 
Salmonella or Campylobacter', Neurogastroenterology & Motility, 23 (11), pp. e479-
e488. 
Seemann, T. (2014) 'Prokka: rapid prokaryotic genome annotation', Bioinformatics, 30 
(14), pp. 2068-9. 
Serichantalergs, O., Dalsgaard, A., Bodhidatta, L., Krasaesub, S., Pitarangsi, C., Srijan, 
A. and Mason, C. (2007) 'Emerging fluoroquinolone and macrolide resistance of 
Campylobacter jejuni and Campylobacter coli isolates and their serotypes in Thai 
children from 1991 to 2000', Epidemiology and Infection, 135 (8), pp. 1299-1306. 
143 
 
Sharma, D. and Saharan, B. S. (2016) 'Functional characterization of biomedical 
potential of biosurfactant produced by Lactobacillus helveticus', Biotechnology Reports, 
11 (2016), pp. 27-35. 
Silva, G. G. Z., Dutilh, B. E., Matthews, T. D., Elkins, K., Schmieder, R., Dinsdale, E. 
A. and Edwards, R. A. (2013) 'Combining de novo and reference-guided assembly with 
scaffold_builder', Source Code for Biology and Medicine, 8 (1), pp. 23. 
doi:10.1186/1751-0473-8-23. 
Singh, P. and Cameotra, S. S. (2004) ‘Potential applications of microbial surfactants in 
biomedical sciences’, Trends in Biotechnology, 22 (3), pp. 142-6.  
SoftBerry - ProtCompB (2017). Available at: 
http://www.softberry.com/berry.phtml?topic=pcompb&group=programs&subgroup=pr
oloc (Accessed: 7 June 2017). 
Sonomoto, K. and Yokota, A. (2011) Lactic acid bacteria and bifidobacteria: Current 
Progress in Advanced Research. Norfolk, UK: Caister Academic Press.  
Spiller, R. and Garsed, K. (2009) 'Postinfectious Irritable Bowel Syndrome', 
Gastroenterology, 136 (6), pp. 1979-1988. 
Suessmuth, S. D., Muscholl-Silberhorn, A., Wirth, R., Susa, M., Marre, R and 
Rozdzinski, E. (2000) 'Aggregation Substance Promotes Adherence, Phagocytosis, and 
Intracellular Survival of Enterococcus faecalis within Human Macrophages and 
Suppresses Respiratory Burst', Infection and Immunity, 68(9), pp. 4900-4906. 
Svetoch, E. A., Eruslanov, B. V., Levchuk, V. P., Perelygin, V. V., Mitsevich, E. V., 
Mitsevich, I. P., Stepanshin, J., Dyatlov, I., Seal, B. S. and Stern, N. J. (2011) 'Isolation 
of Lactobacillus salivarius 1077 (NRRL B-50053) and Characterization of Its 
144 
 
Bacteriocin, Including the Antimicrobial Activity Spectrum', Applied and 
Environmental Microbiology, 77 (8), pp. 2749-2754. 
Szajewska, H., Guarino, A., Hojsak, I., Indrio, F., Kolacek, S., Shamir, R., Vandenplas, 
Y., Weizman, Z and European Society for Pediatric Gastroenterology, Hepatology, and 
Nutrition. (2014) 'Use of probiotics for management of acute gastroenteritis: a position 
paper by the ESPGHAN Working Group for Probiotics and Prebiotics', Journal of 
Pediatric Gastroenterology and Nutrition, 58 (4), pp. 531-539. 
Tajabadi, N., Mardan, M., Saari, N., Mustafa, S., Bahreini, R. and Mohd Yazid, A. M. 
(2013) ‘Identification of Lactobacillus plantarum, Lactobacillus pentosus and 
Lactobacillus fermentum from honey stomach of honeybee, Brazilian Journal of 
Microbiology, 44 (3), pp. 717-722.  
Takahashi, M., Taguchi, H., Yamaguchi, H., Osaki, T., Komatsu, A. and Kamiya, S. 
(2004) 'The effect of probiotic treatment with Clostridium butyricum on 
enterohemorrhagic Escherichia coli O157:H7 infection in mice', FEMS Immunology & 
Medical Microbiology, 41 (3), pp. 219-226. 
Takeda, K., Suzuki, T., Shimada, S., Shida, K., Nanno, M. and Okumura, K. (2006) 
'Interleukin-12 is involved in the enhancement of human natural killer cell activity by 
Lactobacillus casei Shirota', Clinical & Experimental Immunology, 146 (1), pp. 109-
115. 
Tareb, R., Bernardeau, M., Gueguen, M. and Vernoux, J. P. (2013) 'In vitro 
characterization of aggregation and adhesion properties of viable and heat-killed forms 
of two probiotic Lactobacillus strains and interaction with foodborne zoonotic bacteria, 
especially Campylobacter jejuni', Journal of Medical Microbiology, 62 (4), pp. 637-
649. 
145 
 
Treangen, T. J. and Salzberg, S. L. (2011) 'Repetitive DNA and next-generation 
sequencing: computational challenges and solutions', Nature Reviews Genetics, 13 (1), 
pp. 36-46. 
Tribble, D. R., Sanders, J. W., Pang, L. W., Mason, C., Pitarangsi, C., Baqar, S., 
Armstrong, A., Hshieh, P., Fox, A., Maley, E. A., Lebron, C., Faix, D. J., Lawler, J. V., 
Nayak, G., Lewis, M., Bodhidatta, L. and Scott, D. A. (2007) 'Traveler's Diarrhea in 
Thailand: Randomized, Double-Blind Trial Comparing Single-Dose and 3-Day 
Azithromycin-Based Regimens with a 3-Day Levofloxacin Regimen', Clinical 
Infectious Diseases, 44 (3), pp. 338-346. 
Tsai, I. J., Otto, T. D. and Berriman, M. (2010) 'Improving draft assemblies by iterative 
mapping and assembly of short reads to eliminate gaps', Genome Biology, 11 (4), pp. 
R41. 
Turner, P. C., Wu, Q. K., Piekkola, S., Gratz, S., Mykkänen, H. and El-Nezami, H. 
(2008) ‘Lactobacillus rhamnosus strain GG restores alkaline phosphatase activity in 
differentiating Caco-2 cells dosed with the potent mycotoxin deoxynivalenol’, Food and 
Chemical Toxicology, 46 (6), pp. 2118-2123.  
Van Domselaar, G. H., Stothard, P., Shrivastava, S., Cruz, J. A., Guo, A., Dong, X., Lu, 
P., Szafron, D., Greiner, R. and Wishart, D. S. (2005) 'BASys: a web server for 
automated bacterial genome annotation', Nucleic Acids Research, 33 (2), pp. W455-
W459. 
Van Doorn, P. A., Ruts, L. and Jacobs, B. C. (2008) ‘Clinical features, pathogenesis, 
and treatment of Guillain-Barré syndrome, Lancet Neurology, 7 (10), pp. 939-50  
146 
 
Verbeke, S., Gotteland, M., Fernandez, M., Bremer, J., Rios, G. and Brunser, O. (2002 
'Basement membrane and connective tissue proteins in intestinal mucosa of patients 
with coeliac disease', Journal of Clinical Pathology, 55 (6), pp. 440-445. 
Verdenelli, M. C., Coman, M. M., Cecchini, C., Silvi, S., Orpianesi, C. and Cresci, A. 
(2014) 'Evaluation of antipathogenic activity and adherence properties of human 
Lactobacillus strains for vaginal formulations', Journal of Applied Microbiology, 116 
(5), pp. 1297-1307. 
Vernocchi, P., Chierico, F. D. and Putignani, L. (2016) ‘Gut Microbiota Profiling: 
Metabolomics Based Approach to Unravel Compounds Affecting Human Health’, 
Frontiers in Microbiology, 7 (2016), pp. 1144.  
Vijaya, K. G., Lee, E. M., Philip, J. G. and Mark, A. M. (2013) ‘Probiotics: History and 
Evolution’, Journal of Infectious Diseases & Preventive Medicine, 1 (2). 
doi:10.4172/2329-8731.1000107.  
Waligora-Dupriet, A. and Butel, M. (2012) "Microbiota and Allergy: From Dysbiosis to 
Probiotics", Allergic Diseases - Highlights in the Clinic, Mechanisms and Treatment. 
doi: 10.5772/26234. 
Walsh, A. M., Crispie, F., Claesson, M. J. and Cotter, P. D. (2016) ‘Translating Omics 
to Food Microbiology’, Annual Review of Food Science and Technology, 8 (2017), pp. 
113-134  
Wehkamp, J., Harder, J., Wehkamp, K., Meissner, B. W., Schlee, M., Enders, C., 
Sonnenborn, U., Nuding, S., Bengmark, S., Fellermann, K., Schroder, J. M. and Stange, 
E. F. (2004) 'NF-kappaB- and AP-1-Mediated Induction of Human Beta Defensin-2 in 
Intestinal Epithelial Cells by Escherichia coli Nissle 1917: a Novel Effect of a Probiotic 
Bacterium', Infection and Immunity, 72 (10), pp. 5750-5758. 
147 
 
Wine, E., Gareau, M., Johnson-Henry, K. and Sherman, P. M. (2009) 'Strain-specific 
probiotic (Lactobacillus helveticus) inhibition of Campylobacter jejuni invasion of 
human intestinal epithelial cells', FEMS Microbiology Letters, 300 (1), pp. 146-152. 
World Health Organisation (2017) Global priority list of antibiotic-resistant bacteria to 
guide research, discovery, and development of new antibiotics. WHO (Essential 
medicines and health products), pp. 1-7. Available at: 
http://www.who.int/medicines/publications/WHO-PPL-Short_Summary_25Feb-
ET_NM_WHO.pdf?ua=1. 
World Health Organization and, Food and Agriculture Organization of the United 
Nations (2001) Health and Nutritional Properties of Probiotics in Food including 
Powder Milk with Live Lactic Acid Bacteria’. WHO/FAO. Available at: 
http://www.fao.org/3/a-a0512e.pdf. 
World Health Organization, Food and Agriculture Organization of the United Nations, 
World Organisation for Animal Health (2013) The global view of campylobacteriosis: 
report of an expert consultation, Utrecht, Netherlands, 9-11 July 2012. Geneva, 
Switzerland: WHO. Available at: http://www.who.int/iris/handle/10665/80751 
(Accessed: 22 June 2017). 
 Yadav, A. K., Tyagi, A., Kaushik, J. K., Saklani, A. C., Grover, S. and Batish, V. K. 
(2013) 'Role of surface layer collagen binding protein from indigenous Lactobacillus 
plantarum 91 in adhesion and its anti-adhesion potential against gut pathogen', 
Microbiological Research, 168 (10), pp. 639-645. 
Yang, S., Lin, C., Sung, C. T. and Fang, J. (2014) 'Antibacterial activities of 
bacteriocins: application in foods and pharmaceuticals', Frontiers in Microbiology, 5 pp. 
241. 
148 
 
Young, K. T., Davis, L. M. and DiRita, V. J. (2007) 'Campylobacter jejuni: molecular 
biology and pathogenesis', Nature Reviews Microbiology, 5 (9), pp. 665-679. 
Zenner, D. and Gillespie, I. (2011) 'Travel-Associated Salmonella and Campylobacter 
Gastroenteritis in England: Estimation of Under-Ascertainment Through National 
Laboratory Surveillance', Journal of Travel Medicine, 18 (6), pp. 414-417. 
Zhang, Y., Li, L., Guo, C., Mu, D., Feng, B., Zuo, X. and Li, Y. (2016) 'Effects of 
probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by 
Rome III criteria: a meta-analysis', BMC Gastroenterology, 16 (1), pp. 62. 
Zhou, C., Ma, F. Z., Deng, X. J., Yuan, H. and Ma, H. S. (2008) 'Lactobacilli inhibit 
interleukin-8 production induced by Helicobacter pylori lipopolysaccharide-activated 
Toll-like receptor 4', World Journal of Gastroenterology, 14 (32), pp. 5090-5095. 
Zhou, Y., Liang, Y., Lynch, K. H., Dennis, J. J. and Wishart, D. S. (2011) 'PHAST: A 
Fast Phage Search Tool', Nucleic Acids Research, 39 (2), pp. W347-W352. 
Zielenkiewicz, U., Kowalewska, M., Kaczor, C. and Ceglowski, P. (2009) 'In Vivo 
Interactions between Toxin-Antitoxin Proteins Epsilon and Zeta of Streptococcal 
Plasmid pSM19035 in Saccharomyces cerevisiae', Journal of Bacteriology, 191 (11), 
pp. 3677-3684. 
Zyrek, A. A., Cichon, C., Helms, S., Enders, C., Sonnenborn, U. and Schmidt, M. A. 
(2007) 'Molecular mechanisms underlying the probiotic effects of Escherichia coli 
Nissle 1917 involve ZO-2 and PKCzeta redistribution resulting in tight junction and 
epithelial barrier repair', Cellular Microbiology, 9 (3), pp. 804-816. 
 
